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SUMMARY 
9-0-((±)-2-Phenyl-2-hydroxybutyryl]retronecine (82) has been shown to be 
more active than Indicine N-oxide (3), a pyrrolizidine alkaloid (PA) that is active 
against gastrointestinal cancer, leukemia, and melanoma. New semisynthetic PAs 
modeled after 82 have been synthesized to investigate further the structure-activity 
relationships. The new PAs were tested as their freebase and as their N-oxides. 
This research has focused mainly on modifications of the necic acid side chains 
which were synthesized from readily available aromatic ketones. The necic acids were 
prepared by formation of the cyanohydrin of the ketone followed by hydrolysis to the 
acid. The acids were resolved using the Marcwald principle and the method of Pope 
and Peachey. The racemic and resolved acids were then site-specifically coupled to 
the necine using 1,l'-carbonyldiimidazole to give the appropriate ester. Retronecine 
(1) was used to obtain C9 esters and one C7 ester. Other necines used were platyne-
cine (62) and retronecanol (64). 
The semisynthetic PAs were screened in vivo in the 3PS31 tumor system and in 
vitro at the Mayo Clinic. One compound, 9-0-((-)-2-(4'-chlorophenyl)-2-hydroxy-
butyryllretronecine N-oxide (88) was also screened in a tumor panel showing excellent 
activity in 5 different tumor systems. Alkylation rate stud ies and DNA crosslinking 





Pyrrolizidine alkaloids (PAs) are estimated to be found in over 3% of the world's 
flowering plants. ] In recent years, the study of pyrrolizidine alkaloids (PAs) has 
greatly increased due to their wide range of biological activity and their occurrence 
throughout the world. This is evidenced by a 50% increase in literature references 
relating to all phases of the study of PAs. 2 A recent book by Mattocks 2 on the 
chemistry and biology of PAs extensively reviews the literature from 1968 to 1984. 
The literature prior to 1968 has been reviewed in a book by Bull, Culvenor, and 
Dick. 3 Many other reviews covering specific or general aspects of the chemistry and 
biology of PAs are available, particularly in a series of annual reports entitled "The 
Alkaloids." 4 
Many PAs are toxic and have been implicated in the death of livestock and 
poisoning of people. Consumption by cattle of plants containing PAs has been a 
problem in this country in the Pacific northwest. 2 Possible routes of entry into the 
human food supply are through milk, 5 honey, 6 grains by contaminating plant seeds, 7 
and in herbal medicines and teas. 2 Consumption of herbal teas containing PAs has led 
to veno - occlusive disease and then later to liver cirrhosis. 2 Other biological effects of 
PAs includes hepatotoxicitv, 2 embryotoxicity, 8 teratogenicity, 9 mutagenicity, 2 
1 carcinogenicity, - and antitumor activity.O  
Most PAs are esters of retronecine (1) or heliotridine (2), which are epimers at 
the C7 hydroxyl group. Heliotridine esters predominate in Australian and Asian plants 
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bases and as N-oxides [(3), indicine N-oxide (INO)]. Both the free base and N-oxide 
of a particular PA may occur together or alone in varying proportions in the same 
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Figure 1. Some Pyrrolizidine Alkaloids 
PAs have an azabicyclo[3.3.0]octane or pyrrolizidine ring system. The most 
common PAs are diols. The dihydroxylated pyrrolizidine ring portions of PAs (eg. 1 
and 2) are called necines and the acid portions are called necic acids. Trivial names 
are commonly used for these alkaloids due to the complexity and diversity of 
systematic names. The PA ring system is numbered as shown in Figure 2 below for 
indicine (6). The acid portion of monoesters will be numbered starting with l' as the 
3 
carbonyl carbon also shown in Figure 2. Necic acids of acyclic diesters will be 
numbered similar to monoesters with the carbonyl carbon attached at C9 as 1' and the 
carbonyl carbon attached at C7 as 1' as in Figure 2. Macrocylic diesters will be 
numbered consecutively starting with the oxygen at C9 as 010 and continuing to the 
oxygen at C7 as 016 as shown for monocrotaline (5) in Figure 2. Additional carbons 
which are connected to the macrocyclic ring will be numbered from right to left 
starting with the next consecutive number after the oxygen at C7 as shown in Figure 
2 for monocrotaline (5). 
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Figure 2. Numbering System for Pyrrolizidine Alkaloids 
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For over 20 years, the antitumor activity of PAs has been recognized and 
investigated, but to this date the mechanism(s) of action remain unknown. Most 
structure-activity relationship studies have centered on the many toxic effects rather 
than studies to elucidate the mechanism of action for antitumor activity. Culvenorl° 
tested over 18 PAs in 1968 and reported that 10 showed significant activity. 
Crispatine (7), fulvine (8), heliotrine (9) and its N-oxide (10), lasiocarpine (11), 
monocrotaline (5), senecionine (12), 1-chloromethy1-7-a-hydroxy-1,2-dehydropyrroliz-
idine (13), spectabiline (14), and supinine (15) all showed significant activity against 
one or more of four tumor systems: adenocarcinoma 755, sarcoma 180, Walker 
carcinosarcoma 256 (intramuscular and subcutaneous), and lymphoid leukemia L1210. 
It was suggested that the results for activity were due to an optimization of several 
interrelated factors: water solubility, lipophilicity, base strength, and alkylating ability. 
These PAs .ire also known to form pyrrolic metabolites in animal systems. 
Figure 3. PAs Tested by Culvenor 
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Figure 4. PAs Tested by Culvenor 
Senecionine (12) and its N-oxide (16), monocrotaline (5), INO (3), and senkirkine 
(17), an otonecine ester, have also been identified as the active constituent in plant 
extracts using various tumor systems. I3 Sharma and Hebbron 14 have reported that the 
otonecine ester, crosemperine (18), gives some minimal antitumor activity at its toxic 
dosage of 200 mg/Kg on subacute administration. 
CH 3 
HO CH 3 
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17 18 
Figure 5. Otonecine Esters Tested for Antitumor Activity 
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Anderson and Corey 15 reported a series of substituted dihydropyrrolizine esters, of 
general structures 19 and 20 which were tested against P388 leukemia and L1210 for 
antitumor activity and against cell line 9-KB for cytotoxicity. The majority of 
compounds tested in this series showed significant activity in the P388 lymphoid 
leukemia assay. Biscarbamate 21 was "curative" at 12.5 mg/Kg and compound 22 was 
active even at dosages as low as 0.78 mg/Kg. The carbamates 23 and 24 were active 
over a wide range of dosages with no observed acute toxicity. In 1982, Anderson et 
al 16 reported "cures" for three biscarbamate dihydropyrrolizine 25-27 in the B16 
melanocarcinoma assay. Compounds 26 and 27 were once again active in the P388 
lymphoid leukemia assay when administered i.p., not, however when administered 
orally. Other tumor systems used to assay these compounds were L1210 lymphoid 
leukemia, CD8F1 mammary tumor, colon tumor 26, colon tumor 38, Lewis lung 
carcinoma, C3H mammary tumor, C3H mammary adenocarcinoma-I6/C, ependymoblas-
toma, and doxorubin-resistent P388. Later in 1982, Anderson" reported assaying 
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27 and 28, as well as others, against human tumor xenografts: CX-1, human 
adenocarcinoma of the colon; LX-1, human oat cell carcinoma of the lung; and MX-1, 
human duct cell carcinoma of the breast. Compound 28 showed significant activity 
against human breast xenograft, MX-1, and was less active in the other two 
xenografts. Compound 27 was more toxic than compound 28 as well as less active in 
each xenograft. 
In 1981, Wang et a/. 18 reported a study of the antitumor structure-activity 
relationships for retusine (29), usaramine (30), monocrotaline(5), and some synthetic 
derivatives of monocrotaline using mouse sarcoma 180, Walker carcinosarcoma 256, and 
Lewis lung carcinoma 615. It was found that the sulfite (31) and ethoxymethylene 
(32) derivative of monocrotaline were less active and more toxic than monocrotaline 
(5). The diacetyl derivative (33) was more active and less toxic than monocrotaline. 
Retusine (29), a saturated analog of monocrotaline (5), was also active. Usaramine (30) 
and the quaternary methiodide (34) of monocrotaline (5) were inactive. These results 
seem to suggest that the type of derivatization in the necic acid side chain is 
important and that saturation in the necine at Cl and C2 is not necessary for activity. 
Figure 7. PAs Tested by Wang 
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Figure 8. PAs Tested by Wang 
In 1976, Kugelman and co-workers 19 reported the isolation of INO (3) in a 
bioassay directed fractionation of the extracts of Heliotropium indicum using Walker 
carcinosarcoma 256 and leukemia 1210 in mice. In further tests, INO (3) was found 
to also be active against B16 melonoma and murine leukemias P388 and P1534. In 
dog and monkey studies, 2 ° INO (3) exhibited significant antitumor activity and 
reversible alterations in hepatic function with no histological evidence of liver injury 
unlike other PAs. 
INO (3) is the only PA to undergo clinical trials. In clinical studies 21 of 137 
patients with solid tumors, INO (3) produced some partial response accompanied by 
mild reversible toxicity. 
In another study, 22 29 patients with various advanced carcinomas were given INO 
(3) at 0.15-3.0 g/m 2 intravenously for 5 days at 6 week intervals with no 
objective therapeutic response (remission). In 5 of the patients with advanced 
intestinal cancer, the disease was stabilized for at least 4 months. Cumulative 
bone marrow suppression was the main toxic effect observed. Other toxicities 
were mild nausea and vomiting during treatment cycle and reversible hepatic 
9 
toxicities. Fifty percent of the patients who had previously received treatment 
with nitrosoureas had severe myelosuppression. It was suggested, for the next 
study, that patients previously treated with nitrosoureas not receive INO (3). 
A study"' of 10 patients with advanced acute leukemia were given dosages similar 
to that in the first study at four week intervals. Complete remission was reported for 
2 patients and remission was maintained for 90 days or more. Partial remission was 
reported for a third patient after the first cycle of drug administration with no 
improvement afterwards. One patient died after the second cycle of drug administra-
tion, although there was no histological evidence of liver pathology due to INO (3), 
and 2 patients experienced jaundice and liver failure. Myelosuppression was again the 
general toxic effect. Further clinical trials of INO (3) were discontinued. 
In 1982, our research group 24 first reported a semisynthetic PA, 
[(±)-2-hydroxy-2-phenylbutyryl]retronecine and its N-oxide (35,36), which was 
structurally similar to INO (3) and which was more active than INO (3) against the 
P388 murine lymphatic leukemia system. In 1985, we reported 25 the synthesis and 
antitumor activity of a series of semisynthetic PAs (37-45) and their N-oxides. Again, 
antitumor activity was determined using the P388 leukemia system. INO (3) was run 
as a control for each group so that overall comparisons could be made. None of the 
C2' or C3' diastereomers (37-39) of INO (3) were more potent than INO (3) or even 
more potent than 9-O-benzoylretronecine N-oxide (39). A mixture of two PA 
N-oxides (41,42), each substituting a methyl group for the isopropyl group in the side 
chain of INO (3), did show increased activity, but not as much as the PA N-oxides 
(35,36) where an aromatic ring had been substituted for the isopropyl group in INO 
(3). The PA N-oxides (35,36) with aromatic side chains were potent enough to 
warrant further investigation Other PAs (43-45) tested were inactive in the P388 
leukemia system. 
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Figure 9. Semisynthetic PAs tested by Zalkow 
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The agent(s) responsible for antitumor activity of PAs is not known. It is thought 
not to be the N-oxide or free base but perhaps a metabolite, such as a pyrrole. 2 
 Activity may not even be due to the same factor(s) or mechanism(s) in different PAs.
In the case of INO (3), Powis et al. 26 studied its metabolism in rabbits. Most of the 
INO (3) administered by intravenous injection was rapidly eliminated in the urine as 
INO (3) within 2 hours, with only a small amount being reduced and eliminated as the 
free base, indicine (6). N-oxides, in general, are very water soluble and rapid 
elimination in the urine would be as expected. Indicine (6), on the other hand, was 
eliminated steadily during a 24 hour period, making indicine (6) available for absorption 
for 24 hours. In studies 27 with mice INO (3), administered i.p., was more active than 
indicine (6) administered i.p. and INO (3) given orally was inactive, 49% being reduced 
by the gut flora to indicine (6). This suggests that antitumor activity of INO (3) does 
not result from the reduction of INO (3) to indicine (6), otherwise oral administration 
would be the most effective way to administer INO (3). Also, tumor cells reduce very 
little INO (3) to indicine (6), compared to liver cells and the gut flora. According to 
Mattocks, 2 antitumor activity probably does not result from formation of pyrrolic 
metabolites either, since reduction of the N-oxide to the free base would first be 
necessary 28 and this is unlikely since INO (3) is very water soluble and it's metabolism 
is low. This seems to rule out all known metabolites and agents. Due to this type of 
ambiguity, the mechanism(s) of action of INO (3) and other PAs remains unknown. 
Cytotoxicity or cell toxicity and metabolism have been closely linked in animal 
studies. The metabolites thought to be responsible are the pyrrolic derivatives of PAs. 
Some evidence suggesting this is: 29 PAs are toxic to the liver but not at the 
12 
site of application, treatments modifying the activity of liver enzymes considerably 
influence toxicity, and most PAs are relatively unreactive while pyrroles are highly 
reactive in both electrophilic and nucleophilic reactions. Possible pathways of 
metabolism are ester hydrolysis, conversion to the N-oxide, and conversion to the 
pyrrole derivative. Hydrolysis leads to the necic acid and necic base. Neither is known 
to be toxic. Conversion to the N-oxide is thought to be a detoxification mechanism, 30 
 since this converts the PA into a more water soluble compound which is more easily 
excreted in the urine and feces. Pvrroles are known to be much more toxic than their 
PA counterparts and are very reactive alkylating agents. 
One possible pathway for the formation of pyrroles in biological systems is the 
enzymatic oxidation at C8 and subsequent dehydration (Scheme 1). 30 Mattocks has 
shown that conversion of PAs to N-oxides and pyrroles is catalyzed by enzymes having 
mixed-function oxidase characteristics and a requirement for oxygen and reduced 
NADP. Chemical induction of microsomal activity with DDT or phenobarbitone 
increases the amount of pyrrole formation, but only slight increases in N-oxide are 
observed. 30 s 31 Inhibitors of microsomal activity, such as SKF 525A and chlorampheni-
col, reduce formation of pyrrole but not N-oxide. 30,32 This suggests that there is no 
clear relationship between rates of pyrrole and N-oxide formation further suggesting 
that N-oxide formation is not a part of the mechanism of pyrrole formation. 
Mattocks has suggested that pyrrole formation is a 'metabolic mistake'. In an attempt 
to make a compound that is more water soluble and therefore more easily excreted, 
biological systems actually make an unstable intermediate which forms a more 
lipophilic and highly toxic product.2 
OR 
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Scheme I. Enzymatic Pyrrole Formation 
There are three general methods for the formation of pyrrolic derivatives of 
pyrrolizidine alkaloids: 1) dehydrogenation, 2) dehydration of the N-oxide, 3) 
oxidation of the C9 alcohol followed by rearrangement to the pyrrole. Dehy-
drogenation can be accomplished by the use of 2,3-dichloro-5,6-dicyanobenzo-
quinone (DDQ), 33 chloranil, 34 or catalytically using Pt02 or Raney nicke1. 34 N-oxides 
are readily dehydrated by acetic anhydride (Scheme 2) via an unstable N-acetoxy 
intermediate 33 or catalytically by iron (II) complexes (Scheme 3) via a radical 
mechanism. 35 This reaction is catalytic and requires a small amount of water and 
acid. Some reduction to the free base is also observed. Ferrous sulfate, 
ferrous-EDTA complex, and ferrous nitroprusside are the most common complexes 
used. Pyrrole formation by ferrous complexes is a very convenient, qualitative method 
and has now been proposed as a field test for N-oxides in plants. 36 Pyrroles of 
necines may be prepared by oxidation of the C9 alcohol to the pyrroline aldehyde 
(Scheme 4) with potassium nitrosodisulphonate (Fremy's salt) 37 or manganese dioxide 
(Mn02). 33,38 Oxidation is followed by rearrangement to the pyrrolic alcohol which 
may be oxidized further giving the pyrrolic aldehyde. The pyrrolic aldehyde may be 
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Scheme 2. Dehydration of the N-Oxide by Acetic Anhydride 
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Scheme 3. Pyrrole Formation by Iron (II) Chloride 
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Scheme 4. Pyrrole Formation by Manganese Dioxide 
Antitumor activity may be associated with alkylating ability and it has been shown 
that pyrrolic derivatives react with purine and pyrimidine nucleosides and 
nucleotides. 39 The alkylating ability of pyrrolic derivatives can be measured by a 
colorimetric test using 4-(4'-nitrobenzyl)pyridine (NBP, 47) under pseudo first-order 
conditions. 4 ° Alkylation data for most pyrrolic derivatives does not fit a simple first 
order but rather a biexponential equation. 41 A typical plot of both equations is shown 
in Figure 10. Table 1 contains alkylation rate data (71) previously collected 
by Deinzer for monocrotaline (5) and retronecine (1). 
First order: 	C = coo - Coo e -k t 
Biexponential: 	C = Coo - 	- )92e72t 
Mattocks originally proposed that two competing processes were taking place: 
reaction of the nucleophile with the pyrrolic ester and hydrolysis of the pyrrolic ester 
followed by a slower reaction of the pyrrolic alcohol with the nucleophile (Scheme 5). 
Deinzer 41,42 collected rate data for retronecine that also fit a biexponential equation 
which does not fit the hydrolysis mechanism proposed by Mattocks. 
	
Table 1. 	Literature Alkylation Rate Data (ii and 72) 
Pyrrole 	 11 	•i2 	Temp. 	ref. 
Dehydromonocrotaline 0.56 0.004 30°C 41 
0.23 0.0013 20°C 42 
Dehydroretronecine 0.34 0.006 30°C 41 
0.33 0.005 30°C 42 
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Figure 10. Plot of Typical Rate Equations 
Deinzer 4 I has proposed the alkylation of polymeric pyrroles for the second reaction 
giving an adduct similar to compound 48. Both agree that the first reaction is the 
alkylation reaction of interest. Neither group has made correlations between antitumor 









Scheme 5. Alkylation Reaction of PAs with NBP 
48 
Figure II. Alkylated Polymer Adduct 
17 
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DNA damage has been measured for many PAs, usually those which have shown 
high toxicities. 2 PAs which damage DNA are also hepatotoxic and metabolic activation 
seems to be necessary for maximum damage to DNA. The DNA damaging ability of 
pyrrolic derivatives resembles mitomycin C, itself an antitumor agent. 43 Not all test 
have proven effective in measuring DNA damaging ability. Some pyrrolic derivatives 
may be too reactive to give a positive result, reacting with cell membranes or 
polymerizing before entering the cell. Dehydromonocrotaline reacts quickly with the 
mucopolysaccaride surface of ameoba as shown by electron microscopy. 2 No 
correlations between DNA cross-linking or strand-breaking and antitumor activity have 
been made. 
In our continuing efforts to understand the mechanism of antitumor activity and to 
find PAs with increased potency and decreased toxicity, we have synthesized many 
semisynthetic PAs. There are several methods by which PAs may be prepared. 
Culvenor et a/. 34 reformed heliotrine in 50 % yield by refluxing 9-chloroheliotridine 
with the sodium salt of heliotric acid. The high reactivity of allylic halides makes this 
method possible and thus does not work for saturated necines. Another method for 
the formation of monoesters is the reaction of a necine with a stoichiometric amount 
of acid chloride in pyridine. Excess acid chloride and heat gives the diester. Hoskins 
and Crout 44 have used dicyclohexylcarbodiimide and carbonyldiimidazole (CDI) to effect 
esterification of retronecine exclusively at the C9 position. Our research grou p24,25 
has also used CDI to prepare C9 esters from retronecine and acids containing a tertiary 
alcohol group. The usefulness of this method is dependent on the relative reactivities 
of the primary, allylic alcohol at C9 verses the sterically hindered secondary alcohol at 
C7. 
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Scheme 6. Esterification of 9-Chloroheliotridine 
1 
	 52 










    
55 
Scheme 8. Esterification of Retronecine with CDI 






Although there are several elegant total syntheses of retronecine, it was more 
readily available from naturally occurring PAs such as monocrotaline and INO (3). 
Monocrotaline was isolated from the seeds of Crotalaria spectabilis. 45 Hydrolysis of 
monocrotaline gave retronecine. INO (3) was obtained as a gift from Dr. Matt 
Suffness, Head, Plant and Animal Products Section, Natural Products Branch, 
Developmental Therapeutics Program, National Cancer Institute. Reduction of INO 




Scheme 9. Alkaline Hydrolysis of Monocrotaline 
Scheme 10. Reduction and Alkaline Hydrolysis of INO 
21 
The new necic acids, a-aromatic-a-hydroxycarboxylic acids, were modeled after the 
necic acid, (-)-(2R,3S)-trachelanthic acid, from INO (3). The most common method 
for preparing a - hydroxy carboxylic acids, as shown in Scheme 11, is the formation of a 
cyanohydrin from a ketone followed by hydrolysis of the cyano group to an amide 
group then to a carboxyl group. 46 Thus (t)-2-hydroxy-2-phenylbutyric acid was 
prepared from propiophenone. 47 Other a-hydroxy acids have been prepared in this 
manner by our group. 4 • 9 Resolutions of the racemic acids were carried out using 
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Figure 12. Comparison of (-)-Trachelanthic Acid with 






1) HO conc. 
2) NaOH conc. 




Scheme 11. Synthesis of a-Hydroxy Acids 
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In order to better understand the possible modes of antitumor action, new 
semisynthetic PAs were synthesized and their antitumor structure-activity relationships 
were investigated. It was desirable to reinvestigate the antitumor structure-activity 
relationships of INO (3), indicine (6), and monocrotaline (5), as well as some of the 
semisynthetic PAs previously reported, and to correlate these with cytotoxicity, alkylating 
ability, metabolism, and DNA-damaging effects (DNA cross-linking and DNA strand-
breaking). 
THE DETERMINATION OF THE PARTITION COEFFICIENTS FOR 
A VARIETY OF PYRROLIZIDINE ALKALOIDS AND THE RELATIONSHIP 
OF THESE VALUES TO THE ANTI-TUMOR ACTIVITY OF THE ALKALOIDS 
A THESIS 
Presented to 
The Faculty of the Division of Graduate Studies 
By 
Edward Thomas Ryan 
In Partial Fulfillment 
of the requirements for the Degree 
Master of Science in Chemistry 
Georgia Institute of Technology 
July, 1988 
i v 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS 	  iii 
LIST OF TABLES AND SCHEMES 	 vii 
LIST OF FIGURES 	  viii 
LIST OF ABBREVIATIONS 	  
SUMMARY 	 xii 
CHAPTER 
I. INTRODUCTION 	  1 
II. GENERAL METHODS 	 9 
III. EXPERIMENTAL 	 12 
Preparation of Retronecine 	 12 
Preparation of Retronecine N-oxide 	 12 
Preparation of Semisynthetic Pyrrolizidine Alkaloids: 
Resolution of (±)-2-hydroxy-2-phenylbutyric acid 	13 
9-0-[R-(-)-2-hydroxy-2-phenylbutyryl]retronecine  14 
9-0-[R-(-)-2-hydroxy-2-phenylbutyryl]retronecine N-oxide 	15 
9-0-[S-(+)-2-hydroxy-2-phenylbutyryilretronecine 	15 
9-0-[S-(+)-2-hydroxy-2-phenylbutyryl]retronecine N-oxide 	16 
9-0-[(±)-2-hydroxy-2-phenylbutyryl]retronecine 	  16 
9-0-[(±)-2-hydroxy-2-phenylbutyryl]retronecine N-oxide 	16 
Resolved (±)-2-(4'-chlorophenyl)-2-hydroxybutyric acid 17 
9-0-[(±)-2-(4'-chloropheny1)-2-hydroxybutyryl] 
retronecine 	 17 
9-0-[(±)-2-(4'-chloropheny1)-2-hydroxybutyryl] 
retronecine N-oxide 	 18 
9-0-[R-(-)-2-(4'-chlorophenyl)-2-hydroxybutyryl] 
retronecine 	 18 
9-0-[R-(-)-2-(4'-chloropheny1)-2-hydroxybutyryl] 
retronecine N-oxide 	 18 
9-0-[S-(+)-2-(4'-chloropheny1)-2-hydroxybutyryl] 
retronecine 	 19 
9-0-[S-(+)-2-(4'-chloropheny1)-2-hydroxybutyryl] 
retronecine N-oxide 	  19 
9-0-[(±)-2-(4'-chloropheny1)-2-hydroxypropionyl] 
retronecine 	  19 
9-0-[(±)-2-(4'-chloropheny1)-2-hydroxypropionyl] 
retronecine N-oxide 	 20 
Preparation of 0.1 M Phosphate Buffer pH = 7.40 	 20 
Saturation of 1-octanol / 0.1 M Phosphate Buffer 21 
Persilation of C-18 corasil 	  21 
High Pressure Liquid Chromatograph (HPLC) Parameters 	21 
IV. PARTITION COEFFICIENT DETERMINATIONS OF PYRROLIZIDINE 
ALKALOIDS AND RELATED COMPOUNDS 	 23 
Calculations of the Partition Coefficients for: 
9-0-[(±)-2-(4'-chloropheny1)-2-hydroxybutyryl] 
retronecine N-oxide 
9-0-[(±)-2-(4 1 -chloropheny1)-2-hydroxybutyryl] 
retronecine 
9-0-[(±)-2-(4'-chloropheny1)-2-hydroxypropionyl] 
retronecine 	  
9-0-[(±)-2-(4'-cnioropheny1)-2-hydroxypropionyll 




retronecine N-oxide 	  
9-0-[(±)-2,2-dipheny1-2-hydroxyacetyl] 
retronecine 	  
9-0-[(±)-2,2-dipheny1-2-hydroxyacetyl] 
retronecine N-oxide 	  
9-0-[(±)-2,3-dipheny1-2-hydroxypropiony1] 
retronecine 	  
9-0-[(±)-2,3-dipheny1-2-hydroxypropionyl] 




retronecine 	  
9-0-[R-(-)-2-hydroxy-2-phenylbutyryl] 
retronecine N-oxide 	  
9-0-[S-(+)-2-hydroxy-2-phenyibutyryl] 






retronecine N-oxide  
9-0-[R-(-)-2-(4'-chlorophenyl)-2-hydroxybutyryl] 






















Retronecine N-oxide 	 37 
Indicine 	 37 
Indicine N-oxide 	 37 
Monocrotaline 38 
Monocrotaline N-oxide 	 38 
HPLC Partition Coefficient Determinations 	 40 
HPLC PCs on a Corasil C-18 column 	 40 
HPLC PCs on a Alltech C-18 column 41 
V. HPLC-MS ANALYSIS OF PYRROLIZIDINE ALKALOIDS 	 69 
VI. DISCUSSION OF RESULTS 	 82 
REFERENCES 	 93 
x i i 
SUMMARY 
The variations in the anti-tumor activity of a variety of 
pyrrolizidine alkaloids (PAs), and the uncertainty surrounding the 
anti-tumor mechanism of action for these compounds were the impetus for 
undertaking this study. 
The purpose of this endeavor was to determine if there was a 
correlation between a compound's anti-tumor activity and its 
lipophilic-hydrophilic balance, a physical property that is expressed 
by a partition coefficient (PC). 
The C-9 monoesters of retronecine were prepared, via a site 
selective coupling of alpha-hydroxy acids with the primary hydroxyl 
functionality on retronecine using 1,1'-carbonyldiimidazole. The anti-
tumor activity of these compounds has been determined using the P388 
lymphocytic leukemia system. Therefore, what remained was to measure 
the partition coefficients of the PAs. 
The partition coefficients were measured for various semisynthetic 
PAs, as well as some PAs that were isolated as natural products, using 
the shake flask method. A second procedure for measuring the partition 
coefficients was also developed, due to limitations that are involved 
with the shake flask method. This procedure employed a reverse phase 
high performance liquid chromatography technique. 
A comparison of the antitumor activity of the PA's with their 
partition coefficients revealed that the activities are the greatest 
when the PC's are in the range of 1.36 to 2.17, with the only exception 
being the para-fluoro analog. 	Although, with the data available, one 
cannot state unequivocally that the PC alone will determine activity, 
there does appear to be a noteworthy relationship. 	in addition, 
compounds with PC's of 0.02 to 0.60 were inactive at the doses 
measured. 
A HPLC-MS interface demonstrated that a variety of PAs were 
unchanged when injected on a C-18 column and also, that a mixture of 
PAs could be separated sufficiently to obtain the mass spectrum. 
CHAPTER VI 
DISCUSSION OF RESULTS 
Partition coefficients were determined for a variety of 
pyrrolizidine alkaloids and the corresponding N-oxides. Two separate 
procedures were used; the shake flask method and a high pressure liquid 
chromatography technique. The latter proved much more efficient and 
gave results that were consistent with the standard shake flask values. 
The partition coefficients determined have been tabulated and appear on 
the following page, in Table 1. 	The partition coefficients for 
compounds 10 and 32 have been previously determined, by Mattocks, A. 
R.; Bird, I. Chem. Biol. Interact. 1983, 43, 217, and these values are 
in agreement with our values. These workers determined the partition 
coefficients by the shake-flask method, but they determined the 
concentrations by potentiometric titration. Prior to this work, there 
were no reports in the literature concerning the partition coefficients 
of pyrrolizidine alkaloid N-oxides. 
The main purpose of this study was to compare the partition 
coefficients of pyrrolizidine alkaloid N-oxides with tumor activity 
data, in the hope of finding a relationship that would enable one to 
enhance the compounds activity by tuning its absorption and transport 
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NUMBERS SHAKE FLASK 
"COMMERCIAL COLUMN" 
HPLC 
3 0.04 	± 	0.01 0.04 
13 0.02 	± 	0.01 0.01 
11 0.13 	± 	0.02 0.12 
10 0.05 ± 0.02 0.04 
32 0.29 	± 	0.05 0.29 













TABLE 1 (Continued) 
COMPOUND 	 "COMMERCIAL COLUMN" 
NUMBERS SHAKE FLASK 	 HPLC 
34 	1.00 ± 0.12 
35 	0.25 ± 0.07 
27 	3.00 ± 0.61 
28 	 1.36 ± 0.09 
21 	 6.75 ± 0.72 
	
8.02 
22 	 1.78 ± 0.45 
	
2.07 
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TABLE 1 (Continued) 
COMPOUND 	 "COMMERCIAL COLUMN" 
COMPOUND 
	
NUMBERS SHAKE FLASK 	 HPLC 
37 	1.40 ± 0.17 1.30 
38 	 10.66 ± 1.81 
39 	2.34 ± 0.44 
25 	 7.38 ± 0.57 
26 	 1.93 ± 0.31 
23 	 8.00 ± 0.69 
24 	 2.17 ± 0.39 
0 
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SHAKE FLASK 	 HPLC 
17 1.35 ± 	0.17 
18 0.60 ± 	0.09 
15 8.00 ± 0.69 
16 0.65 ± 	0.03 
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properties. The following is a discussion of the antitumor screening, 
and its relationship to the partition coefficients. 
All of the screening data in Table 2 was obtained from the 
National Cancer Institute (NCI), and National Institutes of Health, 
except for those indicated with a superscript B, which were screened at 
Mitsubishi Chemical Company of Japan. 	In two cases (entries 6 and 10) 
the same compounds were screened at both places. For comparison 
purposes, low and comparable dose levels were selected. At low dose 
levels, the model compound indicine N-oxide is known to be inactive, 
whereas the semisynthetic pyrrolizidine alkaloids, such as entries 5-
15, have been shown to show much greater potency than indicine N-oxide. 
Indeed, indicine N-oxide only shows activity at very high doses and 
this was one of the incentives for our laboratory to study 
semisynthetic analogues. Only N-oxides were screened at NCI because of 
the anticipation that free bases would show severe hepatotoxicity as 
seen in the natural alkaloids. NCI does not consider any compound with 
a T/C less than 130 to be of sufficient merit to pursue. 	It should be 
kept in mind that in all screening of this type that there is rather 
large degree of variability and this can be seen for entries 6 and 10 
where the same compounds were screened at the two different places. 
This has also been true in screening of the same compounds at different 
times by NCI. 	In spite of this, reproducible trends have been 
observed. 
With the exception of the para-fluoro analog, entry 5, Table 2 
shows that the most potent compounds show PC's of about 1.36-2.17. 
H,C OH 
I 	I 
CO OH CO 
0 CH,-0 
5 
H 3 C OH 
CH 3 -CH--Q-C-CH3 
CO OH CO 
0 CH, - 0 
4 
GCSE 	PER 	INJECTION 
MG/KG 7/C 	(%) P.C. 
67 110 ° 0.04 
67 99 ° 0.02 
67 97 B 0.29 
67 998 0.15 
87 160 0.25 
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170 1.40 
94 170 2.34 
200 113 0.05 
75 149 
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Table 2 (Continued) 
DOSE PER INJECTION 
MG/KG T/C 	(%) P.C. 
62.5 114 0.60 
81 169 0.65 
50 152 1.78 
60 187 2.17 
60 141 1.93 
A 
 Screening was carried out under the auspices of the National 
Cancer Institute except where otherwise noted. For detailed 
explanations of procedures and data, see Instruction 14, Screening Data 
Branch, Developmental Therapeutics Program, Division of Cancer 
Treatment, National Cancer Institute, Bethesda, MD 20205. c Q01Dx09. 
Single dose for 9 days, given in milligrams/kilogram per injection. 
aThis data was obtained by Mitsubishi Chemical Company, Tokoyo, 
Japan. 
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The most potent compounds show PC's of about 1.36 - 2.17 although 
the p-fluoro analog, entry 5, Table 2, is an exception to this rule. 
Clearly, those compounds with PC's of 0.02 - 0.06 are inactive at the 
doses measured. Obviously, with the data obtained to date, we cannot 
state that the PC alone can be used to determine the potency of the 
alkaloids, but alkaloids with PC's in the 1-2 range generally do 
display noteworthy anti-tumor activity. 
The agreement of the labor intensive shake flask results with the 
much more efficiently obtained HPLC results demonstrates the ever 
expanding utility of high performance liquid chromatography. Another 
example of the HPLC's utility was demonstrated with the HPLC-MS, MAGIC, 
interface. The spectra obtained demonstrated that the PA's were indeed 
stable on the C-18 column, and that a mixture of the compounds could be 
separated and identified by what should prove to be a very useful tool 
for further exploration of the chemistry and biochemistry of the PA's. 
The most active compounds were mildly lipophilic. As previously 
mentioned, increasing the lipophilicity of PA's does increase their 
ability to form pyrroles, and the subsequent alkylation of biopolymers 
might be the mechanism behind the antitumor activity. 	In addition, an 
increase in lipophilicity of PA's will enhance their potential for 
being transported across the lipophilic cell wall; a necessary step if 
alkylation is to occur. Although, the compounds must not be too 
lipophilic or they will not be very soluble in the blood plasma, which 
will ultimately limit the biological systems ability to transport the 
compound throughout the body. A mildly lipophilic PA appears to be an 
92 
ideal antitumor drug, since its lipophilicity will allow it to readily 
undergo pyrrole formation, while still retaining enough hydrophilic 
character to be transported throughout the vascular system. At this 
time, it is not known how the N-oxides are transformed into the 
pyrrolic species or why the N-oxides show increased activity over the 
free bases. There is, at the present, no direct evidence for pyrrole 
formation directly from N-oxides. Although, one could imagine a two 
step mechanism consisting of the previously discussed formation. 	This 
s probably not what is occuring since free bases and their 
corresponding N-oxides are known to have different activities. 
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SUMMARY 
Part I. The pyrrolizidine alkaloid (PA) indicine N-oxide (INO, 8) has been 
shown to be effective against advanced gastrointestinal cancer, and in cases of 
leukemina and melanoma. In order to better understand the structural features 
necessary for the antitumor activity, new PA analogues modeled on INO were 
prepared and tested for their antitumor activity. Modifications of the necic acid 
portion and the necines are described. 
Work has focused on the substituent relationships of C-9 monoesters of 
retronecine (I), where aromatic functionalities have been introduced to the necic 
acid portion. The a-hydroxy-a-aryl-a-alkyl acetic acids were prepared by the by 
hydrocyanoation of the appropiate arylphenone under equilibrating conditions with 
HCN or non-equilibrating conditions with TMSCN, then hydrolysis to the a-hydroxy-
acid, or by autooxidation of the appropiate 2-benzyl-4,4-oxazoline, treatment with a 
Grignard, and hydrolysis to the a-hydroxyacid. The a-hydroxyacids were 
site-specifically coupled to retronecine using carbonyldiimidizole (CDI), and oxidized 
to the N--oxide. Compounds containing substituents in the para position of the 
aromatic ring were prepared to improve on the activity of INO. Derivatives 
containing a para substituted halogen showed considerable improvement in potency 
over INO and significant increases in antitumor activity in the P388 leukemia 
system. Optical resolution of the a-hydroxyacid, then site-specifically coupling to 
retronecine, showed the R configuration at C2' of the side chain confers greater 
activity than the S in the P388 leukemia system. 
C-9 platynecine N-oxide esters were inactive in the P388 leukemia system, thus 
it appears, that the Cl -C2 double bond must be present. 
xvii 
xviii 
The necines prepared for this study were retronecine (1), platynecine (60), 
desoxyretronecine (56), and retronecanol (57) starting from the natural products, 
monocrotaline (4) or INO. The 1 H and I3C NMR analysis of these compounds 
• are included. 
Part II. The reinvestigation of the plant extract of Eupatorium rugosum was 
undertaken to search for the toxic component using a wine yeast respiration 
inhibition assay to guide fractionation. The most inhibitory component isolated was 
hydroxytremetone. Related benzofurans from other sources were purified and 
assayed for comparison to the inhibitory effect of hydroxytremetone. It appears the 
the mechanism of inhibition exhibited by hydroxytremetone is at the coenzyme Q 
site but is less potent than rotenone. 
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SUMMARY 
Ten 12-membered macrocyclic pyrrolizidine alkaloids (PAs) based either on 
retronecine or otonecine were obtained from Senecio anonymus Wood. They are 
senecionine (8), integerrimine (9), retrorsine (10), usaramine (11), senkirkine (12), 
neosenkirkine (13), otosenine (14), hydroxysenkirkine (15), hydrozyneosenkirkine (16), 
and anonamine (17). Eight of these constitute four pairs of double bond isomers. 
Separation of the isomers was achieved by droplet counter current chromatography 
(DCCC). 
From three Middle Eastern plants 9 mono- and diesters (non-macrocyclic) 
based on heliotridine were obtained. The PAs from Cynoglossum creticum were 
echinatine (18), rinderine (19), 7-angelylheliotridine (20), cynoglossamine (21) and 
heliosupine (22). Echinatine and heliosupine were previously isolated from this plant. 
From Nei:wraprum arbainense were isolated the PAs europine (23) and lasiocarpine 
(25) . In addition to europine, heliotrine (24) and 5'-acetyleuropine (26) were found 
in Heliotropium rorundifolium. 
Four of the alkaloids namely: anonamine, hydroxyneosenkirkine, cynoglossamine 
and 5'-acetyleuropine were isolated for the first time. 
Separation methods used were preparative TLC, column chromatography, high 
performance liquid chromatography (reverse phase) and droplet counter current 
chromatography. Structure elucidation was obtained by a combination of the following 
methods: spectroscopic analyses (proton and carbon NMR, MS, IR), comparison with 
authentic samples, x-ray crystallography, degradation reactions and synthesis. 
xvi 
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The technique of 1 H- 13C heteronuclear shift correlated NMR spectroscopy 
(hetcor) enabled the unambiguous assignment of chemical shifts of all hydrogen 
containing carbons in the 13C NMR spectra of isolated alkaloids and semi-synthetic 
analogues. Based on hetcor data, a reassignment of some chemical shifts in the I 3C 
NMR of previously reported pyrrolizidine alkaloids was done. 
X-ray structures were obtained for the seco-pyrrolizidines neosenkirkine (13), 
hydroxysenkirkine (15) and anonamine (17). These included molecular packing 
structures which showed hydrogen bonding involving the C8 carbonyl group. From 
these studies and some literature data, comparative values of the N4-Cg distances of 
seven seco-pyrrolizidines were obtained. Hydroxysenkirkine was shown to have the 
shortest N4-Cg distance, and this was correlated with the presence of an additional 
H-bond involving the C8 carbonyl. 
The isomers of echinatine were prepared by the site-specific coupling of 
heliotridine with the isopropylidine derivatives of the necic acids in the presence of 
carbonyldiimidazole (CDI). The synthesis was needed to identify an echinatine-like 
isolate from C. crencum. Facile identification of rinderine was obtained as a result of 
the synthesis of the isomers. 
For the structure elucidation of the new alkaloids cynoglossamine and 
5'-acetyleuropine, several related semi-synthetic analogues were prepared. 
In vitro anti-cancer screening of most of the isolated alkaloids and some 
semi-synthetic compounds were done by Dr. Garth Powis at the Mayo Clinic in 
Rochester, Minnesota. The screening was conducted with continuous human tumor 
cell lines (A204-rhabdomyosarcoma). Results showed the compounds to be less 
cytotoxic than most of the pyrrolizidines tested, except for cynoglossamine which was 
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Fig. 3. Pyrrolizidine Alkaloids from Heliotropium arbainense 
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Fig. 6. Europine Derived Compounds 
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Fig. 7. Non-Alkaloidal Compounds from Senecio anonymus Wood 
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CHAPTER V 
CONCLUSIONS AND RECOMMENDATIONS 
Ten 12-membered macrocyclic pyrrolizidine alkaloids (PAs) based either on 
retronecine or otonecine were obtained from Senecio anonymus Wood. Eight of these 
constitute four pairs of cis -tram  isomers, namely senecionine and integerrimine, 
retrorsine and usaramine, senkirkine and neosenkirkine, and, hydroxysenkirkine and 
hydroxyneosenkirkine.The other two are otosenine and anonamine. Except for 
hydroxyneosenkirkine and usaramine whose characterization were limited to 1 H NMR 
data due to minute quantities isolated, all the rest were fully characterized by means 
of 1 H- 13 C heteronuclear correlated NMR, EIMS and CIMS, as well as exact mass 
determinations, and optical rotations. In addition, for the compounds neosenkirkine 
(13), hydroxysenkirkine (15) and anonamine (17), their x-ray structures were obtained. 
Hydrogen bonding structures involving the C8 carbonyl were clearly shown in the 
molecular packing structures. The degree of hydrogen bonding was correlated with 
the shortening of the Cg...N4 distance, which in turn, gives evidence for the 
transannular interaction attributed to the seco-pyrrolizidines. Hvdroxysenkirkine, was 
shown to have the shortest transannular C8...N4 bond. 
It would be interesting to crystallize hydroxysenkirkine in an aprotic solvent, for 
x-ray crystallographic studies, to see the effect on the C...N distance. Alternatively, the 
hydroxyl groups can be esterified to eliminate hydrogen-bonding properties and 
see how the C...N distance is affected. 
123 
The use of droplet counter current chromatography (DCCC) was shown to be 
a very powerful tool for the separation of cis-trans isomers. Previous attempts to 
separate the diastereomers using different chromatographic techniques (gravity column, 
preparative TLC, radial, centrifugal TLC and reverse phase HPLC) all proved futile. 
Excellent yields of high purity compounds were obtained from the DCCC separation 
of crude alkaloid mixtures, making possible the in-vitro anti-tumor screening of the 
isolated alkaloids. 
Anonamine and hydroxyneosenkirkine are two new alkaloids, isolated for the 
first time. With more plant material it may be possible to obtain enough sample of 
hydroxyneosenkirkine to sufficiently characterize it. 
An interesting non-alkaloidal compound ( 31) was obtained from Senecio 
anonymus. Further studies on this compound is recommended. It is possible that the 
source of the compound is jacaranone (32), which is a constituent of the plant. 
The mechanism of the transformation of jacaranone during the work-up of the plant 
material can be investigated. Since jacaranone has been shown 24 to have significant 
antitumor activity, jacaranone related compounds can also be screened for anti-tumor 
activity. 
From the three Middle Eastern plants were obtained nine mono-and diesters 
(non-macrocyclic) of heliotridine. The PAs from Cynoglossum creticum were 
echinatine, rinderine, heliosupine, 7 - angelyl heliotridine and cynoglossamine. 
Cynoglossamine is an interesting new pyrrolizidine alkaloid which contains an 
aromatic acid esterifying a hydroxy group of the C9 esterifying acid. 
From Heliotropturn arbainense were isolated the PAs europine and lasiocarpine. 
In addition to europine, heliotrine and 5'-acetyl europine were found in Heliotropium 
rotundifolium. 
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Several semi-synthetic compounds were obtained in the process of confirming 
the structures of cynoglossamine and 5'-acetyleuropine. 
The technique of 1 1-I- 13C heteronuclear correlated NMR was very useful in 
unambiguously assigning chemical shifts in the 13 NMR of both isolated alkaloids 
and the semi-synthetic analogues. The resulting 13C NMR data unifies the previously 
available literature data on 13C NMR of a number of pyrolizidine alkaloids 
encountered in this study, which contains numerous conflicting assignments. 
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ABSTRACT 
Indicine N-oxide (INO) is a pyrrolizidine alkaloid (PA) with 
antitumor activity in animals and man. Prior studies showed that 
despite the known hepatic toxicity of the PAs, INO did not 
produce hepatic toxicity in animals but caused unpredictable 
lethal hepatic toxicity in humans. Tn this study we have 
attempted to find a model system for predicting the hepatotoxic 
potential of antitumor PAs. Primary cultures of rat hepatocytes 
showed toxicity only with the most hepatotoxic PAs such as 
laisiocarpine, but did not detect toxicity with other PAs. 
Subchronic intraperitoneal administration of PAs to weanling rats 
and adult mice gave in surviving animals hepatic megalocytosis 
and centrilobular necrosis with heliotrine (H) and 9-0-(R(-)- 
2-(4'-chloropheny1)-2-hydroxybutyryl)retronecine N-oxide (RC1NO) 
but only megalocytosis with INO. Thus, despite previous reports 
weanling rats offered no advantage over adult mice for detecting 
significant hepatic toxicity with PAs. Phenobarbital 
pretreatment of the mice did not increase the hepatic toxicity of 
any of the PAs. Subchronic oral administration of PAs to adult 
mice produced hepatic megalocytosis and centrilobular necrosis in 
surviving animals with H and RC1NO and megalocytosis with INO. 
Animals that died acutely following oral administration of INO 
showed hepatic centrilobular necrosis. Administration of several 
3 
courses of INO intravenously to dogs produced histological 
evidence of centrilobular hemorrhagic necrosis. It is concluded 
that there is no single animal model that will predict hepatic 
toxicity of the type seen in humans with the antitumor PAs. A 
combination of studies using adult mice and dogs, and lethal 




Pyrrolizidine alkaloid bases and pyrrolizidine alkaloid N-
oxides (PAs) are a widely distributed, diverse group of 
phytotoxins known for their health hazard to man, fowl and 
livestock (Bull et al., 1968). Over 180 different PAs have been 
isolated (McLean, 1970; Phillipson and Handa, 1978). The most 
common mammalian toxicity of PAs is to the liver. A single large 
dose of PA to animals can cause an acute massive centrilobular 
necrosis (Bull et al., 1958a; Davidson, 1935) and death of the 
animal within a few days (Bull and Dick, 1959; Bull et al., 
1958b; Schoental and Magee, 1957). Animals that survive the 
acute toxicity (Schoental and Magee, 1957), or animals 
chronically exposed to lower doses of PAs (Bull and Dick, 1959), 
develop hepatic megalocytosis, bile duct proliferation and 
hepatic tumors (Jago, 1971; Rao and Reddy, 1978; Reddy et al., 
1976). The hepatic megalocytosis can occur without signs of 
hepatic necrosis (Bull et al., 1958b; Jago, 1969). Pyrrolizidine 
alkaloid N -oxides produce similar hepatotoxic effects but at 
higher doses than pyrrolizidine alkaloid bases (Bull and Dick, 
1959; Schoental and Magee, 1959). Lesions comparable to the 
veno-occlusive disease in humans who consume "bush teas" prepared 
from plants containing PAs (Bras et al., 1957) and in domestic 
animals that consume such plants (Mattocks, 1986) have been seen 
in experimental animals as fibrous thickening of the walls of 
central hepatic veins and occasional occlusion of the veins 
(Schoental and Magee, 1959). 
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PYRROLIZIDINE ALKALOIDS FROM CYNOGLOSSUM CRETICUM. 
SYNTHESIS OF THE PYRROLIZIDINE ALKALOIDS ECHINATINE, 
RINDERINE, AND ANALOGUES' 
CLARITA F. ASIBAL, JAN A. GLINSKI, 2 LESLIE T. GELBAUM, and LEON H. ZALKOW * 
School of Chemistry, Georgia Institute of Technology, Atlanta, Georgia 30332 
ABSTRACT.—Reinvestigation of Cynoglossum creticum led to the isolation of the previously 
reported echinatine [1] and heliosupine [21 as well as rinderine [31, 7-angelylheliotridine [41 
and a new alkaloid, cynoglossamine [5]. The structures have been determined by spectral means 
(ir, ms, 'H- 13C HETCOR nmr), comparison with literature data and authentic samples, and/or 
syntheses. In addition, 1 and all three of its isomers 3, 6, and 7 and other semisynthetic 
analogues (8-13) were prepared and characterized. 
The pyrrolizidine alkaloids (PAs) are widely distributed in the plant kingdom ( I). 
Their broad range of pharmacological activity, including hepatotoxicity and antitumor 
activity, has attracted considerable attention (2). Our group has been involved in both 
isolation of PAs from plants (3) and the preparation of semisynthetic analogues (4,5) for 
antitumor screening. In a previous investigation (6), only the major alkaloids 
echinatine [1] and heliosupine [2] were isolated from Cynoglossum creticum 
(Boraginaceae), identified by Dr. A. Danin, Department of Botany, The Hebrew Uni-
versity of Jerusalem, Israel. In this paper we report three minor alkaloids, including a 
new one, as well as the structures of some semisynthetic analogues. 
The crude alkaloid fraction obtained from the zinc/H 2 SO4 reduction of the EtOH 
extract of C. creticum was separated by a combination of droplet counter-current 
chromatography (dccc) and radial centrifugal tic. Monitoring of fractions was done by 
tic and'H-nmr analyses. The isolated compounds, in order of elution from the dcc 
chromatograph, were echinatine N-oxide, heliosupine N-oxide, echinatine [1], rin-
derine [3], the new compound cynoglossamine [5), 7-angelylheliotridine [4), and 
heliosupine [2]. The identities of the previously reported compounds 1, 2, and 4 were 
established by high resolution nmr and ms, as well as comparison with literature data 
and/or authentic samples, and the structure of 3 was established by synthesis. The pres-
ence of N-oxides of 1 and 2 obviously suggests incomplete reduction of the plant extract. 
The N-oxides of 1 and 2 showed H-nmr spectra similar to those of the correspond-
ing free bases, differing significantly only in the region 8 2.6-4.6, with the former 
showing absorption in the downfield region. Confirmation of the structures of the N-
oxides was obtained by the correspondence of their 'H-nmr spectra with those of the N-
oxides obtained from m-chloroperbenzoic acid oxidation of the free bases 1 and 2. 
Compound 3 was sliown to be an isomer of 1 by its molecular ion peak ([M) + 299) 
and very similar 'H-nrnr spectrum, differing significantly only in the chemical shift 
positions and patterns of its H-9 and isopropyl methyl signals. The equivalent iso-
propyl methyl groups (H-6' and H-7' both at 6 0.91 d) and the H-9 pattern (8 4.86, 
4.87 ABq) in 3 suggest a trachelanthyl moiety, in contrast to the viridifloryl moiety in 
1 (5,7). Unequivocal identification of the necic acid as (+)-trachelanthic acid in 3 was 
obtained by synthesis. All four C-9 isomers {(+)- and (--)-viridifloryl and (+ )- and 
(—)-trachelanthyl heliotridinel were prepared by coupling heliotridine and the enan- 
'Taken from the Ph.D. dissertation of Clarita Florendo Asibal, School of Chemistry, Georgia Insti-
tute of 	Atlanta, Georgia, 1987. 
2 Present Address: Boehringer Ingelheim (R&D), 90 Fast Ridge, P.O. Box 368, Ridgefield, Connec-
ticut 06877. 








tiomerically pure necic acids in a manner similar to that used for the preparation of the 
retronecine analogues (5). Thus, the heretofore unknown isomers 6 and 7 have also 
been characterized. 
The (+)- and (—)-trachelanthyl esters 3 and 6, respectively, are readily distin-
guishable (Table 1) from their H-9 AB quartet patterns, with a chemical shift differ-
ence (Av 1 , 9) between the component doublets of 0.02 and 0.31 ppm, respectively. The 
large differences in the magnetic environments of the C-9 protons of the two dia-
stereomers could reflect their preferred solution conformations (4). on the other hand, 
the (+)- and (—)-viridiflorate esters 7 and 1, respectively, show almost identical H-9 
patterns of widely separated doublets, Av H9 = 0.30 and 0.22 ppm, respectively. Ready 
differentiation of 1 and 7 could be shown by the patterns of the H-9 protons in their 
corresponding protected isopropylidene esters: in 1-isopropylidine these appear at 6 
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TABLE 1. 1 H nmr (300 MHz) of Isolated Pyrrolizidine Alkaloids and Semisynthetic Analogues. 
"u = upheld; d =downfield. 




7 12 13 1 2 3 5 9 10 11 
C-1  	135.87 134.09 135.91 135.56 135.86 136.08 134.16 136.06 134.09 134.88 136.00 
C-2  	125.45 129.57 126.92 127.03 126.92 126.32 127.87 126.97 127.78 128.34 127.00 
C-3 61.88 (62.12)' 61.72 61.61 61.79 61.66 62.83 62.03 62.53 62.39 62.38 
C-5 54.16 54.16 54.14 54.04 54.27 54.25 53.89 54.51 53.70 54.29 54.37 
C-6  	33.59 30.20 33.14 33.84 33.77 33.79 36.14 34.39 34.30 30.73 34 28 
C-7 	  74.06 (76.94)". 74.73 74.90 74.13 74.64 71.18 75.22 73.90 77.11 75.26 
C-8  79.62 (79.03)' 79.97 79.72 80.05 79.84 78.60 80.25 75.64 78.74 80.08 
C-9 	  61.59 (62.48)a 62.15 62.02 62.14 61.87 63.43 62.46 62.13 62.23 61.92 
C-1'  173.72 174.01 175.15 173.43 175.22 174.29 174.43 173.68 175.06 174.59 173.63 
C-2'	  83.98 82.76 83.38 82.57 83.38 83.97 81.77 82.61 83.05 83.82 82.39 
C-3'  71.36 69.73 69.43 73.85 69.51 71.59 71.82 74.32 69.35 71.09 74.09 
C-4' 	  (17.40)' 18.56 17.03 15.34 16.91 17.53 14.58 15.59 17.21 17.46 15.47 
C-5'  32.28 73.76 33.06 32.89 33.12 32.16 32.49 33.19 32.93 32.53 33.17 
C-6' 	  17.87 26.00 17.15 16.08 17.13 17.77 	17.40 16.39 17.09 16.27 16.36 
C-7'  (15.79)". 24.84 17.03 17.50 17.13 15.88 16.53 17.76 16.88 17.95 17.67 
C- 168.05 167.09 165.63 166.67 166.01 167.06 	168.34 
C-7" 	  127.33 114.19 117.63 118.09 117.60 117.91 114.45 
C-3"  138.94 145.75 145.49 145.74 145.49 145.83 145.29 
C-4" 	  15.98 125.78 132.09 134.51 133.11 134.47 130.42 
C-5"  20.55 130.21 (1.28.85) b (129.19) 6 (128.89) b (129.21) b 130.29 
C-6" 	  116.17 (128.77) b (128.42) h (128.14)b (128.43) h 116.42 
C-7"  159.87 (130.36) b (130.70 (130.52) b (130.78) b 160.26 
C-8" 	  170.78 
C-9"  21.40 
`Interchanged in Mohanraj and Herz (7). 
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(Av H9  = 0.24). This pattern is analogous to that exhibited by the retronecine analogues 
(5). 
In the "C-nmr data presented in Table 2, we have revised the previously assigned 
chemical shift positions for carbons C-4' and C-7' in 1 (8), based on the H- ' 3 C HET-
COR nmr spectrum (Figure 1); the revision is consistent with the known nonequiva-
lence of the isopropyl methyl groups in the viridifloryl moiety, in this case 
Av6 - 7 , = 1.89-2.08 ppm for 1 and 7. Similar assignments were made for the new 
semisynthetic compou ad 7. For the trachelanthates 3 and 6, the corresponding differ-
ence was w6 . 7 • = 0-0. 12 ppm. Likewise for 2, HETCOR nmr spectroscopy has 
shown that assignments in previous ' 3C-nmr data should be reversed for C-3 and C-9 
and for C-7 and C-8, respectively (8). 
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FIGURE 1. 	Heteronuclear correlated nmr spectrum of ech natine 111. 
The 'H-nmr spectrum of the new alkaloid cynoglossamine [5} shows the H-7 sig-
nal at 8 4.24, and upon acetylation 5 gave the diester 8 in which the H-7 signal was ob-
served at 8 5.10, a value typical for the presence of an esterified C-7 hydroxy group. The 
relative intensities of the mass spectral ion peaks at ml z 138 (27), 136 (8), and 120 (9) 
also indicated that cynoglossamine contained a C-7 hydroxyl group. Other important 
signals shown by the 'H nmr of 5 were those of ap-substituted benzene ring (6 7.37 and 
6.76, both d), trans olefinic hydrogens (8 6.23 and 7.62, each d,J= 15.8 Hz), and vir-
idifloryl methyl groups (8 0.90, 0.98, and 1.37) with a strongly deshielded one-proton 
quartet (for H-3') at 8 5.33 (vs. 8 3.87 in 1), suggesting esterification of the hydroxy 
group at C-3'. ' 3 C-nrnr data of 5 (Table 2) indicated two ester carbonyls (8 173.43 and 
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167.09) and 8 olefinic/aromatic carbons. The it spectrum indicated the presence of a p-
substituted benzene ring at 1605, 1590, 1447, and 828 cm , an aromatic ester group 
at 1260-1200 and 1160 cm I , and a hydroxy group at 3660 (free) and 3540-3200 
cm -1 (hydrogen-bonded). Hrms gave an exact mass, [MHF F 446.2209, and a molecu-
lar formula of C 71 1-1 3  ,N07 . Both eims and cims gave a base peak (rn/z 147) correspond-
ing to a p-hydroxycinnamoyl ion [HO-C 6 H4 -CH=CH-001 ± . Support for the vir-
idifloryl moiety was obtained by comparison of the H-nmr spectrum of 5 with those of 
the closely related cinnamoyl-containing semisynthetic compounds 9 and 10. In 9 (3 '- 
cinnamoylindicine) the methyl resonances were observed at 6 0.92, 0.95, and 1.27, 




spectively. Synthesis of 9 and 10, and also 11 and 12, involved the coupling of indicine 
or echinatine with cinnamoyl chloride via an acyl itnidazole. Final confirmation of the 
structure of 5 was obtained by its synthesis from echinatine and p-acetoxy-trans-cin-
namic acid in the presence of carbonyldiimidazole (CDI), followed by chromatography 
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Cynoglossamine is the first pyrrolizidine alkaloid showing esterification of the (3-
OH of the viridifloryl (or trachelanthyl) necic acid moiety by p-hydroxycinnamic acid. 
Known pyrrolizidine alkaloids with acylated viridifloryl/trachelanthyl P-OH's have 
either acetic (10,11), tiglic (9,12), or angelic acids (13) as esterifying acids. The pyr-
rolizidine alkaloids thesinine and thesine, which contain the esterifying acids p-hydroxy-
cinnamic and et-truxillic acids, respectively, with the saturated necine base (+)-isoret-
ronecanol, have been considered to provide a link between the pyrrolizidine and the 
tropane alkaloid groups. The latter contain esterifying acids related to cinnamic acid 
(14). The 7-monoester 4 which has been previously reported as a constituent of Hello-
tropium currassavicum (15), may be naturally occurring or could have arisen by partial hy-
drolysis of 2. 
EXPERIMENTAL 
GENERAL EXPERIMENTAL PROCEDURES.—Dccc was carried out using a BUchi 670 DCC 
chromatograph containing 500 tubes of 2.7 mm i.d. Radial centrifugal tic was accomplished by the use of 
a Chromatotron model 7924T (Harrison Research, Palo Alto, CA). The rotors were coated with Si gel 60 
PF254 (E. Merck). Tic was performed on precoated Si gel 60 F, 5 4 (Merck) or EM aluminum oxide (Merck 
60 PF 254 or 150 PF 254 ) places. Detection was by iodine vapor or uv lamp. 1 H (300 or 400 MHz) and ' 3C 
(75 or 100 MHz) nmr spectra were obtained on either a Bruker WM-300 spectrometer equipped with an 
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Aspect data system or on a Varian XL-400. 'H- 13C HETCOR nmr spectra were collected as 128 X 4096 
data matrices using the pulse sequence HETCOR supplied with the Varian 6. Ic software on the Varian 
XL-400 (16,17). These were processed using pseudo echo weighting to a 512 x 2048 data matrix for plot-
ting. Mass spectra were run on a Varian MAT 1125 spectrometer interfaced with an SS 200 data system. 
Melting points were taken on a Thomas Kotler micro hot stage equipped with a microscope and are cor-
rected. Optical rotations were measured either on a Perkin-Elmer 141 or on a JASCO DIP 360 digital 
polarimeter. Ir spectra were obtained on a Beckman 4240 I R spectrometer. 
EXTRACTION OF ALKALOIDS. —Air-dried, finely cut, whole plant material of blooming and fruiting 
C. cretiaan (8.0 kg) collected from the mountains of Judea and Carmel (Israel) in July 1984 (voucher speci-
men at the Department of Botany, The Hebrew University of Jerusalem, Israel) was exhaustively extracted 
with EtOH giving 1.03 kg ofdark green residue after removal of the EtOH. The latter was dissolved in 2 N 
H 2SO4 and reduced with Zn dust overnight. The acid solution, after filtration, was extracted with CHCI, 
to remove non-alkaloidal components, then basified with NH 4OH (pH>9) and extracted with CHCI„, .. 
After drying (MgSO4 ), filtration, and concentration in vacuo, 35.8 g (3.45% based on EtOH extract) of 
crude alkaloid fraction was obtained. 
SEPARATION OF THE ALKALOIDS. 	Crude alkaloid fraction (1.7 g) was chromatographed using 
dccc and the solvent system CHC1 I-C 6 H6-MEOH-1-1 20 (5:5:7:2) in ascending mode. Fractions (13-m1 
volume) were collected and monitored by tic and 1 H nmr, giving the following pooled fractions: 11-16 
(141 mg, N-oxide of 1), 23-25 (18.4 mg, N-oxide of 2), 28-40 (845.4 mg, 1), 41-46 [340.2 mg, 1 and 
3 (65:35)), 47-48 (11.0 mg, 3), 49-56 [13.2 mg, 3 and 5 (88% 5)), 57 onwards (from recovered station-
ary phase, 256 mg, mixture of 3, 5, 2, and 4). Fraction 57 was rechromatographed on silica by radial cen-
trifugal tic using 0-20% Me0H in CHC1 3 -Me 2 C0 (1: 1); 10-mi fractions were collected. Pooled fractions 
were as follows: 8-14 (167.8 mg, 2), 17-18 (10.0 mg, 4), 20-23 (21.9 mg, 5), and 26-30 (18.2 mg, 3). 
CYNOGLOSSAMINE [5]. —A non-crystallizable gum, [CO 27 D — 4.9° (c = 0.71, CEICIO; eims mlz (%) 
93 (23), 119 (17), 137 (15), 138 (27), 147 (100); cims 147 (100); exact mass calcd for C 24 H 32N07 , 
[MH1 + 446.2180; found 446.2209; it (CHC1 3) 3660, 3540-3200, 2965, 2935, 2880, 1705, 1630, 
1605, 1590, 1447, 1250-1200, 1160, 1102, 1065, 1020, 980, 828 cm 1 . 
ACETYLCYNOGLOSSAMI NE [8].—Cynoglossamine (2 mg) was treated with a mixture of 0.5 
ml each of Ac 2O and pyridine and left overnight at room temperature. Excess reagent was removed in 
vacuo; the residue was dissolved in H 2O (5 ml) and the solution made basic (pH>9) with NH 4OH, then 
extracted with 3 X 5 ml CHC1 3 . The dried extract was concentrated to give a gummy material. 1 H nmr see 
Table 1. 
HYDROLYSIS OF CYNOGLOSSAMINE.—A 3.0-mg sample of cynoglossamine was treated with a solu-
tion of 40 mg Ba(OH) 2 in 5 ml H 2O and left overnight at room temperature. The solvent was removed in 
vacuo, and the residue was extracted with 15% Me0H in CHC1 3 . A comparison of the tic (alumina, 30% 
Me0H in CHC1 3 ) of the extracted necine with that of retronecine and heliotridine, as well as its mixed tic 
with retronecine and with heliotridine, showed that the necine base of cynoglossamine was heliotridine. 
PREPARATION OF N-OXIDES. The free bases (1 meq) were separately dissolved in 10 ml CHCI 5 , 
meta-chloroperbenzoic acid (1 meq) was added, and the solution was allowed to stand at room temperature 
for 15-30 min. The solvent was removed and the residue dissolved in 10 ml H 2O, then extracted with 
4 X 10 ml Er 20. The aqueous solution was evaporated in vacuo to yield the various N-oxides. 
ECHINATINE N-OXIDE.—Elms //dz. (%) 80 (19), 93 (60), 95 (22), 118 (34), 136 (32), 138 (100), 
[M — 161 + 299 (0.91); 'H nmr (CDO. 3 ) 8 0.85 and 0.90 (each d, J = 7 Hz, 3H), 1.27 (d, J = 7 Hz, 3H), 
1.94 (m, 1H), 2.16 (hept, J= 7 Hz, 1H), 2.31(m, 1H), 3.63 (m, 1H), 3.90 (q, J= 7 Hz, 1H), 4.04 (m, 
1H), 4.32 (d, J = 16 Hz, 1H), 4.61 (d,f = 16 Hz, 1H), 4.62 and 5.07 (each d, J = 14 Hz, 1H), 5.65 (bs, 
H), 5.19 (bs, 2H); 13C nmr (CDC1 3 ) 133.44 (C-1), 121.35 (C-2), 77.06 (C-3), 67.93 (C-5), 32.54 (C-
6), 71.22 (C-7), 96.08 (C-8), 60.07 (C-9), 173.30 (C-1'), 84.04 (C-2'), 71.74 (C-3'), 16.70 (C-4'), 
31.97 (C-5'), 17.51 (C-6'), 15.36 (C-7'). 
HELIOSUPINE N-OXIDE.—Eims miz (%) 55 (74), 56 (37), 59 (84), 70 (56), 80 (38), 83 (22), 93 
(27), 94 (33), 119 (52), 120 (65), 121 (30), 136 (34), 220 (41); cims [MH — 16] + 399 (100); 1 H nmr 
(CDCI 6 1.10 (s, 3H), 1.20 (s, 3H), 1.13 (d, J = 7 Hz, 3H), 1.81 (s, 3H), 1.91 (dd, J = 7, 2 Hz, 3H), 
2.15 (m, 1H), 2.41 (m, 1H), 3.71 (m, 1H), 3.80 (m, 1H), 4.07 (q,1 = 7 Hz, 1H), 4.38 (ABq, J= 16 
Hz, 2H), 4.57 (m, 1H), 4.71 and 5.06 (each, d, J = 14 Hz, 1H), 4.99 (m, 1H), 5.91 (bs, 1H), 6.10 (dq, 
J = 7, 1 Hz, IH); 	nmr (CDC1 3 ) 132.63 (C-1), 122.79 (C-2), 76.83 (C-3), 67.53 (C-5), 30.46 (C-6), 
73.08 (C-7), 94.40 (C-8), 60.75 (C-9), 173.98 (C-1'), 84.64 (C-2'), 69.55 (C-3'), 18.53 (C-4'), 72.81 
(C-5'), 24.42 (C-6'), 24.68 (C-7'), 167.09 (C-1"), 	126.39 (C-2"), 	140.58 (C-3"), 15.99 (C-4"), 20.32 
(C-5"). 
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PREPARATION OF CYNOGLOSSAMINE-RELATED COMPOUNDS.--3 . -Cinnamoylindicine [9] and 7- 
cinnamoylindicine [111.—To indicine (299 mg, 1 meq) dissolved in 20 ml dry THF at 0 ° and under an N2 
atmosphere, was added Nall (24 mg, 1 meq), and the mixture was stirred for about 3 h. Cinnamoyl 
chloride (166.7 mg, 1 meq) was added, the temperature allowed to rise to 25 ° , and the mixture left to stir 
overnight. A 5% solution of NH 4 CI (50 ml) was added, the THF removed in vacuo and the aqueous mix-
ture basified (pH>9) with 20% Na2CO 3 , then extracted with 3 X 50 ml CHC1 3 . The dried extract was 
concentrated to give a gummy material (339 mg) which showed four spots on tic. Separation was obtained 
by centrifugal tic (alumina) using 0-5% Me0H in CHC1 3 as eluent, giving first 3'-cinnamoylindicine [91 
(43 mg, 12.7%) and then 7-cinnamoylindicine [111 (30 mg, 8.8%), both as non-crystallizable gums. 
3'-Cinnamoylindicine [9).—Cims 430 (92), 117 (100). Exact mass calcd for C 24H 32N06 [MH] F 
430.2221; found 430.2233. 'H nmr see Table 1; ' 3C nmr see Table 2. 
7-Cinnamoylindicine [111.—Eims mlz (%) 77 (22), 94 (41), 103 (34), 131 (80), 136 (26), 137 (38), 
138 (100), [M]' 429 (25). Exact mass calcd for C 24 14 31 N06 , 429.2143; found 429.2113. I li nmr see 
Table 1; 13C nmr see Table 2. 
3'-Cinnamoylechinatine [10) and 7-Cinnamoylechinaiine [12].--ln the same manner, 3'-cin-
namoylechinatine and 7-cirmamoylechinatine were obtained from echinatine and cinnamoyl chloride in 
comparable yields as above, with the former eluting first. 
3'-Cinnamoylechinatine [10].—Non-crystallizable gum: eims rniz (%) 93 (58), 94 (21), 103 (34), 120 
(16), 131 (100), 136 (22), 137 (36), 138 (76), 147 (31), 148 (30), [Mr 429 (2); cims 101 (100), 149 
(96), [M1-1] ± 430 (73). Exact mass calcd for C.2 41-1 3 -2 N06 [MH) 4 430.222 1; found 430.2257. 1 H nmr see 
Table 1; C nmr see Table 2. 
7-Cinnamoylechinatine [12].—Non-crystallizable gum: 1 H nmr see Table 1; j C nmr see Table 2. 
3'-(p-AcetylcinnamoyI)-echinatine [13] (or 7"-acetyltynoglossamine) and 3'-(p-hydroxycinnamoy1)- 
echinatine (or cynoglossamine;..—To echinatine (299 mg) dissolved in 20 ml dry THF at 0 ° and under an N 2 
 atmosphere was added NaH (24 mg), and the mixture was stirred for about 3 h. A mixture of 1 meq ofp-
acetylcinnamic acid [trans; prepared by treating p-hydroxycinnamic acid (trans) with Ac 20] and 1.4 meq 
CDI in THF was added. The mixture was left stirring overnight at room temperature. A 5% solution of 
NH4 C 1 (50 ml) was added, the THF was removed in vacuo, and the mixture was extracted with 4 x 40 ml 
CHC1 3 . The combined CHC1 3 extracts were washed five times with equal volumes of H 2 O, dried 
(Na,SO4), filtered, and concentrated to give a gummy material (350 mg). This was separated by radial cen-
trifugal tic (Al 203 , 2 mm) during with 0-10% Me0H in CHO I . The earlier eluting fraction (70 mg, 
20%) was identified (by 1 1-1 nmr) as 3'-(p-acetylcinnamoy1)-echinatine [13] while the later eluting fraction 
(49 mg, 14%) was 3'-(p-hydroxycinnamoy1)-echinatine. The 1 H nmr of the latter was identical to that of 
cynoglossamine [5). The 'H and ' 3C nmr of 13 are shown in Tables 1 and 2, respectively. 
PREPARATION OF ECHINATENE AND ISOMERS.—(+)- and (—)-Trachelanthic and (+)-viridifloric 
acids were available from an earlier synthesis (5). (—)-Viridifloric acid was obtained from the hydrolysis of 
echinatine. The isopropyl idine derivatives of the four necic acids were prepared as previously described (5). 
These derivatives were coupled to heliotridine according to the following procedure: to 1 meq of the iso-
propylidine derivative and 1.4 meq of carbonyldiimidazole (CD1) was added DMF, dropwise, until com-
plete dissolution was accazned (ca. 1 m1/50 mg acid derivative). Then, 1 meq each of heliotridine and 
sodium were added gradually, and the solution was left at room temperature for 16 h. The solvent was re-
moved in vacuo and the residue dissolved in H2O (10 ml), then extracted with 4 x 10 ml CHCI 3 . The com-
bined CHC1 3 extracts were washed five times with equal volumes of H 2O, dried (Na 2SO4 ), filtered, and 
concentrated in vacuo to give yields of 41-80%. The viridiflorate esters were additionally purified by pre-
parative tic (silica) eluting with the mixture CHC1 3-Me 2CO-Me0H (45:45:10). 
9-(+ )-Viridiflorylheliotridine isopropylidine.—Non-crystallizable gum; 'H nmr (CDC13) 8 0.92 and 
0.94 (each d, J = 7 Hz, 3H), 1.20 (d,f = 6 Hz, 3H), 1.31 (s, 3H), 1.49 (s, 3H), 1.79 (m, 1H), 1.90 (m, 
1H), 2.04 (kept, J= 7 Hz, 1H), 2.53 (m, 1H), 3.22 (m, 1H), 3.29 (dd, J= 5,2 Hz, 1H), 3.82 (dd, 
J= 16,2 Hz, 1H), 3.91 (bs, 1H), 4.03 (q, J = 6 Hz, 1H), 4.16 (q, J = 6 Hz, 1H), 4.64 and 4.88 (each d, 
J= 14 Hz, 1H); eims mlz (%) 93 (74), 94 (28), 99 (26), 136 (22), 137 (25), 138 (100), 157 (31), [M] + 
339 (1); cims [MH) + 340 (100). Exact mass calcd for C I8 H 30N05 IMHIF 340.2115; found 340.2121. 
9-( — )-Viridiflorylhehotridine isopropylidine.—Non-crystallizahle gum; 'H nmr (CDC1 3 ) 8 1.00 and 
1.02 (each d, J = 7 Hz, 3H), 1.31 (d, J = 6 Hz, 3H), 1.40 (s, 3H), 1.57 (s, 3H), 1.94 (m, 1H), 2.07 (m, 
1H), 2.11 (hept, J = 7 Hz, 1H), 2.64 (m, 1H), 3.33 (m, 1H), 3.40 (bd, 1H, 3.87 (bd, 1H), 3.91 (bs, 
1H), 4.12 (q, J = 6 Hz, 1H), 4.26 (q, J= 6 Hz, 1H), 4.77 and 4.85 (ABq, J =-- 14 Hz, 2H), 5.72 (bs, 
1H); eims nitz (%) 43 (100), 99 (29), 101 (20), 137 (15), 138 (10), 157 (44), [Mi t  339 (1); cims [MH] 4- 
340 (12), 203 (100). Exact mass calcd for C I8H 30N05 WM + 340.2115; found 340.2121. 
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C-9 ESTERS OF HELIOTRIDINE WITH (+)- AND ( – )-TRACHELANTHIC AND (+)- AND ( 
FLORIC ACIDS.—In each case the protected ester was dissolved in 10 ml 0.6 N HCI, and the solution was 
kept at room temperature for 20 h. The solution was made alkaline with NaHCO 3 , concentrated to dry-
ness, then extracted four times with CHC1 5 . After drying (Na 2 SO4 ) and filtration, the solvent was removed 
in vacuo to give the esters in 65-90% yields. Preparative tic was employed to obtain the pure trachelan-
thate C-9 esters using silica with 30% Me0H in CHCI,-Me 2CO (1: 1). 
+FTrachelanthylheliotridine [3]. —Viscous gum: [ot) 25 D + 18.3 ° (c =1.32, EtOH); 'H nmr see 
Table 1; 13C nmr see Table 2; eims m/z (%) 43 (12), 67 (11), 80 (29), 93 (81), 94 (35), 95 (15), 138 (100), 
139 (36), 154 (14), NY' 299 (2). Exact mass calcd for C, 5 H 26N0 5 WHY' 300. 1812; found 300.1810. 
9 - ( — ) - Trachelanthylheliotridine [6]. —Viscous gum: [a] 25 D +9.0 (c = 1.1, EtOH); 'H nmr see Table 
1; ' 3C nmr see Table 2; eims m/z (%) 43 (56), 80 (57), 93 (84), 94 (41), 138 (100), 139 (37), 156 (22), 
[Ml ÷ 299 (3); cims NM + 300 (100). Exact mass calcd for C , 5 H 26N0 5 [MF11 ± 300.1812; found 
300.1842. 
9 -(+ ) - Virichfiorylheliotridiner). — Viscous gum: [0,1 25 E) +6.7 (c= 0.97, EtOH); 	nmr see Table 
1; ' 3C nmr see Table 2; eims m/z (%) 80 (18), 93 (68), 94 (32), 137 (14), 138 (100), 139 (33), 156 (10), 
LW + 299 (1); cims [ME] + 300 (100). Exact mass calcd for C , 5 H 2 6N05 [ME] + 300.1812; found 
300.1840. 
9 -( — ) - Viridiflorylheliotridine [1]. — Viscous gum: [0] 25 D +9.2 (c = 1. 17, EtOH); 'H nmr see Table 
1; 13C nmr see Table 2; eims m/z (%)43 (20), 80 (15), 93 (67), 94 (27), 138 (100), 139 (31), IM1 + 299 (I); 
cims IMF11 ± 300 (100). Exact mass calcd for C, 5 H 26N0 5 [Mil] + 300.1812; found 300.1810. 
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PYRROLIZIDINE ALKALOIDS FROM HELIOTROPIU M ROTUND] TOLIU M 
CLARITA F. ASIBAL, I LESLIE T. GELBALIM, 2 and LEON H. ZALKOW * 
Siboo/ ChemiilrY. Georgia In.fluitle of Technology. Atlanta, Georgia 30332 
ABSTR ACT.—Helmtroplum roiundifolium was shown to contain, in addition to the prey.- 
ously isolated europine [11, three other alkaloids: heliotrine [2), lasiocarpine [31, and a new 
kaloid identified as 5'-acetyleuropine [4]. The alkaloids were isolated by dccc and the structures 
established by spectroscopic means ( 'H and 'H- ' HETCOR nrnr and ms), physical properties 
(melting points and/or optical rotations), comparison with authentic samples, or by semi-
synthesis. 
The hepatotoxic pyrrolizidine alkaloids (PAs) are of increasing concern as possible 
causes of human poisoning (1). Besides their presence in some traditional herbal 
medicines, they are also low-level contaminants in some foodstuffs. The broad range of 
pharmacological activity associated with pyrrolizidine alkaloids has continued to gen-
erate extensive studies on these compounds. 
The genus Heliotropium (Boraginaceae) is among the genera of plants known to be 
rich in pyrrolizidine alkaloids (1). In line with our continuing objective (2-4) to iden-
tify and isolate PAs due to their potential as antitumor agents, we have reinvestigated 
Heliotropium rotundildium Sieber ex Lehm. from which europine N-oxide [1a) was pre-
viously obtained (3). We report here the isolation of three other pyrrolizidine alkaloids, 
one of which is new. 
RESULTS AND DISCUSSION 
The Me0H extract of H. rotundifolium obtained from Jerusalem, Israel, was directly 
reduced with Zn dust and dilute H 2SO4 in the usual manner. The resulting crude al-
kaloid fraction was separated by dccc. Monitoring of fractions by tic and 'H-nmr spec- 
Me 
e 	I 
Me — C- R 1 
I . 	I 2 , 	3 , 	4' 
0 — 00 — C — CH—Me 
I 	I 
OH OMe 
1 	R I =OH, R 2 =H 	 3a N -oxide of 3 
la N-oxide of 1 4 	R  ' = — OCOCH 4 , R 2 = H 
2 R I = R 2 = H 5 R 1 =0H, R 2 =Ac 
2a N-oxide or 2 
H 
N, 
3, 	Me 	6 R — 000CH,, R 2 = CH,CO — 
2 
3 R 1 =0H, R 2— 4" 	= i t/ 
Me' 
'Taken from the Ph.D. Dissertation of Garita Florendo Asibal, School of Chemistry, Georgia Insti-
tute of Technology, Atlanta, Georgia, 1987. 
'Research Center for Eiorechnology, Georgia Institute of Technology, Atlanta, Georgia 30332. 
5a N-oxide of 5 5 It 
CO— 
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troscopy revealed the following heliotridine-based pyrrolizidine alkaloids in the order 
of their elution by dccc: europine [1), heliotrine [2), lasiocarpine [33, and a new al-
kaloid identified as 5'-acetyleuropine [41. Europine, heliotrine, and lasiocarpine were 
identified by analysis of their 'H-nmr, ' 3 C-nmr, and mass spectra and comparison of 
these spectral properties with those reported in the literature (3 -8) as well as with those 
of authentic samples available in our laboratory from previous isolation work (4). Con-
version of these free bases to their N-oxides provided additional support for their struc-
tures. 'H- and 13C-nmr data were obtained for both free bases and N-oxides. 1 H-"C 
HECTOR nmr was used to assign unambiguously the 13C chemical shifts for all H-con-
taining carbons. Based on this, we have revised the previous ' 3C chemical shift assign-
ments for carbons 3, 5, 7, 8, and 9 in la (3, 5). Tables 1 and 3 give the 'H-nmr data for 
the free bases and N-oxides, respectively, and Tables 2 and 4 give the 13C-nmr data. 
TABLE 1. 400-MHz 'H nmr in CDC' of Alkaloids and Derivatives from Heliotropium rotundifohum. 
Compound 
.......... 
1 	2 3 4 5 6 
H-2 	  5.64s 5.64s 5.77 bs 5.70s 5.75s 5.78 bs 
H-3u  3.26d 3.28m 3.31 m 3.30 dd 3.27m 3.33d 
H-3d 	  3.80d 3.80d 3.89d 3.86d 3.84d 3.91d 
H-5u  2.52 m 2.52 m 2.78 m 2.58 m 2.73 m 2.79 m 
H-5d 	  3.19 m 3.22 m 3.14 m 3.3 	m 3.11 m 3.19 m 
H-6u  1.78 m 1.83m 1.85 m 1.86 m 1.80 m 1.85 m 
H-6d 	  1.90 1.97 m 1.85 m 1.99 m 1.80 m 1.85 m 
H -7  4.07m 4.01 m 5.09m 4.13m 4.99 5.02 bs 
H-8 	  3.92 bs 3.81 s 4.06 bs 3.94 bs 3.99 bs 4.04 bs 
H-9u  4.70 AB 4.60 AB 4.88 s 4.66 AB 4.82 ABq 4_86 s 
H-9d 	  4.92 AB 4.98 AB 4.88 s 4.98 AB 4.82 ABq 4.86 s 
H-3'  3.74 q 3.54 q 3.75 q 3.81 q 3.74 q 3.79 q 
H-4' 	  1.17d 1.07d 1.21d 1.20d 1.20d 1.22d 
H-6'  1.22 s 0.87 d 1.24 s 1.61 s 1.23 s 1.61 s 
H-7' 	  1.17s 0.82d Ills 1.61s 1.11s 1.62s 
H-8'  3.24s 3.27s 3.20 3.25s 3.19s 3.23s 
H-5' 	  2.07 hept - - 
H-3"  - 6.03 q ofq 1.98s 
H-4" 	  - 1.92 dd - - 
H-5"  - 1.81s - - 
H-10' 	 1.96 s 1.96s 
H-2"  - - 2.03s 
The structure of 5'-acetyleuropine [4] was elucidated from its mass and nmr 
spectra. Although eims showed no molecular ion peak, cims gave a strong [MH) + peak 
at tniz 372. This mass was higher than that of 1 by 42 mass units, suggesting the pres-
ence of an acetyl group. This was verified in the 'H-nmr spectrum by a sharp singlet (in-
tegrating for three protons) at 8 1.96. The common diester arrangement (7- 
acetyleuropi ne (5)) was ruled out by the H-7 multiplet at 8 4.13 which is typical for the 
presence of an unesterified C-7 hydroxyl. Evidence was obtained by acetylating 4 to 
give 5' ,7-diacetyleuropine [61 whose H-nmr spectrum showed a broad singlet for H-7 
at 8 5.02. Furthermore, 4 showed a singlet at 8 1.61 integrating for six protons, 
whereas 1 exhibited two singlets, at i 1.17 and 1.22, each integrating for three pro-
tons, accounting for the 6' and 7' methyl protons. This downfield shift of 0.39-0.44 
ppm in 4 is consistent with acylation of the hydroxyl group at C-5'. This is also sup- 
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TABLE 2. 100-MHz 13 C nmr in CDCI 3 of Pyrrolizidine Alkaloids from Heliotropium rotundifolium. 
Compound 






























135.55 136.11 134.68 136.00 134.59 
125.61 126.86 128.32 126.79 128.19 
(61.39;' (61.89)''` 62.21 61.85 62.00 
53.81 54.11 54.22 54.20 53.94 
33.57 34.26 30.44 34.151 30.39 
(74.11) 1' 75.31 (76.71)d 75.07 76.95 
(79.26)' (79.90)' (78.73)'''' d 79.97 78.40 
(61.811' (62.51)''' 62.21 62.46 62.00 
173.40 174.64 173.60 172.67 173.53 
83.88 82.52 83.58 (85.77) 83.57 
78.69 (78.49) b (78.65)''` 78.51 78.66 
12.74 12.39 12.98 12.97 12.96 
72.99 31.94 72.80 (85.13) 72.80 
25.92 17.10 26.47 22.47 26.36 
24.73 16.56 24.53 22.22 24.51 








'Reported as interchangeable in Jones et al. (6). 
b Reported as interchanged in Jones et al. (6). 
`Reported as interchangeable in Mody et al. (7). 
`Reported as interchangeable in Zalkow el al. (4). 
ported by the ' 3 C nmr data (see Table 2), which shows a C-5' signal at 85.13 (or 85.77) 
in 4 compared to 72.99 ppm in 1. 
The fragmentation pattern in the mass spectrum of 4 likewise supports a free C-7 
hydroxyl as shown by the base peak at miz 138 resulting from allylic cleavage. Diesters 
with an acetylated C-7 hydroxyl exhibit typical intense fragment ions at m/z 180, 136, 
and 120 (9). In the case of 7-acetyleuropine [5) obtained from the acetylation of 
europine, these peaks have intensities of 100, 19, and 61, respectively. The '11 nmr 
spectrum of 5 showed the H-7 multiplet at 8 4.99. It also showed two methyl singlets 
at 8 1.11 and 1.23 (for 6' and 7' methyl protons) analogous to those in 1. 
The above data are consistent with structure 4. Precedents for this structure are 
found in 5'-acetylheliosupine (1) and in acetyllasiocarpine (1,10) which is just 7- 
angelyI-5 -acetyleuropine. 
Europine, lasiocarpine, and heliotrine have been reported to occur singly or in com-
bination in several other species of Heliotropium (1, 10-14). 
EXPERIMENTAL 
GENERAL. EXPERIMENTAL PROCEDURES. -All 'H- and l 'C-nmr spectra were obtained using a Var-
ian XL-400 spectrometer. Chemical shifts are reported relative to residual CHCI, (7.24 ppm) for 1 H and to 
CDC1, (77.0 ppm) for 'H-' 'C heteronuclear shift correlated nmr spectra were done as previously de-
scribed (2). Melting points were taken on a Kofler hot stage and are corrected. Optical rotations were taken 
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TABLE 3. 400-MHz I H nmr in CDCI, of Pyrrolizidine N-Oxides. 
Proton 
Compound 
la 2a 3a 5a 
H-2 	  5.69s 5.61s 5.91 bs 5.87 s 
H-3u  4.32 ABy 4.28 AB 4.42 d 4.36 AB 
H-3d 	  4.32 ABq 4.42 AB 4.58d 4.51 AB 
H-5u  3.51m 3.56 m 3.79 m 3.70 m 
H-5d 	  3.81 m 3.96 m 3.92 m 3.86 m 
H-6u  2.01 m 1 96 m 2.20 m 2.11 m 
H-6d 	  2.24 m 2.30 m 2.52 m 2.40 m 
H- 7  4.21 m 4.20 m 5.14 m 5.05 m 
4.52 bs 4.70 s 4.67 bs 4.63 s 
H-9u 	  4.68 AB 4.68 AB 4.95 ABq 4.79 AB 
H-9d  4.81 AB 4.78 AB 4.95 ABy 4.91 AB 
3.70 q 3.59 q 3.79y 3.73 y 
1.11d 1.03d 1.22d 1.18 d 
H-6' 	  1.19s 0.83d 1.25 s 1.21s 
H-7'  1.14s 0.80 d 1.18s 1.15s 
H-8' 	  3.18s 3. 17 s 3.25s 3.20 s 
H-5'  1.85 hept 
H-2" 	  2.60 s 
H-3"  6.17 
H-4" 	  1.99 dd 
H-5"  1.88s 
TABLE 4. 100-MHz I 	nmr in CDCI ; of Pyrrolizidine N-Oxides. 
Carbon 
Compound 









F  "7 















 L.:  
133.58 134.09 132.92 132.82 
121.19 120.15 123.13 122.86 
(78.89)°  77.29 77.28 76.99 
(68.03)' 68.34 67.92 67.74 
32.82 33.23 30.66 30.42 
(71.52)' 71.76 7.3.19 73.25 
(96.05)'' 96.23 94.93 94.53 
(60.76)" 60.77 61.18 60.80 
173.30 173.87 173.49 173.36 
84.45 83.06 83.88 84.22 
78.87 78.77 78.80 78.78 
12.70 11.60 12.95 12.81 
73.34 33.00 70.98 73.25 
25.82 17.07 26.36 26.17 
24.87 17.07 24.84 24.95 
56.29 56.58 56.34 56.31 
167.26 170.71 




'Assignment revised from that given in Zalkow et al. (3) nd Broadbent and Paul (5). 
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with a_JA.SCO DIP 360 digital polarimeter. Mass spectra were obtained on a Varian MAT 1 12S spectrome-
ter interfaced with an SS 200 data system. Tic was performed either on EM aluminum oxide 150 F-254 or 
Si gel 60 F,„ (Merck) plates developed in Me0H/CHCI 5 mixtures. Centrifugal tic was carried out on a 
Chromatotron model 7924 T (Harrison Research, Palo Alto, CA) using rotors coated with either Si gel 60 
PF, 5 . 1 (Merck) or Al 20, 60 PF254 (Merck). For the dccc separation, a Buchi 670 dcc chromatograph, 
equipped with 500 tubes of 2.7 mm i.d. and attached to a Gilson FC-220 fraction collector, was used. 
PLANT MATERIAL. H. rottindifoltum was collected, identified by Dr. A. Damn, and extracted at the 
Chemistry Department of Ben Gurion University of the Negev in Beer-Sheva, Israel, under the direction of 
Prof. A. Shani, and the extracts were shipped to the Georgia Institute of Technology (4). A voucher speci-
men is deposited at the herbarium in The Hebrew University of Jerusalem, Israel. 
EXTRACTION AND SEPARATION OF THE ALKALOIDS.-Me0H extract (31.1 g; extracted in De-
cember 1977) of H. rotundifolium was dissolved in 200 ml of 2 N H,SO, 1 and stirred overnight with excess 
Zn dust. After filtration, the solution was extracted with CHCI, (3 X 200 ml). The acid solution was 
basified with NH ,OH (pH > 9) and reextracced with CHCI,, (3 X 350 ml). After drying over MgSO 4 , the 
solvent was removed in vacuo to give 4.23 g of crude alkaloid fraction (13.89%). 
Separation of the alkaloid fraction was accomplished by dccc using the solvent system CHCI,-C 6H6 - 
Me0H-H,0 (5:5:7:2) in ascending mode. Fractions (20 ml volume) were collected and monitored by a 
combination of tic and 'H-nmr analyses. The alkaloids eluted as follows: europine (fractions 41-53), 
heliotrine (fractions 60-64), 5'-acetyleuropine (fractions 70-80), and lasiocarpine (from the recovered sta- 
tionary phase). Intervening fractions contained mixtures of the alkaloids from which additional pure sam- 
ples were obtained by centrifugal tic. 
5'-ACETYLEUROPINE [4].-Non-crystallizable gum; [et] 2.4 1) +27.2° (c= 1.58, CHC10; I FI nmr 
(CDCI,) see Table 1 ; nrnr see Table 2; eims /dz . (%)59 (74), 93 (75), 94 (36), 138 (100), 156 (18); cims 
[ME] + 372 (55), 312 (96), 254 (100); exact mass calcd for C,,H, 0 NO 7 [MH) ± 372.2013, found 
372.2007; ir (CHC1 i ) 3660, 3650-3300, 2970, 2940, 2830, 1705, 1610, 1412, 1360, 1280-1180, 
1148, 1090 cm I . 
7-ACETYLEUROPINE [5].-To 100 mg of 1 dissolved in 5 ml pyridine was added 5 ml AO), and 
the mixture was left overnight at room temperature. Excess reagents were removed in vacuo, and the resi-
due was taken up in NaHCO, solution and extracted with CHCI The dried CHCI, extract was concen-
trated in vacuo to give a gummy material with the following properties: [a] 24 D +0.44 ° (c =4.06, CHCI.,); 
'H nmr (CDCI,) see Table 1; 13C nmr see Table 2; eims mlz (%) 93 (46), 94 (24), 119 (40), 120 (61), 121 
(21), 136 (19), 18011100); cims IMHI + 372 (49), 81 (100); exact mass calcd for C, 814,907 N, 371.1936, 
found 371.1949; ir (CHCI ; ) 3660, .3500, 2980, 2940, 2890, 2830, 1720, 1450, 1375, 1270-1195 
cm I . 
5',7-D1ACEIYI.EUROPINE [6}.-In the same manner as the acerylation of 1, 4 was acetylated to give 
compound 6, which has the following properties: 1 H nmr see Table 1; eims m/z (%) 43 (96), 59 (90), 93 
(49), 94 (25), 119 (57), 120 (64), 136 (24), 178 (27), 180 (100), 181 (31), 236 (0.12), 295 (15); cims 
[ME] + 414 (9), 131 ( IOU). 
PREPARATION OF N-OXIDES la, 2a, 3a, AND 5a.-The N-oxides were prepared according to the 
following procedure. One meq of the base was dissolved in 10 ml of CHCE,„ m-chloroperbenzoic acid (1 
meq) was added, and the solution was allowed to stand at room temperature for 15-30 min. The solvent 
was removed in vacuo and the residue dissolved in 10 ml I-1,0 and extracted with 4 X 10 ml Et 20. The N-
oxide was obtained by evaporating the aqueous solution in vacuo. 
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MACROCYCLIC PYRROLIZIDINE ALKALOIDS FROM 
SENECIO ANONYM US. SEPARATION OF A COMPLEX 
ALKALOID EXTRACT USING DROPLET COUNTER- 
CURRENT CHROMATOGRAPHY' 
LEON H. ZALKOW, * CLARITA F. ASIBAL, JAN A. GLINSKI, SANDRA J. BONETTI, 
LESLIE T. GELBAUM, 2 DONALD VANDERVEER, and GARTH POWIS 3 
School of Chemistry, Georgia Institute of Technology, Atlanta, Georgia 30332 
ABSTRACT.—Ten 12-membered macrocyclic pyrrolizidine alkaloids, all of them esters of 
the necines, retronecire or otonecine, have been isolated from Senecio anonymus. The separation, 
carried out by droplet counter-current chromatography, afforded senecionine [1], integer-
rimine [2], retrorsine [3], senkirkine [51, neosenkirkine [6], otosenine [10], hydroxysenkir-
kine [7], and a new alkaloid given the trivial name anonamine [9]. Traces of usaramine [41 and 
another new alkaloid, hydroxyneosenkirkine [81, were detected by 'H nmr. In addition, the 
previously unreported 3a13-hydroxy-4-ethoxy-2,6-perhydroindoledione [11] was isolated. X-
ray structures were obtained for neosenkirkine [6], hydroxysenkirkine [7], anonamine [9], and 
[ii]. 1 H- 13 C heteronuclear shift correlated nmr (HETCOR) provided unambiguous chemical 
shift assignments for ' 3C-nmr data. Anritumor activity was assayed using the A204-rhab-
domyosarcoma cell line in soft agarose. 
Of the pyrrolizidine alkaloid (PA) containing plants, the genus Senecio (Corn-
positae), having the largest number of species (ca. 1450), has generated numerous 
studies. The most current lists (1-3) of investigated species, however, indicate that 
only about 10% of the genus has thus far been studied. Most of these contain 
hepatotoxic PAs (esters of 1,2- unsaturated necines), and a number of these hepatotoxic 
alkaloids have been shown to be mutagenic. Pyrrolizidine alkaloids and their pyrrolic 
metabolites have been implicated in megalocytosis and mitotic inhibition (1), and re-
cently semisynthetic pyrrolizidine alkaloid N-oxides have been investigated as an-
titumor agents (4,5). The work described in this paper, which continues our earlier 
work (6) on isolation and structure elucidation of pyrrolizidine alkaloids, involves the 
separation of pyrrolizidine alkaloids from a locally abundant species, Senecio anonymus 
Wood (formerly called Senecio smallii) from which a cytotoxic compound, jacaranone 
ethyl ester, was previously isolated in our laboratory (7). 
RESULTS AND DISCUSSION 
Examination of the alkaloidal fraction from S. anonymus led to the identification of 
ten 12-membered macrocyclic pyrrolizidine alkaloids. Four of these, senecionine 
(8,9), integerrimine [2] (9,10), retrorsine [31(10-12), and usaramine [4], known also 
as mucronatinine (10,13), are esters of retronecine while the six remaining, senkirkine 
[5) (14-16), neosenkirkine [61 (17,18), hydroxysenkirkine [7] (15,19), hydroxy-
neosenkirkine [8], anonamine [9], and otosenine [101(20,21), are esters of otonecine. 
The macrocyclic ester rings are formed by six different but closely related necic di-
carboxylic acids. Thus, 1 and 5 are esters of senecic acid, 2 and 6 are esters of integer-
rinecic acid, 3 and 7 are esters of isatinic acid, and 4 and 8 are esters of trans-isatinic 
acid, while 10 is an ester of jacobinic acid and 9 is an ester of 7-hydroxyintegerrinecic 
acid. Since senecic and integerrinecic acids as well as isatinic and trans-isatinic acids are 
'Taken from the Ph.D. dissertation of Clarita Florendo Asibal, School of Chemistry, Georgia Insti-
tute of Technology, Atlanta, Georgia 30332, June, 1987. 
2 Research Center for Biotechnology, Georgia Institute of Technology, Atlanta, Georgia 30332. 
3 Deparrmenr of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905. 
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geometric isomers, the eight esters 1-8 constitute four pairs of alkaloids differing only 
in the configuration of the C-15—C-20 double bond. Therefore, the physical properties 
of these geometric isomers are very similar, posing a serious problem in separation. 
The initial EtOH plant extract was partitioned to give the N-oxides in an H 2O layer 
and the free bases in a CHC1 3 layer. The ratio of N-oxides to free bases varied from 6:1 to 
10:1 depending on the plant parts (leaves, flowers, stems). Separate analyses of the ex-
tracts from the flowers, leaves, and stems combined with roots revealed a specific distri-
bution of the alkaloids. Thus, the major PAs from the flowers were 10, 1, and 3, from 
the leaves 5, 6, and 7, and from the stems and roots 5, 6, 3, and 1. The total estimated 
alkaloid content of the whole plant was 0.02%, and the relative percentages of the vari-
ous alkaloids were 5 (41.0), 6 (20.5), 1 (13.3), 7 (7.8), 10 (6.7), 3 (4.1), 9 (3.8), 2 
(2.0), 8 (0.5), and 4 (0.3%). 
1 R,` =R 3 = Me, R 2 = H (senecionine) 
2 R I = R2 =Me, R 3 = H (inregerrimine) 
3 R I =CH2OH, R 2 =H, R3 =Me (rerrorsine) 
4 R I =CH 2OH, R 2 =Me, R 3 = H (usaramine) 
Me H 
/ OH R2 	C112 — C 
Rs> co 	CO 
filumfe 
Me 
5 R I -= R 3 = Me, R 2 =H (senkirkine) 
6 R = R 2 = Me, R 3 = H (neosenkirkine) 
7 R'=CH2OH, R2 = H, R3 =Me (hydroxysenkirkine) 
8 R =CH 2OH, R 2 =Me, R 3 =H (hydroxyneosenkirkine) 
9 R'= Me, R 2 =CH 2OH, R 1 =H (anonamine) 
10 R = R 3 = Me, 	= H, epoxide (15S, 205) in place of 6. 15 (orosenine) 
Several chromatographic methods, including gravity column, tic, centrifugal tic, 
hplc, and droplet counter-current chromatography (dccc) were evaluated for their effi-
ciency in the separation of the complex alkaloid mixture. Finally, dccc was chosen as the 
most suitable method for preparative separation. As we have observed many times, PAs 
tend to adsorb irreversibly to solid phases such as alumina, silica, or reversed-phase in 
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hplc, resulting in large losses. Dccc, a technique based on partition between two im-
miscible liquid phases, is free of this drawback. Moreover, with a properly selected sol-
vent system, it gives good separation with low solvent consumption (separation of 3 g of 
a crude mixture consumed only about 4 liters of solvent mixture). 
In an attempt to find a solvent system most suitable for our needs, we measured the 
partition coefficients of the model compounds 9-benzoylretronecine, indicine, mono-
crotaline, and retronecine in the three solvent systems containing CHC1 3 -Me0H-F1 20 
in ratios of 13:7:4, 7:13:8, and 5:6:4 and in CHC1 3 -C6H6 -Me0H-H 70, 5:5:7:2 (22). 
This group of model compounds provides a representation of low, medium, and high 
polarity PAs. The first three solvent systems gave fairly similar results and were suitable 
for separation of more polar PAs, while the C 6H6 -containing system was found to be 
better suited for moderately polar PAs. Because most of the alkaloids present in S. 
anonymus are moderately polar, this system was selected for the initial run. 
The collected fractions were monitored by tic and by 300-MHz 1 Hnmr. The H-
nmr spectra were especially useful in determining compositions of the fractions con-
taining mixtures ofcis-trans isomeric alkaloids; these could be distinguished by their H-
20 absorptions which occur at 8 6.5-6.8 for the cis isomers 2, 4, 6, and 8 and about S 
5.7--5.9 for the trans isomers 1, 3, 5, and 7. Overall results of the dccc separation ex-
ceeded our expectation, affording pure samples of 8 out of a total of 10 alkaloids present 
in the plant plus the non-alkaloidal compound 11. Only two very minor components, 
4 and 8, have not been fully separated from their stereoisomers 3 and 7, respectively; 
their 1 H-nmr data were acquired from the most enriched fractions. Attempts to sepa-
rate the pairs of cis-trans diastereomers using other chromatographic methods (gravity 
columns, traditional and centrifugal tic, and reversed-phase hplc) resulted only in 
slight enrichments, low recoveries, and/or broad peaks. 
The stereoisomers 1 -2, 3 -4, 5-6, and 7-8 differ only in the configuration about the 
C-15-C-20 double bond. 1 1-1-nmr spectroscopy readily distinguishes between stereo-
isomeric pairs by the chemical shift positions of the H-20 quartet which appears at 8 
5.70-5.86 for the trans isomers 1, 3, 5, and 7 and at 8 6.49-6.77 for the cis isomers 2, 
4, 6, and 8 (see Table 1). In the new alkaloid, anonamine [9], instead of a quartet, an 
AB pattern is seen at 5 , 6.63 for H-20. This signal was shown by both decoupling exper-
iment and 1 H- 1 H shift correlated spectroscopy (COSY; Figure 1) to be coupled to the 
two sets of doublet-of-doublets at 8 4. 19 and 4.40. Anonamine {9} differs from neosen-
kirkine [6) only by the replacement of the C-21 methyl with a hydroxymethylene 
group. The postulated structure of another new alkaloid which we have named hy-
droxyneosenkirkine [8) is based on a comparison of its 'H-nmr spectrum with those of 
hydroxysenkirkine [71 and neosenkirkine [61. The 1 1-1-nrnr spectra of 7 and 8 are very 
similar, displaying characteristic and essentially identical AB patterns for the H 2 -18 at 
8 3.66 and 3.74 in 7 and at 8 3.69 and 3.76 in 8. The two spectra differ significantly 
only in the areas of olefinic absorption. Isomer 8 also resembles 6, where the H-20 ab-
sorption is found at 6 6.71. The structures of 6, 7, and 9 were confirmed by single crys-
tal X-ray crystallographic analyses (23). Structures of the other alkaloids were estab-
lished by melting points, optical rotations, high resolution ms and nmr, and direct 
comparisons with authentic samples (1, 3, 10) and/or with literature data (2, 4, 5). 
13C-nmr spectra were obtained for all the alkaloids except 4 and 8 (see Table 2), and 
unambiguous assignments for all H-containing carbons were based on 1 H- 13 C 
heteronuclear shift correlated nmr (HETCOR; Figure 2). For example, the clear dis-
tinction between the chemical shifts of C-2 and C-20 in retrorsine [31, which were pre-
viously interchanged (24) is illustrated in Figure 3. Table 2 indicates chemical shifts 
that were misassigned or interchanged in earlier reports. 









TABLE 1. 400 MHz 'H nmr of Secopyrrolizidine Alkaloids from Senecio anonynws. 
Compound 
....,_,.. 
5 6 7 8 9 
2 	  6.11t( J= 2Hz) 6.14 brs 6.15 brs 6.20 brs 6.12 brs 
313  3.21dt( J= 19,2Hz) 3.18 dt ( J= 19,3 Hz) 3.24 ABq( J = 18Hz) 3.24 ABq( J=- 18Hz) 3.20 dt( J - 18,2 Hz) 
3a 	  3.40 d (J = 19 Hz) 3.35 d( J= 19Hz) 3.41 ABq( J= 18 Hz) 3.37 ABq(_/ = 18Hz) 3.39 d(f = 18 Hz) 
5P  2.71m 2.68m 2.73dt( J= 12,4 Hz) 2.80 m 2.74 m 
5a 	  2.86 dt (J = 19,2Hz) 2.79m 2.86m 2.87m 2.84m 
613  2.33m 2.34 m 2.29 m 2.34 m 2.30 m 
6a 	  2.53 m 2.36 m 2.53 m 2.42 m 2.48 m 
7  4.96 t (J = 3Hz) 4.93 t ( J= 5 Hz) 4.97 t( J= 3 Hz) 4.99 t( J= 3Hz) 5.00 t( J= 5 Hz) 
9u 	  4.33d( J= 11Hz 4.39d( J= 11Hz) 4.41d( J= 11Hz) 4.50 d( J = 11Hz) 4.33d( J= 11Hz) 
9d  5.39d( J= 11Hz) 5.35 d( J=- 11 Hz) 5.39d( J= 11Hz) 5.37 d( J= 11Hz) 5.28d( J= 11Hz) 
13 	  1.67m 1.87 d( J=7 Hz) 1.75m 1.92m 
1413  1 .7 7 d(J = 13 HZ) 1.99 d( J= 12 Hz) 1.82d( J=- 1.3Hz) 2.18d( J = 14 Hz) 
14a 	  2.28d( J= 13Hz) 2.20d( J= 12 Hz) 2.33 d( J= 13Hz) 2.19 d ( J = 14 Hz) 
18  1.31s 1.31s 3.66 AB( J= 11Hz) 3.69 ABq(J -= 11Hz) 1.28s 
3.74 AB (J = 11Hz) 3.76 ABq (J = 11Hz) 
19 	  0.89 d (J = 6 Hz) 0.87 d (J= 7 Hz) 0.84 d( J= 6Hz) 0.84 d(J= 7Hz) 0.87d( J=7 Hz) 
20  5.85 dq( J = 7,1 Hz) 6.71 q ( J= 8Hz) 5.86 dq (J = 7,1Hz) 6.77 q(J= 7Hz) 6.63 AB( J= 5 H z) 
21 	  1.88 dd (J =- 7,2 Hz) 1.76 d (J= 7 Hz) 1.89 dd (J = 7,2 Hz) 1.78 d(J= 7 Hz) 4.19 dd (J= 14,5 Hz) 
4.40dd( J= 14,5 Hz) 












694 	 Journal of Natural Products [Vol. 51, No. 4 
• • 
2 . • • 
0" ' 






■ o IS 





t— 	 I- 	I 
8 	7 	6 5 	4 	3 	2 	1 0 
F1 (PPM) 










TABLE 2. 13C nmr of 12-Membered Macrocyclic Pyrrolizidine Alkaloids. 
Compound 
1 2 3 5 6 7 9 10 
1 	 (131.41)' (131.63)d (132.38) b 134.25 134.30 133.82 134.08 134.08 
2  136.60 136.59 (136.85)d 137.28 137.45 136.71 137.40 137.00 
3 	 (62.87/ 62.62 (62.89) 6 * (58.53)' 58.16 56.72 58.88 (58.80) 1 
5  53.03 53.15 53.05 53.13 53.09 53.31 53.69 52.94 
6 	 (34.79)d 33.88 (37.97)' (36.28)d 34.93 35.83 35.36 (36.96)d.1* 
7  (74.93)1* 75.51 (75.12)` 78.00 79.06 77.87 78.48 78.29 
8 	 (77.62)1* 77.15 (77.56)` 191.77 192.15 185.30 191.71 190.69 
9  (60.64)1 60.99 (61.26)b* (64.27)' 64.70 64.04 64.74 (64.00)1 
11 	 178.19 177.63 175.50 177.97 178.07 175.09 178.30 (177.55) f** 
12  76.75 76.59 81.32 77.31 76.57 81.02 76.37 76.81 
13 	 (38.35)` 39.56 35.77 38.51 39.53 35.56 38.30 38.35 
14  (38.23f 4 29.68 (34.87)' (37.60)" 28.87 37.17 30.34 (35.37)d. f* 
15 	 (133.05r (133.81)" (131.23)b 131.76 132.48 130.79 132.34 63.59 
16  167.55 168.92 167.37 166.39 167.87 160.85 166.72 (167.87) 1** 
18 	 24.92 25.29 66.88 24.47 24.74 66.30 25.52 23.75 
19  11.09 11.97 11.84 10.87 11.46 11.29 12.46 12.35 
20 	 134.13 135.22 (134.58)" 136.99 138.00 137.22 140.61 55.86 
21  14.99 14.32 15.21 15.22 14.46 15.10 59.28 13.44 
22 	 - - - 40.35 41.05 40.47 41.10 39.86 
'4Values in parentheses are interchangeable in the reference indicated by the superscript: "Molyneux et al. (32), bDrewes et al. (24), Nody et al. (33), 
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FIGURE 2. 1 H- 1;C heteronuclear shift correlated nmr (HETCOR) of retrorsine [31. 
29.68, 28.87, and 30.34 ppm, respectively, because of the cis interaction with the C-
21 groups, while corresponding values for the trans isomers 1, 3, 5, 7, and 10 are 
38.23, 34.87, 37.60, 37.17, and 35.37, respectively. The change of the C-18 methyl 
group in 5 to a hydroxymethylene group in 7 is evident from the downfield shift of this 
carbon from 24.47 to 66.30 ppm. In a similar manner, the change from a C-21 methyl 
group in 6 to hydroxymethylene group in 9 results in a chemical shift change from 
14.46 to 59.28 ppm. 
There are a number of reports on the co-occurrence of the diasreromers 1-2 
(11,16,25), 3-4 (9,25), and 5 -6 (17,18). For the pair 7-8, this is the first report of 
isomer 8 and only the third time that 7 has been reported (15,19). On the basis of the 
literature cited above, it seemed to be an unusual coincidence to find 4 pairs of geomet-
ric isomers in one plant. Therefore, we attempted to examine the possibility of cis - trans 
interconversion by subjecting the N-oxide of 1 to the same work-up as that used for the 
crude extract, including zinc-acid reduction. The test revealed no formation of the 
isomeric 2. Cis-trans isomerization has been induced by uv irradiation (25) to convert 4 
into 3 and by bromination/debromination (26) to convert 3 into 4. 
The identity of a r ew, non-alkaloidal compound, isolated from the crude alkaloidal 
extract, was established as 3a-hydroxy-4-ethoxy-2,6-perhydroindoledione [113 by X- 
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FIGURE 3. Expanded portion of 1 H-"C HETCOR nmr of retrorsine [31. 
ray analysis. 4 A quadrant of data (±h, +k, +1) was collected on a Syntex P2 1 diffrac-
tometer using omega scans. A total of 1884 unique data were measured out to 
20 = 500 , and 1197 reflections were used in a full-matrix least-squares refinement on F. 
The refinement converged at R = 0.072, and Rw = 0.68 for 151 parameters varied. 
Most of the hydrogens were located from a difference Fourier map and were included in 
the refinement at fixed positions. The hydrogens on C-10 and C-11 were calculated as 
members of fixed groups. Figure 4 shows a computer-drawn picture of 11. The com-
pound bears close resemblance to a number of natural products isolated recently from 
algae (27,28), but contrary to these, it contains a trans-fused 2,6-perhydroindoledione 
skeleton. The monoclinic crystal belonging to the space group P2 1 /n showed unit cell 
parameters a -= 5.6772(8), b = 26.831(4), c = 7.174(2) A, 3 = 101.00(2)°, Z= 4, 
Dc = 1.317 g cm — , k = 0.71969 A and has a center of inversion, indicating that the 
crystal was racemic. Severe overlap of the nmr signals even at 400 MHz made it neces-
sary to determine the chemical shifts of the individual protons using a COSY experi-
ment. Analysis of the COSY data indicated that H-3a, H-5a, and H-7a overlapped at 
4 Atomic coordinates for this structure have been deposited with the Cambridge Crystallographic 
Data Centre and can be obtained on request from Dr. Olga Kennard, University Chemical Laboratory. 
Lensfield Road, Cambridge, CB2 LEW, UK. 
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02 
FIGURE 4. Computer-drawn picture of compound 11. 
8 2.83 and in addition, H-50 and H-7I3 overlapped at 8 2.53. All chemical shift and 
coupling constant data are consistent with the structure determined from the X-ray 
analysis. The origin of 11 remains unclear; most likely it is not a natural product but 
rather an artifact arising from jacaranone {121, a known constituent of S. anonymus (7), 
during the work-up, which included the use of EtOH and NH 3 . Reexamination of the 
crude plant extract, avoiding the use of NH 3 and EtOH, did not lead to the detection of 
11. Alkaloidal fractions frequently are found to contain neutral compounds carried 
along in the routine work-ups of plant material. 
The relative in vitro cytotoxicities of some of the isolated alkaloids and related com-
pounds were measured against the A204 human rhabdomyosarcoma cell line using the 
soft agar colony forming assay (Table 3). Indicine N-oxide was used as an internal stan-
dard for each group of compounds in Table 3, because it is a pyrrolizidine alkaloid that 
was selected for clinical development as an antitumor agent by the National Cancer In-
stitute (29). Compounds 1, 2, 3, 9, and 10 show similar cytotoxicity, while 5, 6, and 
7 are less cytotoxic, but all of the compounds tested were more cytotoxic than indicine 
N-oxide in this system. Senecionine N-oxide exhibited the same cytotoxicity as 
senecionine. In the bottom of Table 3 (last 3 entries) monocrotaline [141, the 
semisynthetic compound 15, and their N-oxides are compared with indicine [13] and 
)0 	 10 
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its N-oxide. Semisynthetic 15 N-oxide shows excellent cytotoxicity in this assay and 
excellent in vivo activity (5). We have found an excellent correlation between cytotoxic-
ity against the A204 rhabdomyosarcoma cell line and in vivo activity for a large number 
of semisynthetic compounds such as 15, a--1 in every case the N-oxides were more 
cytotoxic than the free bases. 5 The semisynthetic bases were not screened in vivo be-
cause of their expected hepatotoxicity. The natural alkaloids indicine [131 and mono-
crotaline [141 are more cytotoxic than their corresponding N-oxides, but neither 
monocrotaline nor its N-oxide shows much activity in this test. 
None of the naturally occurring macrocyclic alkaloids reported in this study would 
be expected to be useful antitumor agents because their hepatotoxicity would severely 
limit their usefulness (1). 
EXPERIMENTAL 
GENERAL EXPERIMENTAL PROCEDURES.—All separations were carried out using a Buchi 670 dcc 
Chrornatograph equipped with 300 tubes of 2.7 mm i.d. plus 200 tubes of 3.0 mm i.d. The How rates var-
ied between 15 and 24 ml/h, and eluates were collected by an automatic fraction collector. The separation 
process was monitored by a combination of tic analysis on EM A1,0 3 150 F-254 plates developed in a mix-
ture of toluene with 5 to 15% Me0H or in CHC1 3 with 5 to 10% Me0H and 1 H-nmr analysis. All 1 H- and 
"C-nmr spectra were obtained using a Varian XL-400 spectrometer operating at 399.934 MHz and 
100.575 MHz, respectively. Chemical shifts are reported relative to residual CHC1 3 (7.24 ppm) for and 
to CDC1, (77.0 ppm) for NC. 1 F1-"C heteronuclear shift correlated nmr spectra were collected as a 
128 X 4096 data matrix using the pulse sequence HETCOR supplied with the Varian 6.1 c software 
(30,31). This was processed using pseudo echo weighting to a 512 X 2048 data matrix for plotting. The 
hplc experiments were performed on a LDC Constametric III pump equipped with a Rheodyne 7120 sam-
ple injector and either a Universil C 18 , 25 cm X 4.6 mm or an ALI.TECH C,„, 1011, 25 cm X 10 mm col-
umn and a Holochrome Gilson uv detector (at 220 nm). Two solvent systems were employed: 20-35% 
EtOH in 0.01 M (NH, 4 ) 2 CO 3 and 10-50% MeCN in 0.01 M (NH,,),CO, (pH 7.6). Optical rotations were 
taken with a Perkin-Elmer 141 polarimerer. Mass spectra were obtained on a Varian MAT 1 l2S spec-
trometer interfaced with an SS200 data system. Melting points were taken on a Kotler hot stage and are cor-
rected. 
5 L. H. Zalkow, unpublished results. 
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TABLE 3. Cytotoxicity against A204 
Rhabdomyosarcoma Cell Line In Vitro.' 
"See Experimental section for details of prepa-
ration of soft agarose cultures. Cultures were con-
ducted in quadruplicate to allow reliable esti-
mates of the variance of the IC" to be obtained. 
Control cultures with vehicle alone were always 
run at the same time. Dose-response curves were 
constructed using at least four drug concentra-
tions to produce between 10 and 99.9% inhibi-
tion of cell growth. Dose-response curves were 
constructed on at least three different prepara-
tions. 
bTo obtain the IC 50 , the drug concentration 
producing 50% inhibition of cell growth, and its 
variance, the dose-response data was fitted to a 
monoexponential curve using a NONLIN non-
linear least squares regression analysis program. 
Variance of IC SD was obtained from the variance 
of the intercept and slope using Taylor series ex-
pansion. Values are mean ± SE. 
IN VITRO CYTOTOXICITY.—Soft agarose cultures of A204 human rhabdomyosarcoma cells were 
performed as follows: Each 35-mm culture dish contained a base layer consisting of 0.5 ml Dulbecco's 
modified Eagle's medium containing 10% fetal calf serum with 0.5% agarose (growth medium). On day 0 
cells in bulk culture were dissociated with trypsin and EDTA, washed once in growth medium, and sub-
cultured by layering I X 10 4 viable cells in 0.5 ml growth medium with 0.3% agarose over each base layer. 
Cultures were examined with the aid of an inverted stage microscope, and only cultures containing uni-
formly distributed single cell suspensions (< 10 30-p, cell cultures and no 60-p, clusters) were accepted for 
subsequent evaluation. Cultures were maintained in cell culture incubators at 37 ° , 5% CO 2 , 95% air, and 
100% humidity. On day 1 (24 h later) an upper layer of 1 ml growth medium with and without the com-
pound under investigation was added to the dishes. After 24 h, the upper layer of medium was removed by 
aspiration, agarose culture surfaces washed once with 0.5 ml prewarmed growth medium, and then over-
laid with 1 ml of fresh growth medium. Colony formation was examined at daily intervals by conventional 
light microscopy. Cell lines form a sufficient number of detectable colonies (> 60-p, diameter) for analysis 
following 7 to 9 days incubation. Viable colonies were stained using a metabolizable tetrazolium salt (2-p-
iodopheny1-3-p-nitrophenyt-5-phenyltetrazolium chloride), and colonies were counted using a Bausch 81 
Lomb FAS-II image analysis system. Cultures were conducted in quadruplicate. Control cultures without 
drug were run at the same time. 
ISOLATION OF THE. AI.KALOI DAL FRACTION. --Flowering S. anonym/is was collected 10 miles south 
of Atlanta, Georgia, in the third week of May 1984, and identified by Dr. Caywood Chapman, Depart-
ment of Science, Gordon Junior College; a voucher specimen is on deposit at the Georgia Institute of Tech-
nology. Different parts of the plant—flowers, leaves, and stems + roots—were dried separately. The air- 
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dried flowers (3.3 kg) were macerated in a blender with 95% EtOH and allowed to soak in about 5 gal of 
solvent for at least 2 days at room temperature. The solvent was replaced with fresh solvent three times, and 
the combined extract was evaporated on a rotary evaporator to leave 0.7 kg of a dark residue, Out of this, 
333 g was partitioned between H 2 0 and CI-ICI  (2.0 liters each). The organic layer gave 60.6 g of material 
which was partitioned between 0.25 l iter each of hexane and 90% aqueous Me0H. From the aqueous 
Me0H layer 15.0 g ofa residue was obtained. This was dissolved in 200 ml of 5% NaOH and extracted five 
times with 300 ml of Et,O. The Et 20 extract was then washed three times with 150 ml of 10% HCI. 
Basification of the combined aqueous layer with excess of NH ,OH, followed by extraction with CHCI„ 
drying over Mg504 , and evaporation in vacuo, yielded 106 mg of a crude alkaloidal fraction (0.007% dry 
wt). The aqueous layer, 2.0 liters, from the initial CHCI ; -H 20 partition was treated with 120 ml of con-
centrated H,S0,, and 24 g of Zn powder. The reaction mixture was stirred overnight and the decanted so 
lution extracted with 4 X 400 ml of CHCI i . The aqueous phase was then made alkaline with excess ofaque-
ous NH i and extracted four times with 400 ml of CHCI The combined CHCI ; extract was dried over 
MgS0 „ filtered, and evaporated in vacuo leaving I .28 g of a crude alkaloid fraction (0.04% dry w). 
The air-dried leaves, 3.37 kg, were processed in the same manner as the flowers, giving 930 g of a 
concentrated EtOH extract. The workup afforded 187 mg of the free alkaloid fraction plus 1.98 g after Zn 
reduction of the N-oxides (0.006% and 0.06% dry wt, respectively). 
Due to a very low content of PA in the stalks and roots, the EtOH extract (311 g) obtained from 3.0 
kg of the dry material was subjected to Zn-acid reduction without prior separation of the free alkaloids. The 
work-up gave 372 mg of the alkaloid mixture (0.01% dry wt). 
Combined leaves and flowers (4.3 kg), collected in the third week of May 1985 in the same vicinity as 
previously (voucher specimen at Georgia Institute of Technology), were extracted, as before, to give 879 g 
of concentrated EtOH extract which was directly reduced to give 4.67 g of crude alkaloid fraction (0.01% 
dry wt). 
The dcc chromatograph was filled with the stationary phase consisting of the lower layer ofa solvent 
mixture prepared from CHC1 3 -C6H 6-Me0H-H,0 (5:5:7:2). The alkaloidal fraction of S. ananymus (1985 
collection), 3.0 g, dissolved in 15 ml of a 1:1 mixture of the upper and lower phases was aspirated into the 
instrument followed by the mobile phase (upper layer). The fractions, of 20-m1 vol, afforded the following 
alkaloids: 23-26, 9 (37 mg); 27-29, 11 (30 mg); 30, 7 (17 mg); 31-34, 7+ 8 (64 mg); 37-43, 10 (65 
mg); 58-60, 3 + 4 (13 mg); 61-64, 3 (30 mg); 68-69, 5 (29 mg); 70-77, 5 + 6 (556 mg); 78-84, 6 (15 
mg). From fraction 87 on, the stationary phase started to be pumped out and collected, giving: 114-115, 
1 (20.5 mg); 116-119, 1 + 2 (121.5 mg), 120, 2 (8 mg). 
SEPARATION OF SENKIRKINE [5] AND NEOSENKIRKINE [6).—A mixture containing 5 and 6 (Ca. 
1:1) (158.7 mg) was subjected to dccc in the solvent system CHC1 3 -C6H6-Me0H-H 20 (5:5:7:2) in as-
cending mode. At the flow rate of 15 ml/h, fractions of 10 ml were collected. Pure 5 (24.8 mg) was eluted 
in fractions 133-146 while pure 6(5.7 mg) was obtained from fractions 176-182. Fractions 147-175 con-
tained mixtures of varying ratios of 5 and 6. 
SEPARATION OF HYDROXYSENKIRKINE [7] AND ILYDROXYNEOSENKIRKINE 18).—A mixture of 
7 and 8 (ca. 9:1) (94 mg) was subjected to chromatography in the solvent system CHC1 3 -Me0H-H 20 
(13:7:4) in descending mode. At flow rate of 24 ml/h, 20-m1 fractions were collected. Fractions 36-37 af-
forded a mixture of 7 and 8 (9.5 mg) in a 1:2 ratio. Pure 7 (44.1 mg) was obtained from fractions 43-49. 
Intervening fractions contained varying amounts of both isomers. 
ATTEMPTED SEPARATION OF RETRORSINE (31 AND USARAMINE [4].—A mixture of 3 and 4 
(93:7) (40 mg) was subjected to dccc using the solvent system CHCI i -Me0H-H,0 (13:7:4) in descending 
mode. At flow rate of 24 ml/h, 20-m1 fractions were collected. Fraction 14 (20.5 mg) afforded 3 with traces 
of 4, and fractions 15-17 (16 mg) afforded pure retrorsine. Fraction 14 was rerun under the same condi-
tions, but no pure usaramine was obtained. Pure 3 (16 mg) was obtained in fractions 17-22. 
SEPARATION OF SENECIONINE [1] AND INTEGERRIMINE [2).—A mixture of 1 and 2 (1:1) was 
subjected to fractional crystallization from Me 2CO utilizing the fact that 1 was less soluble than 2 in the 
solvent. 
ANONAMINE [9).—Mp 202 ° , [e] 27 D +33.5 ° (c= 1.0, CHCI eims m/z (%) 100 (15), 110 (46), 
122 (29), 123 (49), 124 (19), 150 (16), 151 (63), 168 (50), 169 (24), 248 (21), 266 (13), 282 (23), [M] F 
 381 (2); cims [MH]+ 382 (100); exact mass calcd for C, 9H 27 NO2 , 381.1788, found 381_1742. 
3a13-HYDROXY-4-ETHOXY-2,6-PERHYDROINDOLEDIONE [11).—Mp 170°; eims miz (%) 43 
(100), 44 (42), 55 (24), 70 (28), 71 (23), 73 (24), 97 (16), 99 (39), 125 (37), 14 1(40), 150 (36), 167 (25), 
184 (2), 195 (5), 213 (0.8), 214 (0.6); cims NH:1 4 214 (100); exact mass calcd for C 101-1141\104 WHY* 
2 14.1185, found by cims 214.1048; i H nmr (CDC1 3 ) S 1.1 (t,1 = 7 Hz, CH 2Me), 3.60 and 3.35 (each 
= 9.5, 7.0 Hz, CH iMe), 4.04 (dd,f = 13.7, 4.9 Hz, H-4), 3.72 (cld, J = 4.7, 1.7 Hz, H-7a), 2.83 
702 	 Journal of Natural Products 	 [Vol. 51, No. 4 
and 2.21 (each d, J= 15.0 Hz, I-12-3), 2.81 (m, H-5), 2.52 (d, J = 15.5 Hz, H-5), 2.85 (m, H-7), 2.53 
(d, J= 13.8 Hz, H-7). 
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Abstract. A(Mo Ka) = 0.71069 A, T = 298 K. Anon-
amine (I) (12,21-dihydroxy-4-methyl-4,8-secoseneci-
onan-8,11,16-trione): C 11H27N07 , Mr = 381.2, mono-
clinic, C2, a = 24.247 (7), b = 8.766 (2), c 
9.072 (1) A, ig = 99.21 (2)°, U= 1903.3 (8) A 3, Z = 4, 
Dm = 1.32 (1), Dx = 1.330 g cm-3, p(Mo Ka) = 
1.09 cm- ', F(000) = 816. Neosenkirkine (II) (12- 
hydroxy-4-methy1-4,8-secosenecionan-8,11,16-trione): 
C,91-1 27N06, Mr = 365.2, monoclinic, C2, a = 
24-45 (1), b = 8.7811:2), c= 9.029 (2) A, /J= 
98.99 (3)°, U= 1915 (1) A3, Z = 4, Dm = 1.27 (1), 
Dx = 1.267 g cm-3, p(IvI[o Ka) = 1.01 cm-., moo = 
784. Hydroxysenkirkine (III) [12,18-dihydroxy-
4-methy1-4,8-secosenecionan-8,11,16-trione-methanol 
( : C 19H 27N0 7.0 H 2OH, Mr = 413.2, orthorhombic, 
P2,2 1 2„ a = 9.052 (3), b = 13.150 (4), c = 
17.404 (8) A, U= 2071 (1) A3 , Z = 4, Dm = 1.33 (1), 
Dx = 1.325 g cm-3, p(Mo Ka) = 1.10 cm- ', F(000) = 
888. Full-matrix least squares refinement converged at 
R values of 0.042, 0.043 and 0.051 for 3163, 2894 and 
2896 reflections for (I), (II) and (III), respectively. All 
three crystals exhibit hydrogen bonds, including intra-
molecular 011...H012 and intermolecular 08... 
H012. In addition, intermolecular hydrogen bonds 
appear in (I) between 021...H021' and in (III) 
between 08.••HOCH 3. The observed N•C8 dis-
tances across the eight-membered otonecine rings were 
2.200, 2.245 and 1.712 A in (I), (II) and (III) 
respectively. 
Introduction. Anonaminet (I), neosenkirkine (II) and 
hydroxysenkirkine (III) belong to a sub-group of 
pyrrolizidine alkaloids of the 12-membered macro-
cyclic diester type, which contain the seconecine 
otonecine (IV). At present, approximately two dozen 
members of this sub-group have been reported (Mat-
tocks, 1986) and, of these, X-ray crystallographic 
studies have been reported for otosenine (Perez-
Salazar, Cano, Fayos, Martinez-Carrera & Garcia- 
• To whom all correspondence should be addressed. 
t This is the trivial name which has been given to this new 
alkaloid. 
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Blanco, 1977), fukinotoxin (Furuya, Hikichi & Iitaka, 
1976), senkirkine (Birnbaum, 1974) and clivorine 
(Birnbaum, 1972). 
The 12-membered macrocyclic diesters of otonecine 
show the same pattern of hepatotoxicity observed for 
other pyrrolizidine alkaloids containing a double bond 
at C1-C2 (Mattocks, 1986; Peterson & Culvenor, 
1983). In addition, it has recently been shown that four 
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members of the group (clivorine, fukinotoxin, sen-
kirkine and ligularidine) are mutagenic and one of these 
(fukinotoxin) is a known carcinogen (Yamanaka, 
Nagao & Sugimura, 1979). It has been pointed out that, 
in the past, the danger of pyrrolizidine alkaloids to 
human health has not been sufficiently recognized, 
especially in light of the worldwide presence of plants 
containing them (estimated at 3% of the world's 
flowering plants) (Smith & Culvenor, 1981). The three 
© 1988 International Union of Crystallography 
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Table 1. X-ray data collection and solution 
Anonamine (1) 	 Neosenkirkine (II) 	Hydroxysenkirkine (III) 
Crystal size (am) 0.68 x 0.60 x 0 50 0.88 x 0.32 x 0 - 10 065 x 0.70 .,, 0.31 
No. of reflections for lattice parameters 15 15 15 
Diffractometer Syntex P2, Syntex P2, Syntex P2, 
Radiation Mo Ka A - 0-71069 A: graphite m000chromator 
20 range (°) for orientation matrix and 
lattice parameters 14.15-24.85 14.15-2485 14.15-2485 
Scan type w 
Scan speed (° min 	') 3 91-29.30 3.91-29-30 3.91-29.30 
20 range (data collection) (°) 4-50 4-40 4-50 
h, 8. ( range +28, +10, 0-10 I-28, +10, 0-10 +10. 0-15. 0-20 
No. of reflections measured 3510 3526 3164 
No. of reflections with f > 3a(F) 3163 2894 2896 
R 0042 0-043 0.051 
42 0045 0-043 0-062 
Weight = 811(aF)' + gFl k; g 2. 1 ; 0.0004 1. 5: 0-0004 1.0:0.3 
Max..1/a 0041 0-041 0027 
Max., min. in dp (e A - ') 0.51, -0.29 0.34, -0.24 0.36. -0.26 
alkaloids described in this communication were iso-
lated from a local weed, Senecio anonymus Wood, 
which was found to contain, in addition to these three, 
three other 12-membered macrocyclic diesters of 
otonecine (senkirkine, hydroxyneosenkirkine and 
otosenine) and four 12-membered macrocyclic diesters 
of retronecine (V) (senecionine, integerrimine, retror-
sine and usaramine) (Zalkow, 1988). Anonamine (I) is 
a new pyrrolizidine alkaloid. 
Experimental. Anonamine (I), neosenkirkine (II) and 
hydroxysenkirkine (III) were isolated from the ethanol 
extract of Senecio anonymus Wood using droplet 
counter-current chromatography (Zalkow, 1988). 
Crystals of (I) and (II) were obtained from acetonitrile, 
while crystals of (III) were obtained from methanol 
upon slow diffusion of acetone vapors. Specific optical 
rotations and melting points (corrected) were as 
follows: (I): [a]r + 33.5° (c 1, CHCl 3), m.p. 475 K; 
(II): [a]r + 16.9° (c 1, CHC1 3), m.p. 473-475 K; 
(III): [c(] 2i,5 ° —9.1° (c 1, C 2 1-1 5 0H), m.p. 393 K. 
Experimental details for the X-ray examinations are 
given in Table 1. All densities determined by flotation in 
hexane—CC1 4. Lp corrections but no extinction or 
absorption corrections. Structures (I) and (III) solved in 
the same manner. MULTAN78 (Main, Hull, Lessinger, 
Germain, Declercq & Woolfson, 1978) used to generate 
a series of E maps, one of which correctly located most 
non-H atoms; after three cycles of full-matrix least-
squares refinement (on F), remaining non-H atoms 
located from difference Fourier map; non-H atoms refined 
anisotropically and H atoms located from subsequent 
difference Fourier map. The structure of (II) was solved 
after observing the great similarity between the cell 
constants for (I) and (II), suggesting isomorphous 
structures. Thus, a solution was obtained by refining the 
coordinates of the non-hydrogen atoms [minus 0(21) 
from (I)] with the observed data for (II). Parameters 
varied: overall scale factors, coordinates of non-H 
atoms, anisotropic temperature factors of non-H atoms, 
isotropic temperature factors for H atoms. Scattering 
factors as in SHELX76 (Sheldrick, 1976). 
Fig. 1. ORTEPII view (Johnson, 1976) of anonamine (I) with the 
atom numbering. Thermal ellipsoids are drawn at the 50% 
probability level. 
Fig. 2. ORTEPII view of neosenkirkine (II). 
b 
Fig. 4. Crystal packing in (I) and (II) showing intermolecular 
hydrogen bonds 08- • • HO 12'. 
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The absolute configurations of the three compounds 
are defined by reference to the known absolute 
configuration of otonecine as found in retusamine 
(Wunderlich, 1967). 
Discussion. The ORTEPII (Johnson, 1976) views of 
anonamine (I), neosenkirkine (II) and hydroxysen-
kirkine (III) are shown in. Figs. 1, 2 and 3, respectively, 
using 50% probability ellipsoids. The thermal param-
eters of the H atoms have been artificially reduced to 
clarify the pictures. The crystal packing of both (I) and 
(II), since they are isomorphous, is shown by the same 
figure (Fig. 4). Additional intermolecular hydrogen 
bonding between 021... H021' in (I) is shown in Fig. 
5. Molecules of (III) exhibit intermolecular hydrogen 
Fig. 3. ORTEPII view of hydroxysenkirkine (Ill). 
bonds involving 08 and CH 3OH (see Fig. 6). Final 
atom coordinates, bond lengths and angles are given in 
Tables 2-6.* In Table 7 selected values used in 
describing structures of some secopyrrolizidine 
alkaloids are collected. 
In all the known 12-membered macrocyclic esters of 
otonecine and retronecine with the C15—C20 exo-
cyclic double bond, the esterifying chains assume very 
similar conformations (Mackay & Culvenor, 1982). 
The position of the C16-016 carbonyl on the outer 
side of the pyrrolizidine skeleton remains virtually the 
same in all macrocyclic pyrrolizidine alkaloids, regard-
less of the size of the ester chain, and most likely is 
determined by steric hindrance of the inner (fl) side of 
the pyrrolizidine skeleton. The less sterically restricted 
carbonyl, C11-011, assumes a position roughly 
parallel to C 16-016 but pointing in the opposite 
* Lists of structure factors, H-atom coordinates and anisotropic 
thermal parameters have been deposited with the British Library 
Document Supply Centre as Supplementary Publication No. SUP 
44939 (47 pp.). Copies may be obtained through The Executive 
Secretary, International Union of Crystallography, 5 Abbey 
Square, Chester CH 1 2HU, England. 
Fig. 5. Crystal packing in (I) showing intermolecular hydrogen 
bonds 021...H021'. 
Fig. 6. Crystal packing in (III) showing the hydrogen-bond system 
CH 2OH• • •08—H012'. 
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direction. This orientation results from steric tension of 
the macrocyclic ring. Other influences are the intra-
molecular hydrogen bond 011• • .H012, which con-
tributes to the exceptional flatness of the fragment 011, 
C 11, C 12, 012, and a dipole-dipole repulsion of the 
two carbonyls. The two 1,3-unsaturated systems 
consisting of 08, C8, Cl and C2 and of 016, C 16, C 15 
and C20 present in (I), (II) and (III) are subject to 
steric tension of the otonecine and macrocyclic rings, 
respectively, which results in non-planarity, found also 
in the structures of senkirkine (VI), otosenine (VII) and 
clivorine (VIII). 
Table 2. Final atomic coordinates and Um values (A 2) 
for anonamine (I) 
Here and in Tables 3 and 4 U„ = aU„. 
x y z u„ 
C I -0.82974 (9) -0-2001 -0.0972 (2) 0.037 
C2 -0.8625 (I) -0.1558 (4) -0.0039 (3) 0.060 
C3 -0.9122 (1) -0.2483 (5) 0.0160 (3) 0.078 
C5 -0.9543 (I) -04202 (4) -0.1853 (3) 0.061 
C6 -0.9285 (I) -0.4629 (4) -0.3178 (3) 0.050 
C7 -0.88082 (8) -0.3547 (3) -0.3345 (2) 0.030 
C8 -0.83967 -0.3451 (3) -0.1850 (2) 0.029 
C9 -0.7752 (I) -0.1212 (3) -0.1028 (3) 0.049 
C11 -0.7963 (1) 0-1077 (4) -0.2436 (3) 0.047 
C12 -0.7940 (1) 0-1845 (3) -0.3930 (3) 0.045 
C13 -0.8332 (1) 0.0982 (3) -0.5151 (2) 0.041 
C 14 -0.89317 (9) 0.0987 (3) -0.4813 (2) 0.041 
CI5 -0.9294 (1) -0.0200 (4) -0.5675 (2) 0.042 
C16 -0.91858 (8) -0. 1836 (3) -0.5262 (2) 0.037 
C18 -0.7336 (1) 0.1854 (4) --0.4235 (4) 0.073 
C19 -0.8309 (I) 0.1620 (4) -0.6708 (3) 0.066 
C20 -0.9706 (1) 0.0066(4) -0.6814 (3) 0.060 
C21 -0.9905 (1) 0-1628 (5) -0.7400 (4) 0.079 
C22 -0.8896 (I) -0.5199 (5) 0.0352 (4) 0.079 
N -0.90893 (9) -0.3920 (3) -0.0618 (2) 0.056 
08 -0.80485 (6) -0.4475 (3) -0.1629 (2) 0.041 
010 -0.77666 (7) -0.0352 (3) -0.2422 (2) 0.045 
011 -0.8122 (1) 0.1671 (3) -0.1404 (2) 0.092 
012 -0.81442 (9) 0.3351 (3) -0-3908 (2) 0.059 
016 -0.92665 (8) -0.2893 (3) -0.6123 (2) 0.054 
017 -0.89890 (6) -0.2019 (3) -0.3795 (I) 0.037 
021 -1.0288 (2) 0.1493 (5) -0.8720 (4) 0.147 
Table 3. Final atomic coordinates and tie, values (A 2) 
for neosenkirkine (II) 
x y z 
CI -0.8295 (I) -0-2001 -0.0966 (3) 0.038 
C2 -0.8631 (1) -0.1574 (4) -0.0026 (3) 0.059 
C3 -0.9117 (2) -0.2497 (5) 0.0184 (4) 0.079 
CS -0.9539 (1) -0.4176 (4) -0.1868 (4) 0.065 
C6 -0.9275 (I) -04619 (4) -0.3196 (3) 0.050 
C7 -0.88036 (9) -0.3545 (3) -0.3350 (2) 0.032 
C8 -0.83929 (9) -0.3447 (4) -0.1868 (3) 0.033 
C9 -0.7758 (I) -0.1213 (4) -0.1026 (3) 0.048 
CI 1 -0.7947 (1) 0.1089 (4) -0.2415 (3) 0.044 
C12 -0.7929 (1) 0.1850 (4) -0.3936 (3) 0.044 
C13 -0.8327 (I) 0.0988 (3) -0.5150 (3) 0.040 
C14 -0.8918 (I) 0.0983 (4) -0.4774 (3) 0.043 
C15 -0.9281 (I) -00178 (4) -0.5652 (3) 0.041 
C16 -0.9185 (I) -01807 (4) -0.5257 (3) 0.038 
C18 -0.7336 (I) 0.1833 (4) -0.4250 (5) 0.069 
C19 -0.8308 (I) 0.1653 (5) -0.6715 (3) 0.064 
C20 -0.9682 (I) 0.0108 (4) -0.6805 (3) 0.058 
C21 -0.9870 (1) 0.1653 (6) -0.7409 (5) 0.083 
C 22 -0.8926 (2) -0-5222 (6) 0.0336 (5) 0.097 
N -0.9095 (I) -0.3930 (4) -0.0604 (3) 0.057 
08 -0.80535 (7) -0.4476 (3) -0.1638 (2) 0.047 
010 -0.77741 (7) -0.0360 (3) -0.2423 (2) 0.045 
011 -0.8090 (1) 0.1715(3) -0.1368 (2) 0.064 
012 -0.81237 (9) 0.3354 (3) -0.3910 (2) 0.060 
016 -0.92716 (9) -0.2860 (3) -0.6121 (2) 0.056 
017 -0.89816 (7) -0.2016 (3) -0.3786 (2) 0.037 
One of the most intriguing features of the seco-
pyrrolizidine alkaloids is the short trans-annular dis-
tance of N• • • C8, being well below the sum of the van 
der Waals radii of 2.9 A. This correlates with an 
unusually long C8-08 carbonyl bond. Perez-Salazar et 
al. (1977) found it useful to interpret the results on 
otosenine (VII) with the electron-repulsion distribution 
theory (Linnett, 1966). The extent of the partial bond in 
senkirkine (VI) and clivorine (VIII) has been discussed 
Table 4. Final atomic coordinates and U„ values (A 2) 
for hydroxysenkirkine (III) 
x y u„ 
Cl 0.8408 (2) 0.1694 (2) 0-8916 (1) 0.030 
C2 0-8093 (2) 0-0732 (2) 0.8875 (2) 0.0390 
C3 0.9232 (3) 0.0115 (2) 0.8450 (2) 0.049 
C5 1.1598(3) 0.0766 (3) 0.7842 (2) 0.052 
C6 1.0869 (3) 0.1421 (2) 0-7245 (2) 0.048 
C7 0.9869 (2) 0.2183 (2) 0.7651 ( I) 0.031 
C8 0.9885 (2) 0.1979 (2) 0.8535 (I) 0.029 
C9 0.7564 (2) 0.2468 (2) 0.9364(1) 0.033 
CII 0.5271 (2) 0.2776 (2) 0.8716 (1) 0.031 
C12 0.4499 (2) 03485 (2) 0.8148 (I) 0.033 
C13 0.5370 (2) 0.3479 (2) 0.7383(1) 0.034 
C14 0.5440 (3) 0.2403 (2) 0.7047(I) 0.036 
C15 0.6563 (3) 0.2315 (2) 0.6415 (I) 0.033 
C16 0.8127 (3) 0.2455 (2) 0.6645 (I) 0.032 
C [8 0.4420 (3) 0.4551 (2) 0.8508 (2) 0.046 
C19 0.4727 (3) 0.4209 (2) 0.6791 (2) 0.053 
C20 0.6205 (3) 0.2128 (3) 0.5683 (2) 0.047 
C2I 0.7182 (4) 0.2023 (4) 0.4999 (2) 0.068 
C22 1.1387 (3) 0.0556 (2) 0.9238 (2) 0.052 
N 1.0577(2) 0.0767 (2) 0.8513 (1) 0.038 
08 1.0766 (2) 0.2575 (1) 0.8913 (1) 0.032 
010 0.6651(2) 0-3108 (1) 0.88645 (9) 0.032 
011 0.4744 (2) 02014 (1) 0.8978 (1) 0.046 
012 0.3066 (2) 0-3126 (I) 0.7980 (1) 0.043 
016 0.9093 (2) 0.2839(2) 0.6265 (1) 0.052 
017 0.8369 (2) 0.2094 (1) 0.73610 (9) 0.035 
018 0.3786 (2) 0.4513 (2) 0.9249(1) 0.058 
0 0.0714 (2) 0.4588 (2) 0.9020(1) 0.058 
C -0.0333 (4) 0.4956 (3) 0-9543 (2) 0.057 
Table 5. Bond lengths (A) with their e.s.d.'s in 
parentheses 
(I) (II) (III) 
C I -C2 1.309 (3) 1.324 (4) 1.298 (4) 
CI-C8 1.498 (3) 1.508 (3) 1.539 (3) 
C I-C9 1.500 (4) 1.493 (4) 1.492 (3) 
C2-C3 1.486 (5) 1.476 (5) 1.506 (4) 
C3-1,4 1.453 (4) 1.451 (5) 1.493 (3) 
C5-C6 1.490 (4) 1.499 (4) 1.504 (4) 
C5-N 1.461 (3) 1.463 (4) 1489 (4) 
C6-C7 1.522 (3) 1.512 (4) 1.523 (4) 
C7-C8 1.522 (3) 1.545 (3) 1.562 (3) 
C7-0 I7 1.448 (2) 1.447 (3) 1.454 (3) 
C8-08 1.227 (2) 1.222 (3) 1.298 (3) 
C9-010 1.468 (3) 1.462 (3) 1.466 (3) 
C I I-C12 1.522 (3) 1.534 (4) 1.528 (3) 
C 1 1-010 1.339 (3) 1.341 (3) 1.348 (3) 
C1I-011 1.188 (3) 1.192 (4) 1.200 (3) 
C12-C13 1.537 (3) 1.546 (4) 1.547 (3) 
C12-C18 1.533 (4) 1.520 (4) 1.537 (4) 
C12-012 1410 (3) 1.406 (3)  1412 (3) 
C 13-C14 1.533 (3) 1.535 (4)  1.532 (4) 
C13-C 19 1.529 (3) 1.537 (4) 1.525 (4) 
C14-C15 1•498 (3) 1.495 (4) 1-503 (3) 
CI5-C16 1.494 (3) 1.485 (4) 1-483 (4) 
C 15-C20 1.339 (3) 1.338 (4) 1.336 (4) 
C 16-017 1.350 (2) 1.356 (3) 1.351 (3) 
CI6-016 1.207 (3) 1.207 (3) 1.208 (3) 
CI8-018 - - 1.413 (4) 
C20-C21 1 .520 (4) 1.507 (5) 1-490 (4) 
C21-021 1.398 (4) _ 
C22-N 1.456 (4) 1.438 (5) 1.486 (4) 
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by Birnbaum (1974), who correlated the bond distances 
with the frequencies of the carbonyl peak in the infrared 
spectrum. 
Table 6. Angles (°) with e.s.d.'s in parentheses 
(1) (11) (III) 
C8-CI--C2 122.2 (2) 121.6 (2) 113.8 (2) 
C9--C I -C2 121.0 (2) 1220 (2) 125.5 (2) 
C9-CI-C8 116.2 (2) 115.9 (2) 120.3 (2) 
C3-C2-CI 120.3 (3) 121.3 (3) 113.7 (3) 
N-C3-C2 107.8 (2) 108.7 (3) 102.3 (2) 
N-05-C6 107.4 (2) 107-6 (2) 105.6 (2) 
C7-C6--05 110.4 (2) 1099 (2) 108.5 (2) 
C8-C7--C6 109.9 (2) 1109 (2) 1098 (2) 
017-C7-C6 113.8 (2) 113.7 (2) 110.0 (2) 
017-C7-C8 108.6 (1) 108.1 (2) 1097 (2) 
C7-C8-C I 122.5 (2) 122.8 (2) 117.3 (2) 
08-C8-C1 119-1 (2) 119.0 (2) 117.5 (2) 
08-C8--C7 115.6 (2) 116.0 (2) 113.7 (2) 
010-C9.-C I 111.5 (2) 111.4 (2) 1 11-7 (2) 
010-C I 1 -C 12 111.1 	(2) 110-8 (2) 110.5 (2) 
011-CII-C12 1247 (2) 124-2 (2) 125.0 (2) 
011-C11-010 124.2 (2) 124.9 (3) 124.4 (2) 
C13-C12-C11 108.5(2) 108.5(2) 108.7(2) 
C 18-C12-C1 1 109-5 (2) 109.0(2) 108.3 (2) 
C 18-C12-C13 111.7 (2) 112- I 	(2) 1123 (2) 
012-C12-C11 109.8 (2) 109.7 (2) 110.5 (2) 
012-C 12-C 13 107.1 (2) 107.1 (2) 106.8 (2) 
012-C12-C18 110.2 (2) 110.4 (2) 110.3 (2) 
C 14 -C 13 -C 12 110.5 (2) 110.8 (2) 110 - 8 (2) 
C19-C13-C 12 112.1 (2) 111.0 (2) 112.5 (2) 
C19-C13--C14 111.1(2) 111.7(2) 109.8(2) 
C15-C14--C 13 112.9 (2) 112-7 (2) 112.3 (2) 
C 16-C15-C14 118.1 (2) 118-1 (2) 115.9 (2) 
C20-C15-C14 112.9 (2) 125.9 (2) 123.2 (2) 
C20-C15-C16 116.1 (2) 115.9 (2) 120.8 (2) 
017-C16-C15 112.4 (2) 112.7 (2) 111.1 	(2) 
016-C16-C15 124.8 (2) 125.3 (2) 126.5 (3) 
016-C16-017 122.8 (2) 122.1 (2) 122.4 (2) 
018-C18-C12 - - 111.0(2) 
C21-C20-C15 125.7 (3) 126.5 (3) 129.4 (2) 
021-C21-C20 110.7 (3) - 
C5-N-C3 115.3 (2) 1155 (3) 116.6 (2) 
C22-N-C3 114-3 (2) 115.1 	(3) 110.9 (2) 
C22-N-05 117.7 (3) 117.0 (3) 111.0 (2) 
CI 1-010-C9 116.6 (2) 116.6 (2) 116.8 (2) 
C16-017-C7 115.6 (2) 116.1 (2) 116.3 (2) 
Analysis of molecular packing in the crystals of (I), 
(II), (III), (VI), (VII) and (VIII) led us to the conclusion 
that both the distance of C8• • .N and the carbonyl 
C8-08 bond length are dependent on the presence of 
hydrogen bonds involving 08. While the mcdecules of 
macrocyclic retronecine esters are intermolecularly 
hydrogen bonded through the nitrogen, all known 
X-ray structures of the secopyrrolizidines show hydro-
gen bonds involving 08. Thus, in the crystals of (I), 
(II), (III), (VI) and (VII) there are intermolecular 
hydrogen bonds 08. • • H012'. The H012 hydroxyl is 
also involved in an intramolecular hydrogen bond 
011...H012 [with the exception of (VII), in which the 
distance 011•••H012 exceeds the sum of the van der 
Waals 0...1-1(0) radii of 2.6 Al. This results in an 
exceptional flatness of the fragment 011-C11-C12- 
012. Clivorine (VIII), which has no hydroxyl groups, 
crystallizes with a molecule of water binding molecules 
of the alkaloid through the links 08.. .1-1-0-H...016 
(Birnbaum, 1972). In hydroxysenkirkine the distance of 
C8.•.N is by far the shortest recorded in the series of 
free secopyrrolizidine alkaloids. Analysis of hydrogen 
bonds with 08 reveals the presence of two compared 
with only one in the remaining five alkaloids (Fig. 6). 
Besides the hydrogen bond 08•..H012' already 
mentioned there is a second with a molecule of 
methanol present in the crystal, 08..•HOCH 3 (distance 
OH•08 is 1.548 and 0...08 is 2.653 A). The 
hydroxyl from the methanol forms a second hydrogen 
bond with 018 (OH• • •018 1.841 and 0...018 
2.8I A). 
The hydrogen bonds to 08 decrease the sp2 
character of the carbonyl group and could reasonably 
Table 7. Comparison of selected values for some 12-membered macrocyclic otonecine esters 
lntramolecular distances (A) 
(1) (II) 
C8•.•N 2.200 2.245 
C8•-•08 1.227 1.222 
011...012 2.700 2.700 
011.--H012 2.338 2.462 
C16...C11 4.411 4.448 
017.-010 3.359 3.350 
Intermolecular distances (A) 
012...08 2.794 2.700 
1-1012.•.08 1.974 1.989 
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' Birnbaum (1974). 
'Perez-Salazar et al. (1977). 
'Birnbaum (1972). 
4 Dunitz (1979). 
'Calculated from cell constants and coordinates given in corresponding paper. 
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account for the observed displacement (A) of C8 from 
the plane defined by the atoms to which it is bonded 
(Table 7). For compounds (I), (II) and (III), the 
observed out-of-plane displacements (A) are 0.139, 
0.122 and 0.289 A respectively. The more extensively 
08 is hydrogen bonded, the more electron deficient C8 
becomes and, thus, the more susceptible to interaction 
with the N lone pair. Therefore, the extent of hydrogen 
bonding to 08 can be correlated with the displacement 
(A) and in turn correlated with the C8—N bond length. 
This is consistent with the previous survey by Dunitz 
(1979) involving a number of compounds with inter-
acting carbonyl and amino groups, where the C—N 
distances were correlated with the observed out-of-
plane displacements. 
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Abstract. C 21 H 160, Mr = 284.36, monoclinic, P2,/c, 
a = 14.442 (3), b = 17.917 (3), c = 6.085 (1) A, /3= 
94.17(1)°, V = 1570.4 A 3 , Z = 4, Dx = 
1.204 Mg m -3, A(Cu Ka) = 1.54178 A, ,u(Cu Ka) = 
0.487 mm- ', F(000) = 600, T = 290 (1) K, R = 0.078 
for 1039 observed reflections. In the structure reported 
here, the 13-membered ring contains seven synperi- 
0108-2701/88/091598-03$03.00 
planar, two antiperiplanar and four anticlinal con-
formational units. The diyne system is slightly non-
linear. The phenyl rings are not coplanar but are twisted 
with respect to each other by 27°. 
Introduction. The title compound (1) was prepared 
(Acheson & Lee, 1987) by a synthetic route expected to 
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Semisynthetic Pyrrolizidine Alkaloid N-Oxide Antitumor Agents. Esters of 
Heliotridine 
Leon H. Zalkow,* Jan A. Glinski, Leslie T. Gelbaum, David Moore,t Deborah Melder,t and Garth Powist 
School of Chemistry, Georgia Institute of Technology, Atlanta, Georgia 30332. Received December 9, 1987 
The C-9 and C-7 monoesters and C-7, C-9 diesters of heliotridine with (S)-(+)- and (R)-(–)-2-hydroxy-2-phenylbutyric 
acid were prepared, converted into their N-oxides, and compared with the corresponding C-9 monoesters of retronecine 
in the in vivo P388 lymphocytic leukemia screen. Relative in vitro cytotoxicities of some of the free bases and their 
corresponding N-oxides were also measured against the A204 rhabdomyosarcoma cell line by using the soft agar 
colony forming assay. Stereochemistry at C-7 of the necine and at C-2' of the necic acid appears to have a significant 
effect on the antitumor activity in this system. In the heliotridine series, the configuration of the necic acid has 
a pronounced effect on the site selectivity (C-7 vs C-9) in esterification with carbodiimidazole. An explanation for 
this site selectivity is offered. 
It has been reported that, on a molar basis, diesters of 
retronecine (1) and heliotridine (2) and about 4 times as 
toxic as the respective C-9 monoesters and heliotridine C-9 
monoesters are 2-4 times as toxic as retronecine C-9 mo-
noesters. 1 Thus, it was concluded that an a -OH at C-7 
leads to higher hepatotoxiciity than a 33-OH. Metabolic 
pyrroles such as 3, produced in the liver from pyrrolizidine 
alkaloids containing a double bond at C-1, have been 
identified as the cytotoxic agents.' More recently, the 
formation of N-oxides and pyrrolic intermediates, pro-
duced from unsaturated pyrrolizidine alkaloids by hepatic 
microsomal preparations, has been studied. 5 It was con-
cluded that N-oxides and pyrroles are produced by inde-
pendent pathways and acute pyrrolizidine hepatotoxicity 
was attributed only to the effects of the metabolic pyrroles. 
It has been suggested that pyrrolizidine N-oxides per se 
are not hepatotoxic, and their toxicity arises only to the 
extent that they are reduced to their corresponding bases 6,7 
A comparison of the toxicity of heliotrine (4), with its 
N-oxide (5), by intraperitoneal administration (ip) to the 
rat, showed acute LD 50 of 300 mg/kg for the former and 
5000 mg/kg for the latter. 8 
In 1976, the antitumor activity of indicine N-oxide (6) 
was discovered in a bioassay-directed fractionation of 
Heliotropium indicum. 9 I ndicine N-oxide given ip is a 
more active antitumor agent than indicine (7) or heliotrine 
N-oxide (5) and indicine N-oxide administered orally is 
inactive. 10 Thus, indicine is not responsible for the an-
titumor activity of indicine N-oxide. The mechanism of 
the antitumor activity of indicine N-oxide is unclear at this 
time. As part of our continuing studies of the antitumor 
activity of semisynthetic pyrrolizidine alkaloid N-
oxides, 11,12 we decided to examine the effect of stereo-
chemistry at C-7 of the necine and at C-2' of the necic acid 
moiety. 
Chemistry 
Our first concern was a ready supply of the necine, he-
liotridine (2). Although an elegant total synthesis of he-
liotridine has been reported, it did not lend itself to a 
practical solution to our problem. 13 Our earlier investi-
gations of plants containing pyrrolizidine alkaloids bearing 
the necine heliotridine," together with further attempts 
to find a ready source of this necine, failed to provide a 
ready supply of heliotridine. We were thus required to 
develop a practical conversion of retronecine into helio-
tridine. Retronecine was easily available by hydrolysis of 
monocrotaline (8), available in large quantities from the 
seeds of Crotalaria spectabilis.11- 12 Using the method of 
t Departments of Pharmacology and Oncology, Mayo Clinic, 
Rochester, MN 55905. 
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2 ( heliot rid ine) 
R = CH 3 CH 2CO, R'= PhCO (17 h, 76 °C, 80%) 
(i) PhCOOH (1 equiv), CDI (1.1 equiv), THF, room tempera-
ture, 16 h, 95%. (ii) MeS02C1 (1.3 equiv), Et 3N (1.5 equiv), CH 2- 
C12 , –2 °C, 1.5 h, 93%. (iii) RCOOCs (4 equiv), DMF. (iv) Ba(0- 
H) 2, room temperature, 87%. 
Kellogg et al., 15 we developed an efficient synthesis of 
heliotridine by nucleophilic displacement of the C-7 me- 
(1) Culvenor, C. C. J.; Edgar, J. A.; Jago, M. V.; Outteridge, A.; 
Peterson, J. E.; Smith, L. W. Chem.-Biol. Interact. 1976, 12, 
299. 
(2) Mattocks, A. R. Nature (London) 1968, 217, 723. 
(3) Mattocks, A. R.; White, I. N. H. Chem.-Biol. Interact. 1971, 
3, 383. 
(4) Mattocks, A. R. Pharmacol. Future Man. Proc. Int. Congr. 
Pharmacol., 5th, 1972 1972, 2, 114. 
(5) Mattocks, A. R.; Bird, I. Chem.-Biol. Interact. 1983, 43, 209. 
(6) Mattocks, A. R. Xenobiotica 1971, 1, 563. 
(7) Powis, G.; Ames, M. M.; Kovach, J. S. Cancer Res. 1979, 39, 
3564. 
(8) Downing, D. T.; Ptererson, J. E. Aust. J. Exp. Biol. Med. Sci. 
1968, 46, 493. 
(9) Kugelman, M.; Liu, W.-C.; Axelrod, M.; McBride, T. J.; Rao, 
K. V. Lloydia 1976, 39, 125. 
(10) Powis, G.; Ames, M. M.; Kovach, J. S. Res. Commun. Chem. 
Pathol. Pharmacol. 1979, 24, 559. 
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sylate, in the 7-mesyl-9-benzoate of retronecine (9) with 
various cesium carboxylates in DMF, followed by hy-
drolysis as outlined in Scheme I. A preliminary commu-
nication of this work has appeared." 
Our first choice as the synthetic necic acid, as previously 
mentioned," was 2-hydroxy-2-phenylbutyric acid. We 
chose this acid because, like 2,3-dihydroxy-2-isopropyl-
butyric acid, the necic acid of indicine, the C-2' position 
was chiral and contained a tertiary hydroxyl group and the 
addition of an aromatic ring at C-2' permits a structure-
activity study using various substituents on the aromatic 
ring. Also, 2-hydroxy-2-phenylbutyric acid had been re-
solved and was of known absolute configuration. 17 This 
turned out to be an excellent choice since this necic acid, 
even when used as the racemic mixture, and coupled to 
retronecine at C-9, produced a diastereomeric mixture (10 
+ 11) more potent and more active than indicine N-oxide.' 2 
 In addition, we found a large difference in potency and 
activity between individual diastereomers, thus showing 
that chirality at C-2', at least in this series, did indeed 
effect antitumor activity.' We, later in this paper, discuss 
these results together with the effect of stereochemistry 
at C-7 of the necine. 
2-Hydroxy-2-phenylbutyric acid was prepared as pre-
viously described, but was resolved with (+)- and (-)-
ephedrine rather than quinine as reported earlier. 11 
 Coupling of (S)-(+)- or (R)-(-)-2-hydroxy-2-phenylbutyric 
acid with retronecine using 1,1'-carbodiimidazole is highly 
site specific for the C-9 position, giving respectively 10 and 
11 with no isolatable amounts of the C-7 isomers. In 
contrast, when heliotridine was treated with the R or S acid 
and 1,1'-carbodiimidazole in THF, a mixture of the C-7 
and C-9 monoesters and the C-7, C-9 diesters was produced 
in each case. However, interestingly, the ratio of C-9 to 
C-7 monoesters was dependent on the chirality of the necic 
acid. Thus, with the S acid approximately 3 parts of the 
C-9 ester 12 was formed for every 1 part of the C-7 ester 
13. The diester 14 was formed as a minor product. On 
the other hand, when the R acid was used, the reverse was 
true; that is, the ratio of C-9 (15) to C-7 (16) monoester 
was approximately 1:2. Again, the diester (17) was a minor 
product. 
In order to gain more insight into the site selectivity 
demonstrated by the enantiomeric acids, a series of ex-
periments was run as follows. Under the same experi-
mental conditions, heliotridine (2) was treated with 1 molar 
equiv of racemic 2-hydroxy-2-phenylbutyric acid and CDI, 
and the resulting product mixture was separated by 
preparative TLC into three bands of increasing polarity, 
namely, a band of diesters, a band of C-7 monoesters, and, 
finally, a band of C-9 monoesters. While it was not possible 
to separate mixtures of C-7 diastereomers such as 13 and 
16 or mixtures of C-9 diastereomers such as 12 and 15, it 
was a relatively easy matter to separate mixtures of C-9 
and C-7 esters such as 12 and 13 or 15 and 16. Thus, from 
(11) Gelbaum, L. T.; Gordon, M. M.; Miles, M.; Zalkow, L. H. J. 
Org. Chem. 1982, 47, 2501. 
(12) Zalkow, L. H.; Glinski, J. A.; Gelbaum, L. T.; Fleischmann, T. 
J.; McGowan, L. S.; Gordon, M. M. J. Med. Chem. 1985, 28, 
687. 
(13) Chamberlin, A. R.; Chung, Y. L. J. Am. Chem. Soc. 1983, 105, 
3653. 
(14) Zalkow, L. H.; Bonetti, S.; Gelbaum, L.; Gordon, M. M.; Patil, 
B. B.; VanDerveer, D. J. Nat. Prod. 1979, 42, 603. 
(15) Kruizinga, W. H.; Strytveen, B.; Kellogg, R. M. J. Org. Chem. 
1981, 46, 4321. 
(16) Glinski, J. A.; Zalkow, L. H. Tetrahedron Lett. 1985, 26, 2857. 
(17) McKenzie, A.; Ritchie, A. Chem. Ber. 1937, 70, 23. 




10: R = (S)-(+) - 2 - hydroxy - 2-phenylbutyryl, R'= H 
11: R = (R) - (-) - 2- hydroxy - 2 - phenylbutyryl R'= H 
24: R = (S)-(+)- 2 - hydr oxy - 2- phenylpropionyl, R'= H 
(atrolactic acid) 
25: R = (R) - (-) - 2 - hydroxy - 2 - phenylpropionyl; R'= H 
12: R = (S) - (+) - 2 - hydroxy - 2 - phenylbutyryl; R'=H 
13: R = H R' = (S)-(+)- 2- hydroxy-2-phenyibutyryl 
14: R = R'= (S)-(+)-2- hydroxy-2 -phenylbutyryl 
15: R = (R)-(-)- 2 - hydroxy - 2 - phenylbutyryl, R'= H 
16: R = H; R'= (R)-(-)-2-hydroxy-2-phenylbutyryl 
17: R = R' - (R) ( ) 2 hydroxy - 2 - phenylbutyryl 
18: R = (S)-(+)- 2 -hydroxy- 2 - phenylbutyryl, R'= (R)-(-1- 
2 - hydroxy -2 - phenyl butyryl 
19: R= (R)-(-)-2 -hydroxy- 2 -phenyl butyryl, R'= (S) - (+)- 
2 - hy dr oxy - 2- phenylbutyr yl 
the experiments with pure enantiomeric acids all four of 
the monoesters were obtained in pure form and by 'H 
NMR analysis the compositions of the monoester mixtures 
were determined for the reaction with racemic acid. Sim-
ilarly, pure diesters 14 and 17 were obtained from the 
reactions with the enantiomeric acids. The remaining two 
diesters, 18 and 19, required as NMR references, were 
obtained from esterification of the pure monoesters with 
the enantiomeric acids. From NMR analysis of the 
products obtained from the reaction of heliotridine with 
racemic 2-hydroxy-2-phenylbutyric acid, it was observed 
that the four diesters 14, 17, 18, and 19 were produced in 
about a 1:1:1:1 ratio, while the C-7 monoesters 13 and 16 
were formed in a ratio of 1:2, respectively, and the C-9 
monoesters 12 and 15 were formed in a ratio of 2:1, re-
spectively. Thus, in both the reactions of heliotridine with 
the enantiomerically pure acids and with the racemic acid, 
the S acid was found to have a preference for the C-9 
position, whereas the R acid had a preference for the C-7 
position. 
In another experiment, each of the pure monoesters was 
esterified with use of racemic acid, in the presence of CDI, 
and the mixture of diesters produced was analyzed by 1 H 
NMR. In each case, no site selectivity was observed. Thus, 
12 gave equal amounts of 14 and 18, 13 gave equal amounts 
of 14 and 19, 15 gave equal amounts of 17 and 19, and 16 
gave equal amounts of 17 and 18. It appeared that site 
selectivity was dependent on the availability of both hy-
droxyl groups in heliotridine. This experiment also dem-
onstrated that under the esterification conditions, no ex-
change of acyl groups between C-9 and C-7 OH groups 
occurred. 
Finally, the role of the hydroxyl group in the necic acid 
was investigated. Under similar conditions, heliotridine 
was treated with (R)-(-)- and (S)-(+)-2-phenylbutyric 
acid. 19•2° The S acid afforded the C-9 ester 20 and the C-7 
ester 21 in a ratio of 3:1 while the R acid gave 22 and 23 
in a ratio of 2:1, respectively. We do not think that any 
significance can be placed in the difference between these 
two ratios and conclude that, in this case, the two enan-
tiomeric acids do not show any significant site selectivity. 
(19) Klyne, W.; Buckingham, J. Atlas of Stereochemistry; Oxford 
University Press: New York, 1974; Vol. 1, p 45. 
(20) Petterson, K. Ark. Kemi 1956, 10, 283. 
Figure 1. 
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OR 
20: R = (S)-(+)-2-phenylbutyryl; R'= H 
21: R = H; R' = (S)-(+) - 2 - phenylbutyryl 
22; R = (R)-(-)-2-phenylbutyryl, R'= H 
23: R = H; R'= (R)-(-)-2-phenylbutyryl 
28: R = R'= (S)-(-1-)-2-phenylbutyryl 
29: R =R'=(R)-(-) - 2 - phenylbutyryl 
OR 
26: R = X; R'= H 
27: N - oxide of 26 
	
30' R H, 	= X 
CO 




The observed site selectivity of (R)-(-)-2-hydroxy-2- 
phenylbutyric acid for the C-7 over the C-9 position of 
heliotridine must arise from diastereomerically different 
transition states. The critical intermediates leading to 
these transition states are the 1-acylimidazoles arising from 
the initial reactions of CDI with the acids. In Figure 1, 
we have attempted to illustrate how hydrogen bonding 
between (R)-(-)-(2-hydroxy-2-phenylbutyryl)imidazole and 
helliotridine places the C-7 hydroxyl group in a favorable 
position for nucleophilic attack on the acyl carbonyl group. 
We have recently completed the X-ray structures of 
(S)-(+)-2-hydroxy-2-(p-chlorophenyl)propionic acid and 
11. In each case, the intramolecular hydrogen bonding 
between the 2' a-hydroxyl group and the ester or acid 
carbonyl could be seen, with the torsional angle 0-C2'- 
Cr-0 being 4.1° in the former case and 11.7° in the latter 
case. 18 Infrared evidence has also been presented to show 
intramolecular hydrogen bond in macrocyclic pyrrolizidine 
diester alkaloids. 21 Further intermolecular hydrogen 
bonding between the C-9 hydroxyl group of heliotridine 
and the N-3 of 1-acylimidazole would give the reactive 
intermediate illustrated in Figure 1. Such an intermediate 
would clearly be of higher energy for the (S-(+)-acyl-
imidazole since the phenyl group would now suffer steric 
compression from the pyrrolizidine ring. In the case of 
retronecine, attack of the acyl carbonyl by the more re-
active and less hindered C-9 hydroxyl group is energetically 
favored regardless of which enantiomeric acid is involved. 
Recent X-ray structures of :retronecine and heliotridine 22 
 reveal, in the crystals, subtle conformational differences 
in the A ring. Thus the angle between the least-square 
planes defined by atoms C-1, C-2, C-3, N-4, C-8 and C-5, 
N-4, C-8, C-7 in retronecine was 124.4°, while in helio-
tridine it was 121.6°. In retronecine the left ring is exo 
puckered where the angle between C-5, C-6, C-7, and C-5, 
N-4, C-8 is 40.7°. In contrast, heliotridine is endo puckered 
where the corresponding angle is 42.2°. 
In order to test the effect of the side chain, we initially 
prepared the racemic synthetic necic acids, and as previ-
ously mentioned, reaction of these acids with the more 
readily available retronecine in the presence of CDI gave, 
almost exclusively, the C-9 esters. Thus, the diastereo- 
(21) Bull, L. B.; Culvenor, C. C. J.; Dick, A. T. The Pyrrolizidine 
Alkaloids; North-Holland Publishing: Amsterdam, 1968. 
(22) Gelbaum, L. T.; Glinski, J. A.; VanDerveer, D.; Zalkow, L. H. 
Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1985, C41, 
1342. 
Table I. Cytotoxicity against A204 Rhabdomyosarcoma Cell 
Line in Vitro' 
compd 
base 











10 >100 >100 15 >100 44 ± 2 
11 >100 11 ± 0 16 >100 9 ± 1 
12 >100 15 ± 3 indicine 34 ± 11 125 ± 22 
13 >100 32 ± 1 (and 6) 
14 81 ± 1 ND 26 400 ± 140 320 ± 140 
(and 27) 
8 316 ± 95 721 ± 38 
° See the Experimental Section for details of preparation of soft 
agarose cultures. Cultures were conducted in quadruplicate to al-
low reliable estimates of the variance of the IC 50 to be obtained. 
Control cultures with vehicle alone were always run at the same 
time. Dose-response curves were constructed with at least four 
drug concentrations to produce between 10 and 99.9% inhibition 
of cell growth. Dose-response curves were constructed on at least 
three different preparations. b To obtain the IC 50, the drug con-
centration producing 50% inhibition of cell growth, and its vari-
ance, the dose-response data was fitted to a monoexponential 
curve by using a NONLIN nonlinear least-squares regression analysis 
program. Variance of IC 50 was obtained from the variance of the 
intercept and slope by using Taylor series expansion. Values are 
the mean ± SE. The highest concentration of the compound test-
ed was 100 sg/mL, except for compounds 8, 26, 27, indicine, and 
indicine N-oxide (6) where 1000 Ag/mL was tested. 
meric mixtures of 10 + 11 and 24 + 25 were prepared and 
screened as their N-oxides. 1 H NMR analysis indicated 
that the diastereomers, in each case, were produced in 
equal amounts. Also, in the former case, the acid was 
resolved to give, after coupling, the pure isomers 10 and 
11, which after conversion to their N-oxides were also 
screened hi vivo. In the case of the heliotridine derivatives, 
only resolved necic acids were utilized in preparing samples 
for screening. 
In order to gain insight into the mechanism of action 
of the antitumor activity of the pyrrolizidine alkaloid 
N-oxides and analogues, we required a dihydro N-oxide 
in large amount, in order to screen it at high enough dose 
levels to compare it with indicine N-oxide at its highest 
nontoxic dose. Because of these practical limitations we 
decided to prepare dihydroindicine N-oxide. 23 Indicine 
N-oxide was first reduced to indicine with zinc/acid and 
this in turn was hydrolyzed to retronecine and (-)-tra-
chelanthic acid. 24 Retronecine was reduced with Raney 
nickel to give platynecine,25 which was site selectively 
coupled with the acetonide of (-)-trachelanthic acid at 
C-9, 12 and finally the protecting group was removed to give 
dihydroindicine (26). The C-7 isomer, 7-(-)-trathelan-
thylplatynecine (30), was obtained as a minor product 
isolated from the mother liquor remaining after crystal- 
(23) We thank Dr. Matthew Suffness, Chief, Natural Products 
Branch, Developmental Therapeutics Program, National Can-
cer Institute, Mil, for many helpful discussions and for sup-
plying us with indicine N-oxide. 
(24) Mattocks, A. R.; Schoental, R.; Crowley, H. C.; Culvenor, C. C. 
J. J. Chem. Soc. 1961, 5400. 
(25) Adams, R.; Rogers, E. F. J. Am. Chem. Soc. 1941, 63, 537. 
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Table II. Antitumor Activity in the P388 Lymphocytic Leukemia System° 
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19.5 06/06 -0.5 106 repeat 50 06/06 -1.8 166 
9.75 06/06 1.2 106 25 06/06 -1.1 139 
13 N-oxide 377167 102 05/05 0.1 97 12.5 06/06 -0.4 136 
51 06/06 0.2 103 10 N-oxide 369511 125 06/06 -1,3 125 
25.5 06/06 1.0 100 62.5 06/06 -0.8 114 
12.75 05/06 0.1 95 31.25 06/06 -0.7 110 
14 N-oxide 377166 62 06/06 -0.2 127 15.63 06/06 -0.8 110 
31 06/06 0.1 109 11 N-oxide 369512 162 06/06 -3.4 214 
15.5 05/06 0.1 100 81 06/06 -3.2 169 
7.75 06/06 0.9 106 40.50 06/06 -2.4 151 
15 N-oxide 377171 92 06/06 -0.5 126 20.25 06/06 -2.0 143 
46 05/06 1.8 117 6 reference 132319 1600 06/06 -2.2 142 
23 06/06 -0.1 106 for 10 + 11 800 06/06 -3.2 160 
11.5 06/06 -0.3 106 400 06/06 -1.6 151 



















16.13 06/06 -0.2 100 375 06/06 0.3 106 
17 N-oxide 377169 71 05/06 -0.2 109 187.5 06/06 0.7 94 
35.5 06/06 -0.4 106 26 600089 1300 00/06 NA toxic 
17.75 05/06 0.8 100 650 00/06 NA toxic 
8.88 06/06 1.4 107 325 00/06 NA toxic 
(10 + 11) N-oxide 333058 300 06/06 -2.2 166 162.50 06/06 0.5 92 
150 06/06 -2.1 157 6 reference 132319 800 06/06 -1.5 146 
75 06/06 -1.7 149 for 26 + 27 400 06/06 -1.1 120 
37.5 06/06 -1.1 146 200 05/06 0.0 118 
6 reference for 132319 1600 05/06 -2.9 tox 100 06/06 0.5 101 
(10 + 11) 400 06/06 -1.7 146 30 610331 92 06/06 0.6 98 
N-oxide 200 06/06 -0.7 140 46 06/06 -0.6 105 
(24 + 25) 357486 100 06/06 -3.6 180 23 06/06 -1.1 107 
N-oxide` 50 06/06 -1.9 140 11.50 06/06 -1.2 111 
25 06/06 -1.3 96 26 repeat 600089 325 00/06 NA toxic 
12.5 06/06 -1.3 105 162.5 06/06 -0.9 98 
6.25 06/06 -0.4 105 81.25 06/06 0.0 102 
6 reference for 132319 1600 06/06 -4.9 tox 40.60 06/06 -0.2 96 
(24 + 25) 800 06/06 -3.6 196 6 reference 132319 800 04/04 -1.6 180 
N-oxide 400 06/06 -2.6 175 for 30 + 400 04/04 0.1 123 
200 06/06 -2.1 152 26 above 200 04/04 -0.6 126 
° Screening was carried out under the auspices of the National Cancer Institute. For detailed explanations of procedures and data, see 
Instruction 14, Screening Data Summary Interpretation and Outline of Current Screen, Drug Evaluation Branch, Developmental Thera-
peutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20205. 5 Q01Dx9. Single dose for 9 days. 
`Reference 18. 
lization of dihydroindicine. Isomer 30 was obtained in pure 
crystalline form by use of dropping countercurrent chro-
matography. Dihydroindicine N-oxide (27) was prepared 
in the usual manner. 
Biology 
The relative in vitro cytotoxicities of some of the N-
oxides and their bases were measured against the A204 
human rhabdomysarcoma cell line by using the soft agar 
colony forming assay (Table I). For the retronecine de-
rivatives 11 and the heliotridine derivatives 12,13,15, and 
16, the N-oxides were more active than the bases. The 
retronecine derivative 10 was inactive, either as the base 
or the N-oxide. Indicine was more active than indicine 
N-oxide, but both were less active than the other com-
pounds tested. Dihydroindicine and dihydroindicine 
N-oxide were relatively inactive and showed the same 
cytotoxicity. Monocrotaline was also relatively inactive 
in the in vitro assay but was more active than mono-
crotaline N-oxide. It is possible that some of the inactive 
compounds may also have shown activity if concentrations 
above 100 Ag/mL were tested. 
Table II shows the in vivo P388 lymphocytic leukemia 
screening data for the N-oxides of the heliotridine deriv-
atives 12-17, indicine N-oxide (6), and the N-oxides of 
retronecine derivatives 10,11, diastereomeric mixture 10 
+ 11, and diastereomeric mixture 24 + 25. A comparison  
of the screening data for the heliotridine N-oxide deriva-
tives of 12-17 with that for the retronecine N-oxide dia-
stereomeric mixtures of 10 + 11 or 24 + 25 reveals that 
the stereochemistry of the C-7 hydroxyl group has an effect 
on potency. At comparable doses, the heliotridine deriv-
atives are clearly less potent than the retronecine deriva-
tives, and only 14 and 15 N-oxides appear to show activity 
at the doses measured. However, it should be pointed out 
that indicine N-oxide itself is not a very potent drug, and 
at the doses measured for heliotridine N-oxide derivatives 
of 12-17, it also shows little activity. Thus, at higher doses 
these heliotridine derivatives might show activity compa-
rable to that observed for indicine N-oxide. 
A comparison of the T/C values for the retronecine 
N-oxide diastereomeric mixture of 10 + 11 with those for 
indicine N-oxide (6), run at the same time (compound 6 
just below 10 + 11 in Table I), clearly reveals that the 
former are more potent than indicine N-oxide. Similarly, 
the analogous N-oxide diastereomeric mixture of 24 + 25 
can be seen to be more potent than indicine N-oxide run 
at the same time. Table I includes a repeat of the 
screening of the N-oxide mixture of 24 + 25 run at another 
time, at higher dose level, and it can be seen that this 
mixture showed toxicity at 200 mg/kg, revealing that it 
is also more toxic than indicine N-oxide. The difference 
in the length of the alkyl side chains (Me vs Et) in the necic 
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acids of these retronecine derivatives does not appear to 
significantly effect the T/C values. The most dramatic 
data in Table I is seen for the C-9 retronecine N-oxide 
esters of 2-hydroxy-2-phenylbutyric acid; the ester of the 
R acid (11 N-oxide) is far more potent and active than the 
ester of the S acid (10 N-oxide), and the former is not only 
more potent but it is also more active than indicine N-
oxide, showing a T/C of 214 at 162 mg/kg. This may not 
even be the best T/C value since the toxic dose was not 
reached in this experiment? A comparison of the screening 
results for the N-oxides of the C-9 heliotridine esters of 
12 and 15, run at the same time, shows that in this series 
also, the (R)-necic acid imparts more activity to the system 
than does the S acid. Comparison of 15 N-oxide with 11 
N-oxide reveals that the stereochemistry of the C-7 hy-
droxyl group of the necine is significant in determining 
potency. This is also seen even when comparing isomers 
containing the less active (S)-necic acid in the retronecine 
N-oxide vs heliotridine N-oxide series (10 N-oxide vs 12 
N-oxide). 
Comparing in vitro with in vivo results shows good 
correlations for the N-oxides of the retronecine derivatives. 
The retronecine N-oxide ester of R-(—)-2-hydroxy-2- 
phenylbutyric acid (10) shows high in vitro cytotoxicity 
and good in vivo antitumor activity, while the ester of 
(S)-(+)-2-hydroxy-2-phenylbutyric acid is much less active 
both in vitro and in vivo. Indicine N-oxide (6) shows 
moderate activity, but only at high doses in vivo and at 
high concentrations in vitro. Discrepancies exist between 
the in vivo and in vitro results for the N-oxides of the 
heliotridine derivatives. The derivatives 12 and 16 show 
high in vitro cytotoxicity but no activity in vivo, while the 
derivatives 13 and 15 show moderate in vitro cytotoxicity, 
but only 15 shows any activity in vitro, with derivative 13 
being inactive. We assume that unfavorable pharmacok-
inetic factors account for the relative lack of activity of the 
heliotridine N-oxide derivatives in vivo compared to their 
in vitro cytotoxicity. 
In this paper we have presented some structure—activity 
results, observed in the in vivo P388 lymphocytic leukemia 
antitumor screen, particularly regarding the effect of 
stereochemistry at the C-7 position of the necine in sem-
isynthetic pyrrolizidine alkaloid N-oxides. The preliminary 
results shown here for the effect of stereochemistry in the 
necic acid portion of the drugs will appear in another 
forthcoming publication which will also describe the effects 
of various substituents in the necic acids. Ultimately, it 
is our goal to determine the mechanism of action of these 
compounds. In particular, we wish to determine how the 
N-oxides differ from the free bases in their selectivity for 
cancer cells and whether their toxicity is also mediated via 
pyrroles and whether such pyrroles, if they are the putative 
intermediates, are produced by prior reduction to the free 
bases or by direct formation from the N-oxides. In order 
to gain insight into the mechanism of action, we compared 
dihydroindicine N-oxide (27) with indicine N-oxide (6) in 
the screen. As can be seen in Table I, dihydroindicine 
N-oxide (27) is totally inactive in the screen when run at 
the same time as indicine N-oxide and run at a dose as high 
as 1500 mg/kg. We believe this result suggests that the 
antitumor activity of indicine N-oxide, and related semi-
synthetic pyrrolizidine alkaloid N-oxides, may also involve 
intermediate pyrroles. We are attempting to obtain ex-
perimental validation for this hypothesis. 
Dihydroindicine (26) exhibited unexpected toxicity in 
the in vivo P388 lymphocytic leukemia system at doses of 
1300-325 mg/kg. Since removal of the double bond from 
the necine portion of pyrrolizidine alkaloids results in loss  
of toxicity, it was thought that the toxicity of 26 was due 
to traces of the unnatural isomer 30 present as a contam-
inant. Therefore, the assay was repeated for 26, 30, and 
INO (6) as seen in the last three entries of Table II. While 
26 still exhibited toxicity at 325 mg/kg, but not at lower 
doses, it is clear that the toxicity could not be due to traces 
of 30, since the latter did not exhibit toxicity at any of the 
doses tested (92-11.50 mg/kg). The nature of this toxicity 
remains a mystery. 
Experimental Section 
In Vitro Cytotoxicity. Soft agarose cultures of A204 human 
rhabdomysarcoma cells were preformed as follows: Each 35-mm 
culture dish contained a base layer consisting of 0.5 mL of 
Dulbecco's modified Eagles medium containing 10% fetal calf 
serum with 0.5% agarose (growth media). On day 0 cells in bulk 
culture were dissociated with trypsin and EDTA, washed once 
in growth media, and subcultured by layering 10 4 viable cells in 
0.5 mL of growth media with 0.3% agarose over each base layer. 
Cultures were examined with the aid of an inverted stage mi-
croscope and only cultures containing uniformly distributed single 
cell suspensions (< ten 30-Am cell cultures and no 60-1.4m clusters) 
were accepted for subsequent evaluation. Cultures were main-
tained in cell culture incubators at 37 °C, 5% CO 2-95% air, and 
100% humidity. On day 1 (24 h later) an upper layer of 1 mL 
of growth media with and without the compound under inves-
tigation was added to the dishes. After 24 h, the upper layer of 
medium was removed by aspiration, and agarose culture surfaces 
were washed once with 0.5 mL of prewarmed growth media and 
then overlaid with 1 mL of fresh growth media. Colony formation 
was examined at daily intervals by conventional light microscopy. 
Cell lines form a sufficient number of detectable colonies (>60-am 
diameter) for analysis following 7-9 days incubation. Viable 
colonies were stained with a metabolizable tetrazolium salt (2- 
(p-iodopheny1)-3-(p-nitropheny1)-5-phenyltetrazolium chloride) 
and colonies counted with a Bausch & Lomb FAS-II image 
analysis system. Cultures were conducted in quadruplicate. 
Control cultures without drug were run at the same time. 
General Methods. Proton nuclear magnetic resonance ( 1 11 
NMR) spectra were recorded in CDCI 3 on a Bruker WM 300 
spectrometer equipped with an Aspect 2000 data system. 
Chemical shifts are reported relative to internal Me 4Si (S 0.0). 
Optical rotations were measured on a Perkin-Elmer 141 polar-
imeter. Mass spectra were obtained by using a Varian MAT 112S 
spectrometer interfaced with an SS200 data system. Melting 
points were taken on a Kofler hot stage and are corrected. 
Analytical TLC was performed on EM precoated aluminum oxide 
150 F-254 (type T) plates while preparative TLC was performed 
on 2-mm-thick plates of aluminum oxide (Merck type E 60 
PF254). 
(+)- and (-)-2-Hydroxy-2-phenylbutyric Acid. Racemic 
2-hydroxy-2-phenylbutyric acid was prepared as previously de-
scribed, 11 but was resolved by a different procedure using (+)- 
and (-)-ephedrine as described previously 12 for the resolutions 
of trachelanthic and viridifloric acids with (-)- and (+)-a-
phenylethylamine. (S)-(+)-2-Hydroxy-2-phenylbutyric acid gave 
the less soluble salt with (-)-ephedrine, which, after three re-
crystallizations from ethyl ether containing 1-5% ethanol, showed 
mp 126-127 °C, [a] 26D -4.8° (c 1, EtOH); (R)-(-)-2-hydroxy-2- 
phenylbutyric acid gave the less soluble salt with (+)-ephedrine, 
which after similar recrystallization, gave mp 127-128 °C, [a] 25D 
 +4.5° (c 1, EtOH). The salts were hydrolyzed with 6 M sulfuric
acid and the acids were extracted into ethyl ether, evaporation 
of which gave the acids (S)-(+)-2-hydroxy-2-phenylbutyric acid, 
mp 129-130 °C, [a]24D +29.8° (c 1, EtOH) [lit. 11 mp 127-129 °C, 
[a] 20D +29.0° (c 1.97, EtOH)] and (R)-(-)-2-hydroxy-2-phenyl-
butyric acid, mp 129-130 °C, [a1 200 -28.1° (c 1, EtOH) [lit. 11 mp 
119-124 °C, [a] 24D -27.9° ]. 
Heliotridine Esters of 2-Hydroxy-2-phenylbutyric Acid. 
Heliotridine was synthesized from retronecine as previously de-
scribed. 16 To 55 mL of tetrahydrofuran was added 1.21 g (1 equiv) 
of (S)- or (R)-2-hydroxy-2-phenylbutyric acid and 1.20 g (1.15 
equiv) of 1,1'-carbonyldiimidazole (CDI), and after 5 min, 1.04 
g (1 equiv) of heliotridine was added to the solution. After the 
mixture was allowed to stand for 2 days at room temperature, 
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the solvent was removed in vacuo and the residue was partitioned 
between water and chloroform. The chloroform layer was washed 
with water, dried over sodium sulfate, and finally concentrated 
to dryness. From the S acid, 1.9 g of an ester mixture containing 
the 7,9-diester, the 7-monoester, and the 9-monoester was ob-
tained, while the R acid yielded 1.6 g of a similar mixture. 
The ester mixtures were separated by preparative TLC on 20 
x 20 cm plates of aluminum oxide of the type previously described. 
Each plate was loaded with 190 mg of the reaction mixture, and 
the plates were developed with chloroform-acetone-methanol 
(47:47:6). The Rf values of the three bands, visualized with iodine 
vapor, were 0.71 for diesters 14 and 17, 0.59 for C-7 monoesters 
13 and 16, and 0.29 for C-9 monoesters 12 and 15, respectively. 
For the S acid, the ratio of C-9 to C-7 monoester was approxi-
mately 3:1, while the diester comprised about 7 molar % of the 
mixture. For the R acid the C-9 to C-7 monoester ratio was 
approximately 1:2 and the diester comprised about 14 molar % 
of the mixture. All of the esters were isolated in a pure form and 
characterized by 111 NMR, MS, and elemental analysis. 
Heliotridine Ester N-Oxides. The heliotridine esters were 
converted into the corresponding N-oxides as follows. To 300 
mg of the ester in 40 mL of chloroform was added 300 mg of 85% 
m-chloroperbenzoic acid. After the mixture was allowed to stand 
at room temperature for 25 min, excess gaseous ammonia was 
passed through the solution, resulting in precipitation of the acids 
as their ammonium salts. The resulting slurry was cooled below 
10 °C and filtered through Celite, and the filtrate was evaporated 
to yield the N-oxides as noncrystallizing gums, which were 
characterized by their 300-MHz 1HNMR spectra, sealed under 
vacuum, and submitted for screening. The following properties 
were obtained for the various esters. 
7,9-Di-0 -[(S )-2-hydroxy-2-phenylbutyryl]heliotridine 
(14): noncrystallizing gum; 1 1-I NMR 6 0.86 (t, 3 H, C-4'), 0.91 
(t, 3 H, H4'), 1.84 (m, 1 H, H6), 1.96 (m, 1 H, H6), 2.03 (m, 2 H, 
H3'), 2.18 (m, 2 H, H3'), 2.81 (m, 1 H, H5), 3.16 (m, 1 H, H5), 
3.26 (dm, 1 H, H3), 3.86 (br s, 1 H, H8), 3.89 (br d, 1 H, H3), 4.69 
& 4.74 (AB quartet, 2 H, H9), 4.99 (br s, 1 H, H7), 5.48 (s, 1 H, 
H2), 7.2-7.4 (m, 6 H), 7.5-7.6 (m, 4 H); EIMS, m/e (relative 
intensity) 43 (100), 58 (27), 77 (10), 105 (11), 119 (9), 135 (19), 
300 (4); CIMS, m/e (relative intensity) 480 (M + 1, 100). Anal. 
(C28H33N06•11 20) C, H, N. 
7,9-Di-O -[(S)-2-hydroxy-2-phenylbutyryl]ieliotridine 
N-oxide: noncrystallizing gum; 1H NMR 6 0.83 (t, 3 H, H4'), 0.90 
(t, 3 H, H4'), 2.0 (m, 1 H, H6), 2.03-2.15 (m, 4 H, H3'), 2.32 (m, 
1 H, H6), 3.60 (m, 1 H, H5), 3.96 (m, 1 H, H5), 4.25 (br d, 1 H, 
H3), 4.46 (br d, 1 H, H3), 4.67 (s, 1 H, H8), 4.77 & 4.80 (AB quartet, 
2 H, H9), 4.91 (s, 1 H, H7), 5.38 (s, 1 H, H2), 7.2-7.4 (m, 6 H), 
7.45 (d, 2 H), 7.60 (d, 2 H). 
7-0-[(S)-2-Hydroxy-2-phenylbutyryl]heliotridine (13): mp 
92 °C; 1H NMR 6 0.95 (t, 3 H, H4'), 1.95 (m, 2 H, H6), 2.03 (dq, 
1 H, H3'), 2.20 (dq, 1 H, H3'), 2.84 (m, 1 H, H5), 3.10 (m, 1 H, 
H5), 3.28 (br d, 1 H, H3), 3.85 (s, 1 H, H8), 3.89 (br d, 1 H, H3), 
4.18 (s, 2 H, H9), 5.10 (br s, 1 H, H7), 5.59 (s, 1 H, H2), 7.26 (t, 
1 H), 7.33 (t, 2 H), 7.59 (d, 2 H); EIMS, m/e 43 (22), 57 (46), 71 
(20), 80 (100), 94 (23), 106 (80), 111 (76), 120 (46), 137 (90), 165 
(18), 270 (4), 317 (15); exact mass calcd for C i8H23N04 317.1627, 
found 317.1660. Anal. (C i8H23N04- 1 / 4H20) C, H, N. 
7-0 -[(S )-2-Hydroxy-2-phenylbutyryl ]heliotridine N - 
oxide: noncrystallizing gum; 1 I-1 NMR 6 0.84 (t, 3 H, H4'), 2.1 
(m, 1 H, H6), 2.10 (dq, 1 H, H3'), 2.18 (dq, 1 H, H3'), 2.29 (m, 
1 H, H6), 3.68 (m, 1 H, H5), 3.82 (m, 1 H, H5), 4.22 (s, 2 H, H9), 
4.35 (br d, 1 H, H3), 4.51 (br d, 1 H, H3), 4.79 (s, 1 H, H8), 5.16 
(br s, 1 H, H7), 5.68 (s, 1 H, H2), 7.28 (t, 1 H), 7.36 (t, 2 H), 7.56 
(d, 2 H). 
9-0 -[(S )-2-Hydroxy-2-phenylbutyryl]heliotridine (12): 
noncrystallizing gum; 1 1-1 NMR 6 0.97 (t, 3 H, H4'), 1.80 (m, 1 H, 
H6), 1.93 (m, 1 H, H6), 2.05 (dq, 1 H, H3'), 2.25 (dq, 1 H, H3'), 
2.52 (ddd, 1 H, H5), 3.20 (m, 1 H, H5), 3.26 (m, 1 H, H3), 3.77 
(br d, 1 H, H3), 3.85 (br s, 1 H, H8), 3.97 (q, 1 H, H7), 4.74 (d, 
1 H, H9), 4.84 (d, 1 H, H9), 5.52 (br s, 1 H, H2), 7.27 (t, 1 H), 
7.33 (t, 2 H), 7.56 (t, 2 H); EIMS, m/e 43 (35), 57 (51), 71 (36), 
80 (84), 83 (100), 85 (67), 93 (65), 105 (20), 111 (46), 135 (52), 138 
(72), 155 (13), 273 (2), 317 (1); exact mass calcd for C1gH23N 04 
317.1627, found 317.1600. Anal. (C 18H23N04) C, H, N. 
9-0 -[(S )-2-Hydroxy-2-phenylbutyry 1 ]heliotridine N - 
oxide: noncrystallizing gum; 1 H NMR 6 0.84 (t, 3 H, H4'), 1.88  
(m, 1 H, H6), 2.14 (m, 1 H, H6), 2.06 & 2.15 (dq each, 2 H, H3'), 
3.55 (m, 1 H, H5), 4.11 (m, 1 H, H5), 4.15 (s, 1 H, H7), 4.27 (br 
d, 1 H, H3), 4.51 (br d, 1 H, H3), 4.78 (br s, 2 H, H9), 4.97 (br 
s, 1 H, H8), 5.48 (s, 1 H, H2), 7.2-7.4 (m, 3 H), 7.56 (d, 2 H). 
7,9-Di-0 -[(R )-2-Hydroxy-2-phenylbutyryl]heliotridine 
(17): noncrystallizing gum; 1 H NMR 6 0.89 (t, 3 H, H4'), 0.91 
(t, 3 H, H4'), 1.68 (m, 1 H, H6), 2.05 (m, 1 H, H6), 2.05 (m, 2 H, 
H3'), 2.20 (m, 2 H, H3'), 2.86 (m, 1 H, H5), 3.10 (m, 1 H, H5), 
3.30 (dm, 1 H, H3), 3.93 (br d, 1 H, H3), 4.05 (br s, 1 H, H8), 4.77 
& 4.91 (AB quartet, 2 H, H9), 4.93 (br s, 1 H, H7), 5.64 (s, 1 H, 
H2), 7.2-7.4 (m, 6 H), 7.56 (d, 4 H); EIMS, m/e 43 (18), 57 (98), 
77 (26), 93 (50), 94 (39), 105 (26), 119 (100), 120 (71), 135 (68), 
136 (39), 282 (9), 300 (60), 432 (0.4); CIMS, m/e 163 (100), 480 
(M + 1, 4). Anal. (C28H33N06•1120) C, H, N. 
7,9-Di- 0 -[(R )-2-Hydroxy-2-phenylbutyryl]heliotridine 
N-oxide: noncrystallizing gum; 1H NMR 6 0.87 (t, 3 H, H4'), 0.89 
(t, 3 H, H4'), 2.0 (m, 1 H, H6), 2.07 (m, 2 H, H3'), 2.18 (m, 2 H, 
H3'), 2.35 (m, 1 H, H6), 3.65 (m, 1 H, H5), 3.93 (m, 1 H, H5), 4.32 
(d, 1 H, H3), 4.50 (d, 1 H, H3), 4.64 (s, 1 H, H8), 4.61 & 4.91 (AB 
quartet, 2 H, H9), 4.90 (s, 1 H, H7), 5.63 (s, 1 H, H2), 7.2-7.4 (m, 
6 H), 7.50 (d, 2 H), 7.57 (d, 2 H). 
7-0 -[(R)-2-Hydroxy-2-phenylbutyryl]heliotridine (16): 
mp 98 °C; 1HNMR 5 0.93 (t, 3 H, H4'), 1.86 (m, 2 H, H6), 2.05 
(dq, 1 H, H3'), 2.29 (dq, 1 H, H3'), 2.86 (m, 1 H, H5), 3.14 (m, 
1 H, H5), 3.31 (dm, 1 H, H3), 4.09 (dd, 1 H, H8), 3.92 (d, 1 H, 
H3), 4.29 (s, 2 H, H9), 5.07 (s, 1 H, H7), 5.63 (s, 1 H, H2), 7.2-7.4 
(m, 3 H), 7.56 (d, 2 H); EIMS, m/e 43 (16), 57 (80), 77 (26), 80 
(71), 105 (27), 106 (76), 111 (54), 120 (38), 135 (100), 137 (74), 165 
(14), 270 (2), 317 (7); exact mass calcd for C 18H23N04 317.1627, 
found 317.1657. Anal. (C,8H23N04) C, H, N. 
7-0 -[(R )-2-Hydroxy-2-phenylbutyryl]heliotridine N-
oxide: noncrystallizing gum; 1H NMR 6 0.88 (t, 3 H, H4'), 2.18 
(m, 1 H, H6), 2.10 (dq, 1 H, H3'), 2.20 (dq, 1 H, H3'), 2.38 (m, 
1 H, H6), 3.72 (m, 1 H, H5), 3.90 (m, 1 H, H5), 4.16 & 4.12 (AB 
quartet, 2 H, H9), 4.34 & 4.39 (AB quartet, 2 H, H3), 4.75 (s, 1 
H, H8), 5.13 (br s, 1 H, H7), 5.66 (s, 1 H, H2), 7.28 (t, 1 H), 7.33 
(t, 2 H), 7.58 (d, 2 H). 
9-0 -[(R)-2-Hydroxy-2-phenylbutyryl]heliotridine (15): 
noncrystallizing gum; 1H NMR 6 0.92 (t, 3 H, H4'), 1.80 (m, 1 H, 
H6), 1.90 (m, 1 H, H6), 2.07 (dq, 1 H, H3'), 2.26 (dq, 1 H, H3'), 
2.58 (m, 1 H, H5), 3.24 (m, 1 H, H5), 3.27 (m, 1 H, H3), 3.78 (br 
d, 1 H, H3), 3.88 (br s, 1 H, H8), 4.03 (m, 1 H, H7), 4.69 & 4.94 
(AB quartet, 2 H, H9), 5.57 (s, 1 H, H2), 7.30 (t, 1 H), 7.34 (t, 2 
H), 7.59 (t, 2 H); EIMS, m/e 57 (19), 68 (14), 80 (91), 93 (74), 94 
(38), 111 (68), 135 (22), 138 (100), 155 (27), 273 (3); CIMS, m/e 
138 (95), 156 (100), 318 (M + 1, 54). Anal. (C 18H23N04) C, H, 
N. 
9-0 -[(R )-2-Hydroxy-2-phenylbutyryl]heliotridine N - 
oxide: noncrystallizing gum; 11-1 NMR 6 0.84 (t, 3 H, H4'), 1.88 
(m, 1 H, H6), 2.14 (m, 1 I-I, H6), 2.06 & 2.15 (dq each, 2 H, H3'), 
3.55 (m, 1 H, H5), 4.11 (m, 1 H, H5), 4.15 (s, 1 H, H7), 4.27 (br 
d, 1 H, H3), 4.51 (br d, 1 H, H3), 4.78 (br s, 2 H, H9), 4.97 (br 
s, 1 H, H8), 5.48 (s, 1 H, H2), 7.26 (t, 1 H), 7.31 (t, 2 H), 7.55 (d, 
2 H). 
Mixed Diesters 18 and 19. Diester 18 was prepared by 
treating 12 with (R)-(-)-2-hydroxy-2-phenylbutyric acid under 
conditions analogous to those described above; similarly, 19 was 
prepared by the reaction of 15 with the corresponding S-(+) acid. 
These crude diesters were isolated by preparative TLC and their 
NMR spectra were utilized for analyses by comparing the portions 
of their NMR spectra which were different, such as the C-2, C-9, 
and C-7 proton areas. 
(+)- and (-)-a-Phenylbutyric Acid. Racemic a-phenylbutyric 
acid was resolved by a procedure analogous to that of Pettersson 2° 
 using (+)- and (-)-a-phenylethylamine except that only ethanol 
was used as the solvent. The salt of (+)-a-phenylethylamine and 
(-)-a-phenylbutyric acid showed mp 156-159 °C and [a] 27D -7.3° 
(c 1, EtOH), while the salt of (-)-a-phenylethylamine and (+)- 
a-phenylbutyric acid gave mp 158-162 °C and [a] 25D +12.3° (c 
1, EtOH). The salts were hydrolyzed with 30% sulfuric acid and 
the acids were extracted into ethyl ether, evaporation of which 
gave the acids as oils, the former giving [a] 250 -76.5° (c 1, EtOH) 
and the latter [a] 2% +80.5° [lit. 20 [a] 250 -78.5° and [a]' 50 +78.6°]. 
Heliotridine Esters of 2-Phenylbutyric Acid. The helio-
tridine esters of (+)- and (-)-2-phenylbutyric acid were obtained 
similarily to the esters of 2-hydroxy-2-phenylbutyric acid. The 
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reaction was carried out on a 1-mmol scale for 6 days at room 
temperature and then worked up in the usual manner, affording 
246 mg of a mixture of (+)-2-phenylbutyric acid esters and 267 
mg of a mixture of (-)-2-phenylbutyric acid esters. The mixtures 
of 7-mono-, 9-mono-, and 7,9-diester were separated by preparative 
TLC on alumina, eluting with toluene-methanol (9:1) with the 
order of elution 7,9-diester > 7-monoester > 9-monoester. For 
the S-(+) acid, the ratio of C-9 to C-7 monoester was approxi-
mately 3:1, while for the R-(--) acid the C-9 to C7 monoester ratio 
was approximately 2:1. The (Hester comprised about 7 molar % 
of the mixture in each case. All of the esters were isolated in a 
pure form and characterized by 111 NMR and mass spectral 
analysis, including exact mass determination as indicated below. 
7,9-Di-0 -[(S)-2-phenylbutyryl]heliotridine (28): non-
crystallizing gum; 'H  NMR (5 0.87 (t, 6 H, H4'), 1.84 (m, 1 H, H6), 
2.07 (m, 1 H, H6), 1.80-2.07 (in, 4 H, H3'), 2.72 (m, 1 H, H5), 3.10 
(m, 1 H, H5), 3.22 (m, 1 H, I-13), 3.41 & 3.40 (2 t, 2 H, H2'), 3.91 
(s, 1 H, H8), 3.87 (br d, 1 H, 1-13), 4.73 & 4.76 (AB quartet, 2 H, 
H9), 4.97 (s, 1 H, H7), 5.36 (s, 1 H, H2), 7.24 (br m, 10 H); RIMS, 
m/e 91 (88), 93 (49), 119 (100), 120 (55), 136 (40), 205 (12), 284 
(99), 301 (8), 447 (4); exact mass calcd for C28H33N04 447.2410, 
found 447.2396. 
7,9-Di-0 -[(R)-2-phenylbutyryl]heliotridine (29): non-
crystallizing gum; 1 H NMR 5 188 (t, 6 H, H4'), 1.80 (m, 1 H, H6), 
2.08 (m, 1 H, H6), 1.65-2.10 (m, 4 H, H3'), 2.68 (m, 1 H, H5), 3.05 
(m, 1 H, H5), 3.24 (m, 1 H, Ii3), 3.41 & 3.46 (2 t, 2 H, H2'), 4.01 
(s, 1 H, H8), 3.87 (br d, 1 H, H3), 4.79 & 4.70 (AB quartet, 2 H, 
H9), 4.94 (s, 1 H, H7), 5.49 (s, 1 H, H2), 7.26 (br m, 10 H); EIMS, 
m/e 91 (66), 93 (36), 119 (92), 120 (50), 136 (38), 205 (14), 283 
(62), 284 (100), 301(8), 447 (4); exact mass calcd for C28H33N04 
447.2410, found 447.2387. 
7-0 -[(S)-2-Phenylbutyryl]heliotridine (21): noncrystal-
lizing gum; 1H NMR 5 0.88 (t, 3 H, H4'), 1.80 (m, 2 H, H3'), 1.81 
(m, 1 H, H6), 2.06 (m, 1 H, 116), 2.78 (m, 1 H, H5), 3.00 (m, 1 H, 
H5), 3.26 (m, 1 H, H3), 3.44 (t, 1 H, H2'), 3.79 (br s, 1 H, H8), 
3.85 (br d, 1 H, H3), 4.21 (s, 2 H, H9), 5.00 (s, 1 H, H7), 5.54 (s, 
1 H, H2), 7.26 (m, 5 H); EIMS, m/e 56 (36), 71 (70), 80 (94), 106 
(100), 111 (77), 124 (22), 137 (82), 173 (5), 205 (1), 283 (4), 301 
(5); exact mass calcd for C IE H23NO3 301.1678, found 301.1755. 
7-0 -[(R)-2-Phenylbutyryl]heliotridine (23): noncrystal- 
lizing gum; 11-I NMR S 0.90 (t, 3 H, H4'), 1.82 (m, 3 H, H3' & H6), 
2.12 (m, 1 H, H6), 2.80 (m, 1 H, H5), 3.10 (m, 1 H, H5), 3.29 (m, 
1 H, H3), 3.46 (t, 1 H, H2'), 4.01 (br s, 1 H, H8), 3.92 (br d, 1 H, 
H3), 4.30 (s, 2 H, H9), 5.00 (s, 1 H, H7), 5.59 (s, 1 H, H2), 7.26 
(m, 5 H); ELMS, m/e 80 (84), 91 (44), 106 (100), 111 (65), 124 (22), 
137 (72), 173 (1), 205 (1), 283 (2), 301 (3); exact mass calcd for 
C 18H23NO3 301.1678, found 301.1676. 
9-0 -[(S)-2-Phenylbutyryl]heliotridine (20): noncrystal-
lizing gum; 1H NMR 5 0.89 (t, 3 H, H4'), 1.86 (m, 2 H, H3'), 1.77 
(m, 1 H, H6), 2.10 (m, 1 H, I-16), 2.56 (m, 1 H, H5), 3.20 (m, 1 H, 
H5), 3.23 (m, 1 H, H3), 3.48 (t, 1 H, H2'), 3.78 (br s, 1 H, H8), 
3.81 (br d, 1 H, H3), 4.01 (q, 1 H, H7), 4.81 & 4.62 (AB quartet, 
2 H, H9), 5.53 (s, 1 H, H2), 7.25 (m, 5 H); EIMS, m/e 43 (71), 
56 (67), 71 (100), 89 (48), 93 (71), 138 (60), 173 (9), 257 (2), 301 
(1); exact mass calcd for C 161-1 23NO3 301.1678, found 301.1685. 
9-0 -[(R)-2-Phenylbuty ryl]heliotridine (22): noncrystal-
lizing gum; 1I-1 NMR (5 0.89 (t, 3 H, H4'), 1.84 (m, 2 H, H3'), 2.12 
(m, 1 H, H6), 1.75 (m, 1 H, H6), 2.54 (m, 1 H, H5), 3.20 (m, 1 H, 
H5), 3.23 (m, 1 H, H3), 3.51 (t, 1 H, H2'), 3.79 (br s, 1 H, H8), 
3.81 (br d, 1 H, H3), 3.93 (q, 1 H, H7), 4.85 & 4.61 (AB quartet, 
2 H, H9), 5.55 (s, 1 H, H2), 7.24 (m, 5 H); EIMS, m/e 43 (24), 
56 (20), 71 (28), 91 (40), 93 (100), 138 (81), 155 (5), 173 (1), 257 
(2), 301 (1); exact mass calcd for C i8H23NO3 301.1678, found 
301.1667. 
Dihydroindicine (26). A solution of 10 mmol (2.02 g) of 
(-)-trachelanthic acid acetonide 12 and 11 mmol (1.75 g) of CDI 
in 25 mL of freshly distilled DMF was warmed at 70 °C for 5 min, 
after which the evolution of CO 2 ceased. Then, a solution of 10 
mmol (1.67 g) of platynecine 25 in 50 mL of DMF was added, 
followed by 0.8 g of sodium irnidazole. The reaction mixture was 
heated at 73 °C for 19 h. DMF was stripped off and 50 mL of 
water was added to the residue, which was then extracted with 
CHC13. The combined CHC1 3 layer was washed with water and 
finally dried over Na2SO4. Evaporation left 2.9 g (85%) of a glassy 
residue. The NMR spectrum of this material was consistent with 
that expected for dihydroindicine acetonide (C-9 protons as ABX 
pattern at 4.62 & 4.55, isopropylidene methyls singlets at 1.51 
& 1.41), but the NMR spectrum also showed traces of C-7 ester 
(<7%) by the presence of a signal at S 5.4. This material was 
dissolved in 50 mL of 0.6 N HC1 and the solution was kept at 25 
°C for 22 h. The solution was then treated with an excess of 
NaHCO3 and washed with 10 mL of CHC13. The aqueous layer 
was concentrated to 8 mL, treated with 1.5 mL of K 2CO3, and 
concentrated in vacuo again to give a wet solid, which was ex-
tracted with CHC1 3-Me0H (97:3). On concentration, the solution 
afforded 2.4 g of a solid, which on recrystallization gave 1.8 g of 
dihydroindicine, which showed the following properties: mp 175 
°C; 1 1-1 NMR (5 0.92 (d, 3 H, H6'), 0.96 (d, 3 H, H6'), 1.20 (d, 3 
H, H4'), 1.80 (m, 3 H), 1.99 (hept, 1 H, H5'), 2.64 (m, 1 H), 2.78 
(m, 2 H), 3.08 (m, 1 H), 3.20 (t, 1 H), 3.29 (dd, 1 H), 4.07 (q, 1 
H, H3'), 4.24 (s, 1 H, H7), 4.52 & 4.65 (ABX, 2 H, H9); EIMS, 
m/e 82 (100), 95 (48), 96 (30), 114 (16), 140 (42), 158 (37), 240 
(4), 257 (2), 268 (2), 283 (2); CIMS 302 (M + 1, 100). Anal. 
(C 15H271\105) C, H, N. 
The mother liquor containing the C-7 ester was chromato-
graphed with use of a Dropping Counter Current Chromatograph 
and the solvent system CHC13-C6H6-CH 3OH-H 20 (5:5:7:2) in the 
ascending mode of operation. By this method 160 mg of the C-7 
ester, 7-(-)-trachelanthylplatynecine (30), was eluted first followed 
by 360 mg of the C-9 ester. 7-(-)-Trachelanthylplatynecine (30) 
showed the following properties: mp 187 °C; 1H NMR (5 0.91 and 
1.00 (2 d, 6 H, H6'), 1.24 (d, 3 H, H4'), 1.87 (m, 2 H), 1.95 (hept, 
1 H, H5'), 2.10 (m, 2 H), 2.61 (m, 1 H), 2.75 (m, 2 H), 3.22 (dt, 
1 H), 3.32 (m, 1 H), 3.48 (dd, 1 H), 3.78 (d, 2 H, H9), 4.10 (q, 1 
H, H3'), 5.34 (s, 1 H, H7); EIMS, m/e 43 (100), 113 (20), 139 (81), 
140 (35), 156 (34), 158 (24), 256 (3), 301 (0.4); exact mass calcd 
for C I5H27 1\10 5 301.2108, found 301.1940. Anal. (C 15H27N05) C, 
H, N. 
Dihydroindicine N-Oxide (27). A sample of 4.4 g of di-
hydroindicine was dissolved in a mixture of 47 mL of CHC1 3 and 
3 mL of Me0H a treated with 5.2 g of m-chloroperbenzoic acid. 
After 1 h the solvent was removed and the residue was partitioned 
between E 20 (40 mL) and H 2O (40 mL). The aqueous layer was 
separated and washed three times with 40 mL of Et 20. Evapo-
ration and drying gave 4.4 g of dihydroindicine N-oxide: mp 
165-167 °C; 1 1-1 NMR S 0.92 (d, 3 H, H6'), 0.98 (d, 3 H, H6'), 1.21 
(d, 3 H, H4'), 1.92 (hept, 1 H, H5'), 2.00 (m, 2 H), 2.32 (m, 1 H), 
2.58 (m, 1 H), 3.22 (m, 1 H), 3.62 (m, 2 H), 3.77 (dd, 1 H), 3.85 
(m, 2 H), 4.10 (q, 1 H, H3'), 4.62 (t, 1 H, H7), 4.40 & 4.74 (ABX, 
2 H, H9). Anal. (C15H27N 06) C, H, N. 
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Structure of 2a-Bromo-0,7fi-epoxytrachelanthamidine: 
A New Heterocyclic Ring System 
BY JAN. A. GLINSK1, DONALD V ANDERVEER AND LEON H. ZALKOW• 
School of Chemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, USA 
(Received 17 July 1985; accepted 7 March 1986) 
Abstract.. C,H 12 BrNO r M r = 234 .1, orthorhombic, 
P2,2,2„ a = 6.196 (2), b = 8-971 (2), c =- 
15.797 (5) A, U= 878.1 (4) A 3 , Z = 4, D„,= 1.770, 
Di = l• 767 g cm -3, ,i(MoKE)= 0-71069 A, a= 
39.71 cm - ', F(000) = 472, T = 298 K, R = 0.037 for 
1395 observed reflections. The pyrrolizidine rings of the 
title compound (I) are planar within 0-277 A, and both 
assume envelope conformations. The oxetane ring of (I) 
has all angles close to 90°. The distances 0(2)• • •N' 
(2.826 A) and H(02).••N' (1.82 A) suggest inter-
molecular H bonding between N and the 0 atom of the 
CH 2OH group. The absolute configuration of (I), which 
can be related to its precursor retronecine j Warren & 
Von Klemp,erer (1958). J. Chem. Soc. pp. 4574-4575; 
Warren (1970). The Alkaloids, Vol. XII, edited by 
Manske, ch.. 4, pp. 246-262. London: Academic Press; 
and references therein), was confirmed by comparison 
of the refinement values of (I) with as enanuomer for 
which R = 0.057 was obtained. 
Introduction. The pyrrolizidine alkaloids continue to be 
of great interest because of their broad range of 
biological activity (Roitman, 1983; Huxtable, 1979). 
Recently, there have been intensive studies of the 
antitumor activity of the N-oxides of the pyrrolizidine 
alkaloids and of their semisynthetic analogs (Zalkow, 
Glinski, Gelbaum, Fleischmann, McGowan & Gordon, 
1985; Gelbaum, Gordon, Miles & Zalkow, 1982). Most 
of these alkaloids are esters of the necine base 
retronecine (II). Recently, we reported the X-ray struc-
ture of retronecine and its C7 epimer heliotridine 
(Gelbaum., Glinski, VanDerveer & Zalkow, 1985). As 
To whom correspondence should be addressed. 
0108-2701/86/091237-03S01.50 
part of a program to modify the retronecine skeleton, in 
anticipation of altering biological activity, we attempted 
to prepare epoxides of retronecinc and heliotridine, and 
have recently reported X-ray structures of such 
epoxides (Glinski, VanDerveer & Zalkow, 1985). 
Surprisingly, treatment of retronecine with N-bromo-
acetarnide gave the expected epoxide only as a minor 
product, and as a major product the new heterocyclic 
compound, 2a-bromo-1A713-epoxytrachelantharnidine 
(I) whose structure is reported here for the first time. 
Experimental. The compound (I) is a major constituent 
of a reaction mixture resulting from the treatment of 
(II) with N-bromoacetamide in 30% sulfuric acid 
followed by basification. The reaction mixture, after 
chromatography, afforded crystalline (I), m.p. 444.5-
446 K (uncorrected), [di 271."0°C = + 0.6° (ethanol, 
1.6 g dm - r]. Crystal density by flotation in CBrC1 3- 
hexane. Axial photographs showed the crystal of (I), ca 
0.60 x 0 , 10 x 0.15 mm (from methanol), to be ortho-
rhombic and systematic extinctions indicated space 
group P2 1 2 1 2 3 . Unit-cell parameters and orientation 
matrix for (I) determined on a Syntex F2, four-circle 
diffractometer equipped with a graphite mono- 
o 1986 International Union of Crystallography 
Table 2. Angles (°) with e.s.d.'s in parentheses 
C(81-CM-C(2) 105.413) C(91-C) 11-0121 118 	5 (4) 
C(91-Cl 0-C(8) 1199141 0(11-C(1(-C(2) 108 	1 (41 
0(1)-C(1)-C(8) 89-6)31 0( 1-CM-C(9) 111.4(31 
C(11•.C(21-11r 110 9 (3) C;3/-C(2)-Br 109 	(31 
C(3)--C(21-C(1) 103-7 (4) N-C13)-C12) 104 2 (31 
C(51-N-C(3) 109- 7 (4) C(8)-N-00) 108-0 (3) 
C18)-N-C(5) 1048 (31 C16)-C15)-N 105 	5 (3) 
C(71-C(6)-C(5) 104 	1 141 C181-C1 7 1-061 106-6141 
011)-07)-061 115 6 44i 0111-C(7)--081 898 (31 
N-C(8)-C(1) 107-4 (31 C(71-C(81-C111 87 	1 (3) 
C(71-C(81-N 105-4 (3) 0(21-C(91--C(11 113-1 	(4) 
C(7)-0(1)-C(1) 92-0 (31 
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chromator (Bragg 20 angle = 12.2°), take-off angle 
6.74° using Mo Ka radiation. 15 strong reflections (20 
from 14.11 to 24.22°) machine centered and used in 
least-squares refinement of lattice parameters and 
orientation matrix. Intensity data collected using 0-20 
scans, background counts at beginning and end of each 
scan with X-ray source and monochromator settings 
identical to those used to determine unit-cell 
parameters. Intensities of three standard reflections: 
0,0,10, 060 and 400 measured every 97 scans did not 
vary significantly (+5%). A variable scan rate from 
2.02 to 29.3° min - ' used to collect a total of 1759 
reflections in a complete quadrant +h, +1 of data 
out to 20= 50° (sing/) . = 0.5947 A - '), 1558 unique 
reflections. R,„, = 0-023. of these, 1395 accepted as 
statistically above background on the basis that 
F > 3o(I) Icr(F)= (total counts + sum of back-
grounds)" x scan rate]. cr(F) = a(f)/(2FLp). 
w scans of several low-2 0-angle reflections gave peak 
width at half height of less than 0.20° indicating a 
satisfactory mosaic spread for the crystal. Intensity 
data for zero and upper levels collected at a rapid scan 
rate and intensities examined for systematic absences. 
A Lorentz-polarization correction applied. Absorption 
and extinction corrections not applied. Direct methods 
using SHELX76 (Sheldnck. 1976) generated a series of 
£ maps. one of which correctly located the Br atom. A 
subsequent difference Fourier map based on the Br 
position contained the remaining non-H atoms. All H 
atoms located from a difference Fourier map. Coordi-
nates of the H atoms remained fixed and their tem-
perature factors refined isotropically. Full-matrix least-
squares refinement with all non-H atoms anisotropic 
gave R = 0.037 and i.y.R = 0.038 using F (S = 1 - 16). 
Maximum least-squares shift to e.s.d. ratio 0.31: final 
difference Fourier map maximum + 1.27 (0.91 A from 
Br) and minimum -0.91 e A . Goodness of fit = 1-13, 
atomic scattering factors as in SHELX. A weighting 
scheme with = 1 •025/I OP' + 0.00091r (SHELX) 
was used. When the reported structure was inverted and 
refined. the following results were obtained: R = 0.057, 
= 0-063. maximum shift to e.s.d. 0.37, maximum 
residual electron density 1 39 e A - ', 0.89 A from Br. 
goodness of fit = 2.62. 
Discussion. Atomic parameters for (11 are given in 
Table I.' 
The ORTEPH (Johnson. 1976) view of (I) is shown 
in Fig. 1, using 50% probability ellipsoids. The thermal 
parameters of the H atoms have been artificially 
• Lists of structure factors. H•atom coordinates and anisotropic 
thermal parameters have been deposited with the Bnush Library 
Lending Division as Supplementary Publication No. SUP 42911 
( 11 pp.). Copies may be obtained through The Executive Secretary. 
International Union of Crystallography. 5 Abbey Square. Chester 
CHI 2HU. England . 
Table 1. Final atomic coordinates and equivalent 
isotropic thermal parameters 
(U„ + U„ + U11)/3. 
Br -0.02645 (8) -0-01701 (6) -0.79104 (3) 
U,„(A 1 ) 
0045 
C(1)  0 2378 (6) 0.0096 (5) -0.6422 (3) 0033 
C(2)  0.0951 (81 -0.1019 (5) -0-6865 (3) 0 038 
C(3)  -0.0880 (8) -0.1303 (5) -0.6226 (3) 0 - 038 
-0.1178 (5) 0 - 0164 (4) -0-5793 (2) 0032 
C(5)  -0.1579 (7) -0-0082 (6) -04872 (3) 0 042 
C(6)  0.0652 (9) -0.0398 (6) -0.4483 (3) 0-049 
C(7)  02228 (7) 0.0353 (6) -0-5088 (31 0042 
C(8)  0.0872 (7) 0 0969151 -05829 (3) 0.032 
C(9)  0.4047 (8) 0-0910 (6) -06933 (4) 0 - 048 
0(11 0 3355 (51 -0.06417 (4) -0 5676 (2) 0 042 
0(2) 0.5360(6) 0-1875 14) -0.6435 (2) 0-054 
reduced to clarify the picture. Bond distances (A) are 
indicated in Fig. 1, and bond angles are listed in Table 
2. 
The three rings of (I) constitute the previously 
unreported heterocyclic system laH-oxeto12,3,4-g,hi-
pyrrolizine. The loline group of alkaloids (Yunusov & 
Akrarnov. 1955: Bates & Morehead. 1972. and 
references therein) similarly possess an oxygen bridge 
joining C(7) and C(2). The presence of an oxygen 
bridge between C(1) and C(7) in (I) introduces unusual 
strain into the pyrrolizidine skeleton, reflected by the 
dihedral angle between the planes of N, C(8), C(7), and 
N, C(8). C(1) of only 91.8°, while in the closely related 
but more flexible molecules of a-epoxyretronecine or a-
and fl-epoxyheliotridine (Glinski, VanDerveer & Zal-
kow, 1985) the same value vanes from 122-2 to 
124.9°. In (I), C(7) as well as C(1) are parts of a rigid 
structure, leaving some conformational freedom only to 
C(2), C(3), C(5) and C(6). Ring A, consisting of C(1), 
C(2), C(3), N and C(8) is planar within 0.200 A, and 
ring B. consisting of C(5). C(6), C(7), C(8) and N is 
planar within 0.227 A. Both rings assume 'envelope' 
conformations in which C(1), C(2), C(8) and N are 
planar within 0.071 A with C(3) endo-buckled 0.477 A 
off-plane. and in which C(S), C(6), C(7) and C(8) are 
coplanar within 0.024 A with N exo-buckled 0.527 A 
off-plane. The oxetane ring, consisting of C(1). C(8). 
02 
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C(7) and 0(1). has all angles close to 90° (4-2.9°) with 
0(1) 0.233 A out of the plane of C(1), C(8) and C(7). 
The intermolecular distance 0(2)• • • N' (N' at -1+x, 
zi of 2 826 A is below the combined van der Waals 
radii and the distance H(02)• • •' of 1.82 A is 
considerably less than the combined van der Waals  
radii (Hamilton & Ibers. 1968) suggesting the existence 
of a hydrogen bond. 
We gratefully acknowledge financial support of this 
work by the National Cancer Institute of NIH 
(CA31490) and we thank Professor J. Aaron Bertrand 
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Structure of 5,5,6-Trimethy1-1,4-dipheny1-2,3,7-trioxa[2.2.11bicycloheptane 
BY A sHFAouz.z.AmAN S YID. * GARY P. KERSCHENNEUTER_ VINOD JAIN, GARY W. GRIFFIN AND 
EDWIN D. STEVENS 
Department of Chemistry, University of New Orleans, New Orleans. LA 70148. USA 
(Received 23 July 1984; accepted 3.4prd 1986) 
Abstract C 	M. = 296-37, monoclinic. P2,/n, 
a = 19.078 (7), b = 7-149 (1). c = 24.221 (4)A, fl= 
104.37 (4)°, V= 3199.9 A'. Z = 8, D1 = 
1-230 g cm i, ,i(Mo Ka) = 0.71069 A. p = 0.80 cm - ', 
F(000) = 1264, T = 298 K. final R = 0.038 for 1656 
unique observed reflections based on 1 > 3c(1). The two 
molecules of the asymmetric unit are very similar. 
including the torsion angles of the phenyl groups. 
• Present address. Enraf-Nonius Service Corp., 390 Central 
Avenue. Boherrua, New York 11716, USA. 
0108-2701/86/091239-04501.50 
Relatively long 0-0 bond lengths of 1.484 (4) and 
1.485 (3) A and small C-0-C angles of 95.7 (3) and 
96.7 (3)° are observed. 
Introduction. We recently reported (Kirschenheuter & 
Griffin, 1983) that the photoinduced 9,10-dicyano-
anthracene (DCA) sensitized photooxidation of 3.3,4- 
trimethy1-1,2-diphenylcyclobutene (1) gives a pair of 
epimeric ozonides: 5,5,6-trimethy1-1,4-dipheny1-2,3.7- 
trioxa12.2.11bicycloheptanes (2) and (3), respectively. 
These epimeric ozonides were tentatively assigned the 
c 1986 International Union of Crystallography 
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THE SYNTHESIS OF HELIOTRIDINE AND RELATED ALKALOIDS 
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Atlanta. Georgia 	30332 U.S.A. 
2. , stra:! 	An efficient 	synthesis C' 	hellOtridlne from readily available retronecine was 
accomp;isned ty nuCleopfilliC displacement of the 7-mesylate, in the 7-mesy1-9-tenzoate of 
retronecine with various cesium carooxylates in DmF, followed by hydrolysis. 'he synthetic 
procedure also permits the ready Synthesis of a number of naturally occurring pyrrolizidine 
alkaloids possessing dissimilar acyl groupS at C-7 ana C-:.i. 
has been estimated that 3t of the world's flowering plants contain pyrroHzidine 
alkaloids. 2 These alkaloids, as a class, Show extensive biological activity and have resulted 
In heavy loss of livestock in many countries of the world 3 and are also a human health 
hazard. 4  One of the alkaloids, indicine N-oxide, has progressed to clinical evaluation as an 
anti-tumor 	agent s 	and 	efforts 	are 	underway 	to 	exploit 	the 	subtle 	structure-activity 
relationships which distinguish between toxicity and anti-tumor activity 5,6,7 . 
most 	of 	tne biologically active pyrrolizidine alkaloids are eitner 9-monoesters of 
retronecine W or heliotridine '2', unsymmetrical 7,9-dlesters of retronecine or hellotridine 
or 7 .9-macrocyclic diesters of retronecine e . 	For the preparation of pyrrolindine a:Kaioid 
analogs for anti-tumor screening, we required rather large amounts of hellotridine. 	Recently, 
Thamberlin and Chung' reported an elegant synthesis of neliotridine from S-malic acid. nowever. 
this procedure did not lend itself to a practical solution to our problem. 
Since we had in hand relatively large quantities of retronecine, readily available tO uS 
from natural sources 7 , we sought an efficient means of converting it into hellotflo'ne. 	- hree 
methods have frequently been used for the inversion of secondary alcohols10.11.12, 	of these 
three methods, practicality and preliminary experimental work suggested that the metnod of 
Kellogg et al. would be best suited for our purposes. 	Initial attempts to utilize 7 ,9- 
dimesylretronec ine revealed that this compound was too unstable to be useful. 	Therefore, 9- 
benzoylretronecine (31 was prepared by site-specific coupling of retronecine with benzoic acid 
using :,1'-cartodiimidazole (C01 )7 . 	This, in turn, was converted, in high yield, into the key 
intermediate 413, 	The inversion of the 7-mesylate in 4 was examined with the cesium sa'ts of 
acetic, proploric, tiglic, angelic and benzoic acids under the conditions and with tne results 
















3: R • H. R' • PhCO. 
4: R • MeS0 2. R' • PhCO. 
iii 
RO 
5a . R • CH ICO, R' • PhCO (12h, 76°C, 7551. 
5b: R 	CH;CH2CO, R' • PhCO (17h. 76 ° C, 805). •  
Sc: R ■ angelyl, R' - PhCO (18h, 76°C, 72%). 
5d: R • tiglyl, R' • PhCO (18h, 76 ° C, 7 2%). 
5e: R • R' • PhCO (40h, 85°C, 30%). 
7: R • CH 3CO, R' • 1-viridifloryl. 
8: R • angelyl, R' • 1-viridiflOryl. 
9: R • angelyl, R' • H. 
i 	PbCOOm( 1 eq.),CDI(1.1 eq.),THF, 
r.t.,16 h,95%: ii 	MeS0 2C1(1.3 eq.), 
Et3N(1.5 eq.),CH 2C1 2 ,-2 ° C,1.5 h, 
93%; iii 	RCOOCs(4 eq.),DMF; iv: 
8a(OH1 2 ao.,r.t.,875 from pure 5b. 
H 	Ma 	me 	Me 
>--- 	CO Me 	0 	H 
angelyl 	 tiglyl 
nucleoprille, approximately 75% of the inverted product 5b is obtained, accompanied by 
unsaturated products. Pure 5b 14 could be isolated by chromatography on alumina; however, as a 
general method for the preparation of heliotridine, the crude product was used directly for the 
next step. Yields in the diagram represent isolated yields and are not optimized. It is 
worthwhile noting that substitution by cesium angelate led to the isolation of the 70-angelate 
(5c) uncontaminated with the Isomeric 7o-tiglate (5d), whereas attempted esterification of 
retronecine with angelic acid, using CD1 led to a mixture of angelate and tiglate esters; a 
similar mixture of products has been obtained by the use of dicyclohexylcarbodiimide 15 . 
Finally, heliotridine could be obtained from the diesters either by hydrolysis with barium 
hydroxide or by reductive cleavage using lithium aluminiri hydride; comparable yields were 
obtained by both methods. Crystalline heliotridine was obtained from the reaction mixture, 
identical in physical properties and chromatographically with that previously reported 9 and with 
an authentic sample prepared by hydrolysis of europine 5 . When crude diesters 5a-5e were used 
directly for the preparation of heliotridine, two minor products were isolated by 
chromatography. One of these has been identified as the previously unreported a6-supinidine 
2 859 
16) 16 while the second has not been characterized but is a dimeric product of MA 274. 
with the ready availability of retronecine from natural sources, the procedure outlined 
here provides an efficient means of obtaining not only hellotridine but, in principle, all of 
the alkaloids containing the neliotridine nucleus. As an example, we report here, for the first 
time, :he syntheses of the three alkaloids 7-acetylechinattne (7) 17 , 7-angely1-9-1- 
viridiflorylheliotridine ;8) 18 and 7-angelylhellotridlne (9) 18 . Esterificatlon of retronecine 
with the acetonide of l-viridifloric acid using COI gave site specifically the C-9 ester (10) 
which on mesylation gave the desired 7-mesy1-9-1-virIdiflorylretroneCIne acetonide (11). 
Reaction, as above, with cesium acetate or cesium angelate, followed by deprotection and 
chromatography gave 7 19 and 820 , respectively. Oxidative cleavage of 8 or its acetonide by 
periodic 	acid directly gave 9. 	All 	the three natural 	alkaloids: 	7, 8 and 9 were 
:hromatographically homogeneous. Their physical properties were consistent with those 
ubliShed 17 ' 18 and tnelr 300 MHz AN PR and mass spectra were consistent with the assigned 
st rJc tJ-es. 
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0 5_ < 6), corrected for Lorentz and polarization 
effects and, semi-empirically, for absorption (North, 
Phillips & Mathews., 1968) with maximum correction 
factor 1.60. Three standard reflections monitored every 
270 measurements with maximum intensity variation 
2.1%; 1805 independent reflections collected with w/20 
scan technique, 196 [I < 3a(1)] considered unobserved. 
Maximum value of sinO/A, 0.5271 A- '. Structure solved 
by direct methods (.RANTAN, Yao Jia-xing, 1981); F 
magnitudes used in least-squares refinement. Out of 52 
H atoms [coordinates calculated by geometrical con-
siderations (XANADU, Roberts & Sheldrick, 1975)1, 
only 31 H atoms, located on a difference density map, 
were included in the refinement with positions and .8 190 
 factors fixed. Coordinates and anisotropic thermal 
parameters of non-H atoms refined by block-diagonal 
least squares; 341 independent parameters refined. 
Final R = 0.081, wR = 0.101, 
w  = 1/62(Fobs), 
S = 
8.60; secondary-extinction final value 1.57 (8) x 10 -2. 
No significant peaks in final difference map, highest 
peak 0.21 e A-3, final value Nu = 0.15. Atomic 
scattering factors from International Tables for X-ray 
Crystallography (1974). All calculations performed on 
a Honeywell DPS 8/44. 
Table 1. Fractional atomic coordinates (x104) with 
e.s.d.'s in parentheses and equivalent isotropic tem- 
perature factors (A 2) 
B„ =1.>_;‘),Ja,.a,. 
x y z B„ 
C(I) 3225 (8) 4092 (21) 2512 (23) 4-06 
C(2) 2381 (7) 3662 (21) 1627 (20) 3 	15 
C(3) 2029 (7) 1647 (20) 1188 (21) 3-22 
C(4) 2377 (7) 122 (22) -716 (21) 3-38 
C(5) 3254 (7) 552 (20) --39 (19) 2 76 
C(6) 3746 (8) 767 (21) -1616 (22) 4.07 
C(7) 4521 (8) -787(21) -431(22) 4.00 
C(8) 4886 (8) 1249' 1192 (21) 3.22 
C(9) 4525 (7) 2823 (18) 1748 (20) 2.87 
C(10) 3704 (7) 2760 (20) 719 (20) 2.77 
C(111 4914 (8) 4804 (21) 3365 (23) 4.21 
C(12) 5770 (7) 5117 (20) 4170 (19) 2 92 
0(12) 5802 (5) 5443 (18) 6555' 4.45 
C(131 6187 (7) 3399 (21) 2775 (22) 306 
C(14)  5659 (7) 1386 (21) 2439 (21) 3-14 
C(15)  6193 (8) -80(22) 1291 (22) 3-98 
C(16)  7014 (7) 875 (22) 2519 (22) 3 78 
C(17) 6976 (7) 3112 (20) 3841 (20) 3.34 
C( 18) 6348 (7) 3702 (21) 446 (19) 3.36 
C(19)  3831 (8) 3609 (21) -1256 (21) 4.00 
C(20)  7734 (7) 4461 (22) 3761 (21) 3-41 
C(21)  7710 (7) 6670 (22) 4795 (21) 3.09 
C(22)  8428 (7) 4050 (21) 4980 (22) 4.09 
C(23) 8446 (7) 5088 (23) 7564 (23) 4 25 
C(24) 8284 (8) 7152 (22) 8176 (21) 3 90 
C(25) 8807 (8) 8550 (24) 7077 (25) 4.90 
0(24) 7533 (5) 7098 (17) 7120 (16) 3.90 
0(25) 8456 (6) 7799 (18) 4792 (17) 4.72 
C(26) 9710 (8) 8334 (26) 7051 (30) 7 01 
C(27) 8723 (8) 10739 (22) 8233 (27) 5 42 
C(28) 2022 (8) -2002 (22) 778 (26) 5 38 
C)29) 2176 (8) 231 (24) -3054 (23) 4 84 
C130) 5465 (8) 1005 (21) 4699 (2)) 4.09 
C)31) 1087 (8) 3566 (24) 2499 (23) 4-84 
C(32)  710 (9) 3274 (26) 4591 (26) 6-02 
C(33) 624 (8) 4551 (25) 1302 (24) 5. 57 
0(2) 1865' 4698 (18) 3209 (17) 4.91 
0(3) 1212 (6) 1668 (19) 914 (17) 4.84 
* Coordinates selected to establish the origin. 
Table 2. Bond lengths (A) and angles (°) with e.s.d.'s in 
parentheses 
CM-C(2) 	1.51 (2) C(131-C(17) .59 (2) 
C(I)-C(10) 1.55 (2) C(13)- C(18) -57 (2) 
C(2)-C(3) 	1.43 (2) C( I4)-C( 15) -52 (2) 
C)2)-O(2) 1.43 (2) C(14)-C(30) -56 (3) 
C(3)--C(4) 	-53 (2) C(15)-C(16) -55 (2) 
C(3)-0(3) I -42 (2) C(16)-C(17) -57 (2) 
C(4)-C(5) 	1.52 (2) C(17)-C(20) .52 (2) 
C(4)-C(28) 1.56 (3) C(20)-C(21) -53 (3) 
C(4)-C(29) 	1.54 (3) C(20)-C(22) -54 (3) 
C(5)-C(6) 1.50 (2) C(21)-0(25) .41 (2) 
C(5)-C( 10) 	.58 (2) C(21)-0(24) -43 (2) 
C(6)-C(7) -54 (2) C(22)-C(23) -54 (2) 
C(7)-C(8) 	1.53 (2) C(23)-C(24) .50 (3) 
C(8)-C(9) 1-34 (2) C(24)-C(25) -58 (3) 
C(8)-C(14) 	1.52(2) C(24)-0(24) -44 (2) 
C(9)-C(I0) 1.54 (2) C(25)-C(26) -59 (2) 
C(9)-C( I I) 	1.51 (2) C(25)-0(25) .45 (2) 
C(10)-C(19) .56(3) C(25)-C(27) .55 (3) 
C(11)-C(12) 	1.52 (2) C(31)-C(32) -53 (3) 
C(12)-C(131 1.55 (2) C(31)-C(33) -50 (3) 
C(I2)-0(12) 	1.43(2) C(3I)-0(2) -44 (2) 
C(13)-C(14) 1.55 (2) C(31)-0(3) -46 (2) 
C(2)-C(1)-C(10) 	108.8 (1 , 1) C(14)-C(13)-C(17) 101.1 (1.1) 
CM-C(2)-0(2) 114.1 (1.0) C(8)-C(14)-C(13) 110.1 (1.0) 
C(1)-C(2)-C(3) 	112-5 (1.2) C(13)-C(14)-C(30) 113.6 (1.1) 
C(3)-C(2)-0(2) 101.8 (1.1) C( 1 3)-C(14)-C(15) 102.6 (1•1) 
C(2)-C(3)--0(3) 	103.3 (1.2) C(8)-C(14)-C(30) 107.9 (1.0) 
C(2)-C(3)-C(4) 115.5 (1.2) C(8)-C(14)-C(15) 117-7(1.0) 
C(4)-C(3)-0(3) 	116.2(1.1) C(15)-C(14)-C(30) 104.9 (1.1) 
C(3)-C(4) 	C(291 111.8 (1•2) C(14)-C(15)-C(16) 104.4 (1• I)  
C(3)-C(4)-C(28) 	109.8(1.1) C(15)-C(16)-C(I 7) 106.9 (I 
C(3) -C(4)-C(5) 104.1 (1.0) C(13)-C(17)-C(16) 102.3 (1.0) 
C(28) -C(4)--C(29) 	106.7 (1.2) C(16)-C(17)-C(20) 112.2 (1.1) 
C(5)-C(4)-C(29) 114.8 (1.1) C(13)-C(17)-C(20) 118.4 (1.2) 
C(5)-C(4)-C(28) 	109.7 ( I -1) C(17)-C(20)-C(22) 111-4(1.2) 
C(4)-C(5)-C(10) 119.2 (11) C(I7)-C(20)-C(21) 115•1(1•I) 
C(4)-C(5)-C(6) 	115-6 (I-I) C(21)-C(20)-C(22) 107.0 (1.1) 
C(6)-C(5)-C(10) 109.0 (1-0) C(20)-C(21)-0(24) 108.4 (1.2) 
C(5)- C(6)-C(7) 	111.8 (11) C(20)-C(21)-0(25) 110.9 (I-1) 
C(6)-C(7)-C(8) 112.6 (1.1) 0(24)-C(21)-0(25) 106.2 (1.0) 
C(7)-C(8)-C(14) 	116.6 (0.8) C(21)-0(25)-C(25) 108.3 (I.1) 
C(7)-C(8)-C(9) 123.8 (1.0) 0(25)-C(25)-C(26) 110.2 (1.2) 
C(9)-C(8)-C(14) • 	119.1 (0.8) 0(25)-C(25)-C(27) 110.6 (1.2) 
C(8)-C(9)-C(11) 121.6 (1-1) 0(25)-C(25)-C(24) 100.6 (1.1) 
C(8)-C(9)-C(10) 	122.6(1-I) C(26)-C(25)-C(27) 110.0 (1.3) 
C(10)-C(9)-C11 I) 115.9 (1-1) C(24)-C(25)-C(26) 113.3 (1.3) 
C(5)-C(10)--C(9) 	108.1 (1-1) C(24)-C(25)-C(27) 111.8 (1.2) 
C(1)-C(10)-C(9) 	( I.0) 110.4 C(25)-C(24)-0(24) 98.0 (1.1) 
C(I)-C(10)--C(5) 	108.7(1.0) C(23)-C(24)-C(25) 116.7 (1-2) 
C(9)-C(10)--C(19) 107.4(1.0) C(23)-C(24)-0(24) 108.7 (1.2) 
C(5)-C(10)--C(19) 	114.1 (1.0) C(22)-C(23)-C(24) 112.1 (1-2) 
CM-CO0)-C(19) 108.2 (1.1) C(20)-C(22)-C(23) 111-7 (1.1) 
C(9)-C(11)--C(12) 	120.1 (1.2) C(21)-0(24)-C(24) 102.1(0.9) 
C( I 11-C(12)-0(12) 	108-3 (9.9) 0(2)-C(31)-0(3) 105.2 (1.0) 
Q1 I)-C(12)-C(13) 	111-9 (1.1) C(33)-C(31) -0(3) 109.3 (1.1) 
C(13)--C(12)-0(12) 	113.5 (1-0) C(33)-C(31)-0(2) 110.6 (1.3) 
C(12)-C(13)-C(18) 	106-4 (I-I) C(32)-C(31)-0(3) 109.7 (1.3) 
C112)--C(13)- C(17) 	118-2 (I -0) C(32)-C(31)-0(2) 107.4 (1.1) 
C(12)--C(13)-C(14) 	110.4(1-0) C(32)-C(3I)-C(33) 114.2 (1.2) 
C) 17)-C(13)-C(18) 	109.6 (1.0) C(2)-0(2)-C(31) 105.6 (0.9) 
C(14)--C(13)-C(18) 	111.0(1.1) C(3)-0(3)-C(3 I) 105.0 (1.0) 
Fig. 1. ORTEP view (Johnson, 1965) of the molecule with the atom 
numbering. Thermal ellipsoids are drawn at the 20% probability 
level. 
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Discussion. Atomic coordinates and equivalent iso-
tropic temperature factors of non-H atoms are reported 
in Table 1;* bond lengths and angles (PARST, Nardelli, 
1983) are given in Table 2 and agree well with generally 
accepted values. Fig. 1 is a computer-generated 
perspective drawing of the final X-ray model of the title 
compound, H atoms are omitted for clarity. 
- The X-ray crystallographic study of (II) confirmed 
the oxygenation pattern of the molecule and the overall 
relative stereochemistry of the lanostane nucleus; 
assuming that the chiral centres of (II) have the same 
configuration as the natural (+)-lanosterol, the 
configuration of C(24) is R. 
Rings A-C adopt the chair, half-chair and 1,2- 
diplanar conformations, respectively (Bucourt, 1974), 
though they are somewhat deformed. Ring A is slightly 
flattened, probably to relieve the severe 1,3-diaxial 
methyl-methyl interaction and to allow the formation 
of the 1,3-dioxolane ring. In ring B C(5) is -0.61 (2) 
and C(6) 0.15 (2) A out of the mean plane through 
C(7)C(8)C(9)C(10), whereas in ring C C(12) is 
0.33 (2) and C(13) 0.85 (2) A above the mean plane 
through C(8)C(9)C(11)C(14). The cyclopentane ring D 
is closer to the 'half-chair' than to the 'envelope' form, 
C(13) is 0.36 (2) and C(14) -0.40 (2) A out of the 
mean plane through the other three atoms. 
* Lists of structure factors, anisotropic thermal parameters, 
H atom coordinates and least-squares-planes' data have been 
deposited with the British Library Lending Division as Supplemen-
tary Publication No. SUP 42242 (18 pp.). Copies may be obtained 
through The Executive Secretary, International Union of Crystal-
lography, 5 Abbey Square, Chester CHI 2HU, England. 
As far as the conformations of the heterocyclic rings 
are concerned, the 1,3-dioxolane ring is in an almost 
perfect half-chair conformation, whereas the five-, six-
and seven-membered rings constituting the bicyclo-
13.2.1 loctane system adopt the half-chair, chair and 
boat conformations, respectively. 
The largest distortion is suffered by the seven- 
membered ring to relieve the otherwise intolerable 
repulsive interaction between the axial H(22) and one of 
the geminal methyls at C(25). 
We thank the National Research Council of Italy 
(CNR) 'Progetto Finalizzato Chimica Fine e Secon-
daria' for financial support and Professor G. Chiari 
(University di Torino) for RANTAN calculations. 
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Retronecine and Heliotridine, C 8 H 13NO2 : Diastereoisomeric Pyrrolizidine Necine Bases 
BY LESLIE T. GELBAUM, JAN A. GLINSKI, DONALD VANDERVFER AND LEON H. ZALKOW* 
School of Chemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, USA 
(Received 22 August 1984; accepted 17 May 1985) 
Abstract. Mr = 155.20, orthorhombic, P2 1 2,2„ Z = 4, 
A(Mo 	= 0.71069 A, F(000) = 336, T = 298 K. 
Retronecine: 	a = 7.944 (4), 	b = 8.536 (5), 	c = 
12.062 (6) A, V = 817.9 (7) A 3 , D m = 1.25, Dx = 
1.26 g cm -3 , 	p = 0.54 cm -1 . 	Heliotridine: 	a = 
11-904 (2), b = 7.620 (1), c= 8.800(1) A, V= 
798.2 (2) A 3 , Dm = 1.32, Dx = 1.29 g cm -3, p = 
0.55 cm'. Final R = 0.040 and 0.038 for 825 and 
1328 observed reflections for retronecine and heliotri- 
* To whom correspondence should be addressed. 
dine respectively. The ring system in retronecine (I) is 
exo- and in heliotridine (II) endo-puckered. In both 
structures 0(1) and 0(2) are in an antiparallel 
conformation. There are no unusual bond distances or 
angles. The intermolecular distances N(4).• .0(2) for (I) 
(2.69) and for (II) (2.72 A) indicate the existence of 
hydrogen bonding. 
Introduction. The pyrrolizidine alkaloids have attracted 
a great deal of attention, primarily because of their 
causative effects in the heavy loss of livestock in many 
0108-2701/85/09134 2-04$01.50 	© 1985 International Union of Crystallography 
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countries of the world (Bull, Culvenor & Dick, 1968). 
More recently, the human-health hazards in, for 
example, herbal teas, honey, and grain contaminants 
have become of increasing concern (Huxtable, 1979; 
Roitman, 1983). The toxicity (hepatotoxicity) has been 
ascribed to the alkylation of biological nucleophiles 
(protein and nucleic acids) by 'metabolic pyrroles' 
produced in the liver from the pyrrolizidine alkaloids 
(McLean, 1970). On the cellular level, pyrrolizidine 
alkaloids also exhibit antimitotic action (McLean, 
1970). Related to this is the antitumor activity of 
certain pyrrolizidine alkaloids (Culvenor, 1968), in 
particular, the pyrrolizidine alkaloid N-oxide, indicine 
N-oxide (Kugelman, Liu, Axelrod, McBride & Rao, 
1976), and semisynthetic analogs (Gelbaum, Gordon, 
Miles & Zalkow, 1982). Almost all of the biologically 
active (toxic and antitumor) pyrrolizidine alkaloids and 
N-oxides contain, as their necine bases, either retrone-
cine (I) or heliotridine (II) and are esterified at C(9) 
and/or C(7) (macrocyclic diester or diesters). 
The absolute configurations of (I) and (II) are known 
from chemical interrelationships and degradations 
(Warren & Von Klemperer, 1958; Warren, 1970, and 
references therein) and the relative configurations have 
been confirmed numerous times by X-ray studies on 
alkaloids containing these necine bases, beginning with 
that on jacobine bromohydrin (Fridrichsons, Mathieson 
& Sutor, 1960). However, X-ray structures of these 
necines themselves have never been reported, and we 
provide here this information for the first time. 
Experimental. (I) prepared by hydrolysis of mono-
crotaline (Gelbaum et al., 1982) and suitable crystals 
obtained from acetone. Specific rotation, [a]g .' 
= + 55.0° 'ethanol, 1.0 g dm -3 1. (II) prepared by 
inversion of the C(7) hydroxyl group in (I) (Glinski & 
Zalkow, unpublished work) and the material so 
obtained was identical in physical properties and 
spectroscopically with synthetic (+)-heliotridine which, 
in turn, was identical to that derived from natural 
sources (Chamberlin & Chung, 1983). Suitable crystals 
obtained from toluene-methanol. Specific rotation, 
[a.11,5 .° ° c = +31.0 [ethanol, 1.0 g dm -3 ]. 
Experimental details for X-ray structures are in 
Table 1. Densities determined by flotation in hexane-
carbon tetrachloride, Lp corrections in usual manner 
but no absorption or extinction corrections. Both 
structures solved using direct-methods program 
MULTAN78 (Main, Hull, Lessinger, Germain, De-
clercq & Woolfson, 1978). Most non-H atoms located 
from E map, remaining non-H atoms from subsequent 
difference Fourier map, H coordinates for (I) calculated 
and H atoms refined as parts of C-H groups, hydroxyl 
H atoms located from difference Fourier map and 
refined. H atoms for (II) located from difference 
Fourier map and coordinates fixed. Parameters varied 
in full-matrix least-squares refinement on F: overall 
Table 1. X-ray data collection and solution 
Crystal size (mm) 
No. of reflections for lattice 
parameters 
28 range of reflections ( 0 ) 
Diffractometer 
Radiation 
Max. 28 for data collection ( 0 1 
Scan type 
Scan speed ( 0 min ') 
h,k.I range 
Standard reflections 
Max. variations of /(%) 
No. of reflections measured 
No. or reflections >3a(F) 
wR 
Max. LS shiftio 




scale factor, coordinates and anisotropic temperature 
factors for non-H atoms, isotropic temperature factors 
for H atoms. Scattering factors as in SHELX76 
(Sheldrick, 1976). 
Discussion. Atomic parameters for (I) and (II) are 
given in Tables 2 and 3 respectively.* The ORTEPH 
(Johnson, 1976) drawings for (I) and (II) can be seen in 
Figs. 1 and 2 respectively The bond distances (A) are 
indicated on the drawings. Bond angles are listed in 
Tables 4 and 5 respectively. 
The ring system in retronecine exists in the exo-
puckered form where the angle between C(5), C(6), 
C(7), and C(5), N(4), C(8) is 40.7°. This agrees well 
with the other retronecine-based alkaloids previously 
reported: fulvine 46° (Sussman & Wodak, 1973), 
axillarine 42° (Stoeckli-Evans & Crout, 1976), mono-
crotaline 37° (Stoeckli- Evans, 1979), incanine 42° 
(Tashkhodzhaev, Telezhenetskaya & Yunusov, 1979), 
trichodesmine 35° (Tashkhodzhaev, Yagudaev & 
Yunusov, 1979) and junceine 36.7° (Stoeckli-Evans, 
1982). In contrast, heliotridine is endo-puckered with 
the angle between C(5), C(6), C(7) and C(5), N(4), 
C(8) being 42.2°. This value falls between those 
reported previously for the heliotridine alkaloids lasio-
carpine 34.0° (Hay, Mackay & Culvenor, 1982) and 
heliotrine 45° (Wodak, 1975). The angle between the 
least-square planes defined by atoms C(1), C(2), C(3), 
N(4), C(8), and C(5), N(4), C(8), C(7) is 124.4° for 
retronecine. This compares well with the values 
previously reported for the retronecine-based alkaloids. 
This angle in heliotridine is 121.6° which is very close 
to the 120-6° reported for lasiocarpine but less than the 
* Lists of structure factors, anisotropic thermal parameters and 
H-atom coordinates have been deposited with the British Library 
Lending Division as Supplementary Publication No. SUP 42234 
(16 pp.). Copies may be obtained through The Executive Secretary, 
International Union of Crystallography, 5 Abbey Square, Chester 
CH 1 2HU, England. 
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Table 2. Final atomic coordinates for (I) with e.s.d.'s in 	130° reported for heliotrine. The ring-fusion distances 
parentheses and 110 values (A 2) 	 N(4)-C(8) can be seen on the ORTEP drawings and 
(4„ =IUji . 
are consistent with the values for other pyrrolizidine 
4  
x y z Lie, 
N(4) -0.3130 (2) 0.1355 (2) 0.2012 (I) 0.035 
0(1) -0.0931 (2) 0.1805 (2) 0.4161 (2) 0.044 
0(2) -0.4431(2) 0.5220 (2) 0.4317(1) 0054 
C(I) -0.2838 (3) 03806 (3) 0.2913 (2) 0038 
C(2)  -0.2262 (3) 0.3984 (3) 0.1891 (2) 0.059 
C(3)  -0.2356 (4) 0.2500 (3) 0.1242 (2) 0.054 
C(5)  -0.2097 (4) -0.0038 (4) 0.2252 (2) 0.042 
C(6)  -0.2498 (4) -0.0415 (3) 0.3449 (2) 0.034 
C(7)  -0.2574 (3) 0.1190 (3) 0.3986 (2) 0.043 
C(8)  -0.3456 (3) 0.2159 (3) 0.3093 (2) 0.057 
C(9)  -0.2834 (3) 0-5006 (3) 0.3811 (2) 0.043 
alkaloids. 
It can be seen in the ORTEP drawings that in both 
retronecine and heliotridine 0(1) and 0(2) are in an 
antiparallel conformation. In all of the previously 
reported X-ray data for macrocyclic diesters of 
retronecine, the 0 atoms corresponding to 0(1) and 
0(2) are fixed by the macrocyclic ring so that they must 
be on the same side. This is also observed in the 
recently published X-ray structures of the two C(9)-
monoesters of retronecine, lycopsamine and inter-
medine (Mackay, Sadek & Culvenor, 1983). 
Table 3. Final atomic coordinates for (II) with e.s.d.'s 
in parentheses and (leg values (A 2) 
Ueq - 
Ueq 
C(I) -0.7883 (2) -0.5340 (2) -0.6071 (2) 0.033 
C(2) -0.6915 (2) -0.6157 (3) -0.6194 (2) 0.043 
C(3) -0.5961 (2) -0-5050 (3) -0.5703 (3) 0.055 
N(4) -0.6479 (I) -0.3363 (2) -0.5207 (2) 0.039 
C(5) -0.6098 (2) -0-1808 (4) -0.6078 (3) 0.058 
C(6) -0.6921 (2) -0.1633 (3) -0.7385 (2) 0.052 
C(7) -0.8025 (2) -0.2030 (2) -0.6605 (2) 0.038 
C(8) -0.7720 (I) -0.3498 (3) --0.5483 (2) 0.033 
C(9) -0.9038 (2) -0.6036 (2) -06407 (2) 0.038 
00) -0.8419 (2) - 0.0589 (2) -0.5724 (2) 0.057 
0(2) -0.9020 (I) -0.7584 (2) -07303 (1) 0.040 
Table 4. Bond angles (°) for (I) with e.s.d.'s in 
parentheses 
C(5)-N(4)-C(3) 115.1 (2) C(7)-C(6)-C(5) 102.9 (2) 
C(8)-N(4)-C(3) 108.4 (2) C(6)-C(7)-O(I) 111.1 (2) 
C(8)-N(4)-C(5) 107.2 (2) C(8)-C(7)-O(1) 109.0 (2) 
C(8)-C(1)-C(2) 110.8 (2) C(8)-C(7)--C(6) 101.9 (2) 
C(9)-C(1)-C(2) 126-7 (2) C(1)-C(8)-N(4) 104.3(2) 
C(9)-C(1)-C(8) 122.0 (2) C(7)-C(8)-N(4) 106.7(2) 
C(3)-C(2)-C(1) 112.0 (2) C(7)-C(8)-C(1) 117.2 (2) 
C(2)-C(3)-N(4) 104.6 (2) CM-C(9)-0(2) 113.5 (2) 
C(6)-C(5)-N(4) 104.0 (2) 
Table 5. Bond angles (°) for (II) with e.s.d.'s in 
parentheses 
C(8)-C(I)-C(2) 110.9 (2) C(9)-C(I)-C(2) 128.2 (2) 
C(9)-C(1)-C(8) 120.9 (2) C(3)-C(2)-C(1) 112.3 (2) 
N(4)-C(3)-C(2) 105.0 (2) C(5)-N(4)-C(3) 114.3 (2) 
C(8)-N(4)-C(3) 107.5 (2) C(8)-N(4)-C(5) 105.8 (2) 
C(6)-C(5)-N(4) 105.4 (2) C(7)-C(6)-C(5) 101.5 (2) 
C(8)-C(7)-C(6) 103.4 (2) 0(1)-C(7)-C(6) 112.3 (2) 
0(1)-C(7)-C(8) 106.8 (1) N(4)-C(8)-C(1) 104.2 (2) 
C(7)-C(8)-C(1) 115.3 (1) C(7)-C(8)-N(4) 106.7 (2) 
O(2)-C(9)-C(1) 112.9 (1) 
Fig. 1. Retronecine (the bond-length errors are within 0.003 A). 
Fig. 2. fleliotridine (the bond-length errors are within 0.003 A). 
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Intermolecular contacts between N(4) and 0(2) 
indicate hydrogen bonding in both structures (Hamilton 
& Ibers, 1968). For (I) N(4). • .0(2) is 2.69 and 
N(4)•H(02) is 1.79 A. For (II) N(4)...0(2) is 2.72 
and N(4)• • •H(02) is 1.74 A. The combined van der 
Waals radii are N ..• 0 2.9 and N• • -1-1(0) 2.7 A. 
We gratefully acknowledge financial support of this 
work by the National Cancer Institute of NIH 
(CA31490) and we thank Professor J. Aaron Bertrand 
for his assistance in various calculations. 
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Diastereoisomeric Epoxides of Heliotridine and Retronecine, C 8 H 13 NO 3 
BY JAN A. GLINSKI, DONALD VANDERVEER AND LEON H. ZALKOW * 
School of Chemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, USA 
(Received 22 August 1984; accepted 26 March 1985) 
Abstract. M r = 171.1, A(Mo Ka) = 0.71069 A, T= 
298 K. 13-Epoxyheliotridine (I): orthorhombic, P2 12,2„ 
a = 6.2951 (3), b = 7.7019 (5), c = 17.722 (1) A, U 
= 859.25 (9) A 3 , Z = 4, Dm = 1.321, D, = 
1.322 g cm -3, p(Mo Ka) = 0.63 cm - ', F(000) = 368. 
a-Epoxyheliotridine (II): monoclinic, P2 1 , a = 
6.251 (2), b = 8-578 (1), c = 8.069 (2) A, # = 
110.68 (2)°, (../= 404.8 (2) A 3 , Z = 2, Dm = 1.403, 
D, = 1.405 g cm -3, p(Mo Ka) = 0.66 cm-1, F(000) 
= 184. a-Epoxyretronecine (III): monoclinic, P2„ 
a = 6.509 (1), b 8-340 (1), c= 7.799 (1)A, /3 = 
105.85 (1)°, U = 407.29 (1) A 3 , Z = 2, Dm .= 1.395, 
* To whom correspondence should be addressed. 
0108-2701/85/091345-04$01.50 
Dx = 1.396 g cm-3 , ,u(Mo KEE) = 0.66 cm - ', F(000) =- 
184. Full-matrix least-squares refinement converged at 
R values of 0.037, 0.038 and 0.032 for 1389, 1299 and 
1395 reflections for (I), (II) and (III), respectively. 
There are no unusual bond distances or angles. There is 
intermolecular H bonding between N and the 0 atom of 
the CH 2OH group (N...0 2.70, 2.73 and 2.77 A, 
respectively). The absolute configurations of the three 
diastereomers are defined by reference to the absolute 
configurations of the parent alkaloids heliotridine and 
retronecine [Warren & Von Klemperer (1958). J. 
Chem. Soc. pp. 4574-4575; Warren (1970). The 
Alkaloids, Vol. XII, edited by Manske, ch. 4, pp. 
246-262. London, New York: Academic Press; and 
references therein]. 
© 1985 International Union of Crystallography 
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Introduction. It has been estimated that 3% of the 
world's flowering plants contain pyrrolizidine alkaloids 
and such plants can be expected to be present in most 
environments (Smith & Culvenor, 1981). Approxi-
mately 300 pyrrolizidine alkaloids have been charac-
terized and many have been shown to be responsible for 
the long-known hepatotoxicity in humans and animals 
(Roitman, 1983: McLean, 1970). We have been 
interested, for several years, in the antitumor activity of 
certain of these alkaloids (Zalkow et al., 1979; Zalkow, 
Glinski, Gelbaum, Fleischmann, McGowan & Gordon, 
1985) and semisynthetic analogs (Gelbaum, Gordon, 
Miles & Zalkow, 1982). Almost all of the biologically 
active (toxic and antitumor) pyrrolizidine alkaloids and 
N-oxides contain, as their necine bases, either retro-
necine (IV) or heliotridine (V) and the biological activity 
is reportedly dependent upon the allylic oxygen function 
in ring A (Culvenor, 1968). In a previous communi-
cation, we reported the X-ray structures of retronecine 
(IV) and heliotridine (V) (Gelbaum, Glinski, Van 
Derveer & Zalkow, 1985). 
(IV) 
We felt it was essential to prepare epoxides of 
retronecine and heliotridine in order to gain insight into 
the role of the double bond and the oxirane ring in these 
biologically important molecules. We report here, for 
the first time, the preparation and X-ray structural 
information of fi-epoxyheliotridine (I), a-epoxyhelio-
tridine (II) and a-epoxyretronecine (III). 
Experimental. fi-Epoxyheliotridine (I) and a-epoxy-
heliotridine (II) were prepared by the reaction of 
heliotridine (V) with N-bromoacetamide followed, in 
situ, by treatment with base, and these products were 
isolated after chromatography on alumina. Similar 
treatment of retronecine (IV) gave a-epoxyretronecine 
(III) and several other products. None of the isomeric 
/7-epoxyretronecine was detected in the reaction 
product. 
Crystals of (I), (II) and (III) were obtained from 
methanol. Specific rotations ralL' [ethanol, 
1.0 g dm -3 1 and melting points (uncorrected) for (I), 
(II) and (III) were +2.5°, 424-425.5 K; -17.3°, 
426.5-428 K; and -24.0°, 447-449 K, respectively. 
Experimental details for the X-ray determinations are 
in Table 1. All densities determined by flotation in 
hexane-carbon tetrachloride. Lp corrections but no 
extinction or absorption corrections. Structures all 
solved in same manner. MULTAN78 (Main, Hull, 
Lessinger, Germain, Declercq & Woolfson, 1978) used 
Table 1. X-ray data collection and solution 
(1) 4-Epoxy- 
	




Crystal .vine (Mal ) 
	
0.35 s 0-28 
	
0-36 x 0-25 0-43 x 0.34 
0.20 x 0-10 
	
x 0-17 











1\10 Kit. A 	0-71069 A: graphite roonochrernator 
26 range 20,35-3901 	7-15-24-55 	9.76-2546 
Max. 20 for data collection I ° 
	









k.- 1 	 +h.sk,+( 
No. of reflections measured 
	
1710 1540 	 1571 
No, of reflections with F r 301F) 
	
1389 	 1299 1395 
0.037 0-038 	 0-032 
w/2 
	
0-045 	 0047 0.037 
,e tr 	1.0d (an' + 0'1 
	
0.005 0008 	 0.002 
Max. :lin 
	
0-016 	 0-007 0.075 
Max.. min. in ,lp(e A ') 
	
0 29. -0.27 0-38.-0.33 	0.30.-0.32 
to generate a series of E maps, one of which correctly 
located most non-H atoms; after three cycles of 
full-matrix least-squares refinement (on F), remaining 
non-H atoms located from difference Fourier map; 
non-H atoms refined anisotropically and H atoms 
located from subsequent difference Fourier map. 
Parameters varied: overall scale factor, coordinates of 
non-H atoms, anisotropic temperature factors of non-H 
atoms, isotropic temperature factors for H atoms. 
Scattering factors as in SHELX76 (Sheldrick, 1976). 
Discussion. The ORTEPII (Johnson, 1976) views of 
fl-epoxyheliotridine (I), a-epoxyheliotrodine (II) and 
a-epoxyretronecine (III) are shown in Figs. 1, 2 and 3, 
respectively, using 50% probability elipsoids. The 
thermal parameters of the H atoms have been 
artificially reduced to clarify the pictures. 
Final atom coordinates, angles and selected torsional 
angles are given in Tables 2-6.* The dihedral angle 
between the planes of N(4), C(8), C(7) and N(4), C(8), 
C(1) is 124.5 (I), 122.2 (II) and 124.9° (III). The 
conformational features of the ring A, consisting of 
N(4), C(8), C(1), C(2) and C(3), exhibit very close 
similarities in all three molecules, mainly because of its 
fusion with a 1,2-oxirane ring, making the plane of 
C(8), C(1), C(2), C(3) coplanar within 0.012 (I), 
0.003 (II), and 0.016 A (III). The N forms the top of 
an envelope which is 0.231 (I), 0.373 (II) and 
0.0320 A (III) from the plane of C(8), C(1), C(2) and 
C(3). The atoms C(9) and 0(3) are 0.595 and 
1.211 (I), 0.569 and 1.204 (II) and 0.588 and 
1.213 A (III) from the same plane. The dihedral angle 
between the plane of C(8), C(1), C(2), C(3) and the 
oxirane ring is 105.2 (I), 106.1 (II) and 105.0° (III). 
* Lists of structure factors, anisotropic thermal parameters and 
H-atom coordinates have been deposited with the British Library 
Lending Division as Supplementary Publication No. SUP 42147 
(28 pp.). Copies may be obtained through The Executive Secretary, 
International Union of Crystallography. 5 Abbey Square, Chester 
CH 1 2HU, England. 
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Intermolecular contacts between N(4) and 0(2) 
indicate hydrogen bonding in both structures (Hamilton 
& Ibers, 1968). For (I) N(4). • .0(2) is 2.69 and 
N(4)-•-14(02) is 1-79 A. For (II) N(4)...0(2) is 2.72 
and N(4)• • •H(02) is 1.74 A. The combined van der 
Waals radii are N•..0 2.9 and N...H(0) 2.7 A. 
We gratefully acknowledge financial support of this 
work by the National Cancer Institute of NIH 
(CA31490) and we thank Professor J. Aaron Bertrand 
for his assistance in various calculations. 
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Diastereoisomeric Epoxides of Heliotridine and Retronecine, C 8 H13 NO3 
BY JAN A. GLINSKI, DONALD VANDERVEER AND LEON H. ZALKOW* 
School of Chemistry, Georgia Institute of Technology, Atlanta, Georgia 30332, USA 
(Received 22 August 1984; accepted 26 March 1985) 
Abstract. M r = 171.1, A.(mo Ka) = 0.71069 A, T = 
298 K. fi-Epoxyheliotridine (I): orthorhombic, P2 2 1 2 1 , 
a = 6.2951 (3), b = 7.7019 (5), c = 17.722 (1) A, U 
=859.25 (9)A 3, Z = 4, D m = 1.321, D.,= 
1.322 g cm-3, p(Mo Ka) = 0.63 cm- I, F(000) = 368. 
a-Epoxyheliotridine (II): monoclinic, P2 1 , a = 
6.251 (2), b 8-578 (1), c = 8.069 (2) A, Q= 
110.68 (2)°, U = 404.8 (2) A 3 , Z = 2, Dm = 1.403, 
DX = 1.405 g cm -3, *MO Ka) = 0.66 cm - '9 F(000) 
= 184. a-Epoxyretronecine (III): monoclinic, P2 1 , 
a = 6.509 (1), b = 8.340 (1), c= 7.799 (1)A, # = 
105.85 (1)°, U = 407-29 (1) A 3 , Z = 2, Dm = 1.395, 
• To whom correspondence should be addressed. 
0108-2701/85/091345-04801.50 
D, = 1.396 g cm -3, p(Mo l‘d)= 0.66 cm- ', F(000) = 
184. Full-matrix least-squares refinement converged at 
R values of 0.037, 0.038 and 0.032 for 1389, 1299 and 
1395 reflections for (I), (II) and (III), respectively. 
There are no unusual bond distances or angles. There is 
intermolecular H bonding between N and the 0 atom of 
the CH 2OH group (N...0 2.70, 2.73 and 2.77 A, 
respectively). The absolute configurations of the three 
diastereomers are defined by reference to the absolute 
configurations of the parent alkaloids heliotridine and 
retronecine [Warren & Von Klemperer (1958). J. 
Chem. Soc. pp. 4574-4575; Warren (1970). The 
Alkaloids, Vol. XII, edited by Manske, ch. 4, pp. 
246-262. London, New York: Academic Press; and 
references therein]. 
© 1985 International Union of Crystallography 
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Introduction. It has been estimated that 3% of the 
world's flowering plants contain pyrrolizidine alkaloids 
and such plants can be expected to be present in most 
environments (Smith & Culvenor, 1981). Approxi-
mately 300 pyrrolizidine alkaloids have been charac-
terized and many have been shown to be responsible for 
the long-known hepatotoxicity in humans and animals 
(Roitman, 1983; McLean, 1970). We have been 
interested, for several years, in the antitumor activity of 
certain of these alkaloids (Zalkow et al., 1979; Zalkow, 
Glinski, Gelbaum, Fleischmann, McGowan & Gordon, 
1985) and semisynthetic analogs (Gelbaum, Gordon, 
Miles & Zalkow, 1982). Almost all of the biologically 
active (toxic and antitumor) pyrrolizidine alkaloids and 
N-oxides contain, as their necine bases, either retro-
necine (IV) or heliotridine (V) and the biological activity 
is reportedly dependent upon the allylic oxygen function 
in ring A (Culvenor, 1968). In a previous communi-
cation, we reported the X-ray structures of retronecine 
(IV) and heliotridine (V) (Gelbaum, Glinski, Van 
Derveer & Zalkow, 1985). 
We felt it was essential to prepare epoxides of 
retronecine and heliotridine in order to gain insight into 
the role of the double bond and the oxirane ring in these 
biologically important molecules. We report here, for 
the first time, the preparation and X-ray structural 
information of /3-epoxyheliotridine (I), a-epoxyhelio-
tridine (II) and a-epoxyretronecine (III). 
Experimental. /3-Epoxyheliotridine (I) and a-epoxy-
heliotridine (II) were prepared by the reaction of 
heliotridine (V) with N-bromoacetamide followed, in 
situ, by treatment with base, and these products were 
isolated after chromatography on alumina. Similar 
treatment of retronecine (IV) gave a-epoxyretronecine 
(III) and several other products. None of the isomeric 
/3-epoxyretronecine was detected in the reaction 
product. 
Crystals of (I), (II) and (III) were obtained from 
methanol. Specific rotations f a l;, 5 `c [ethanol, 
1.0 g dm-3 I and melting points (uncorrected) for (I), 
(II) and (III) were +2.5°, 424-425.5 K; -17.3°, 
426.5-428 K; and -24.0°, 447-449 K, respectively. 
Experimental details for the X-ray determinations are 
in Table 1. All densities determined by flotation in 
hexane-carbon tetrachloride. Lp corrections but no 
extinction or absorption corrections. Structures all 
solved in same manner. MULTAN78 (Main, Hull, 
Lessinger, Germain, Declercq & Woolfson, 1978) used 
Table 1. X-ray data collection and solution 
Crystal site (mm) 


















Radiation Mo kr, A 
Syntex 02, 
0 , 71069 A; graphite enonoehrornator 
20 range 2035-39-01 7.15-2455 9.76- 2546 
Max. 20 For data collection (°) 50 50 50 
Scan type 0-24) 
Scan speed 	min 	'1 2.02-29.30 
//Ai range t A., / I - h.f 	A. 	n.l I h, i4,0l 
No. of reflections measured 1710 1540 1571 
No. of reflections with P > 3a(k) 1389 1299 1395 
0037 0.038 0-032 
hf? 0 045 0-047 0-037 
.t1 	tt• 	-0/1 ton' 0 005 0-008 0002 
Max. dla 0016 0007 0075 
Max. 	min. in dp(e 0.29. 	0-27 0.38, -0.33 0.30.--0.32 
to generate a series of E maps, one of which correctly 
located most non-H atoms; after three cycles of 
full-matrix least-squares refinement (on F), remaining 
non-H atoms located from difference Fourier map; 
non-H atoms refined anisotropically and H atoms 
located from subsequent difference Fourier map. 
Parameters varied: overall scale factor, coordinates of 
non-H atoms, anisotropic temperature factors of non-H 
atoms, isotropic temperature factors for H atoms. 
Scattering factors as in SHELX76 (Sheldrick, 1976). 
Discussion. The ORTEPII (Johnson, 1976) views of 
/3-epoxyheliotridine (I), a-epoxyheliotrodine (II) and 
a-epoxyretronecine (III) are shown in Figs. 1, 2 and 3, 
respectively, using 50% probability elipsoids. The 
thermal parameters of the H atoms have been 
artificially reduced to clarify the pictures. 
Final atom coordinates, angles and selected torsional 
angles are given in Tables 2-6.* The dihedral angle 
between the planes of N(4), C(8), C(7) and N(4), C(8), 
C(1) is 124.5 (I), 122.2 (II) and 124.9° (III). The 
conformational features of the ring A, consisting of 
N(4), C(8), C(1), C(2) and C(3), exhibit very close 
similarities in all three molecules, mainly because of its 
fusion with a 1,2-oxirane ring, making the plane of 
C(8), C(1), C(2), C(3) coplanar within 0.012 (I), 
0.003 (II), and 0.016 A The N forms the top of 
an envelope which is 0.231 (I), 0.373 (II) and 
0.0320 A (III) from the plane of C(8), C(1), C(2) and 
C(3). The atoms C(9) and 0(3) are 0.595 and 
1.211 (I), 0.569 and 1.204 (II) and 0.588 and 
1.213 A (III) from the same plane. The dihedral angle 
between the plane of C(8), C(1), C(2), C(3) and the 
oxirane ring is 105.2 (I), 106.1 (II) and 105.0° (III). 
* Lists of structure factors, anisotropic thermal parameters and 
H-atom coordinates have been deposited with the British Library 
Lending Division as Supplementary Publication No. SUP 42147 
(28 pp.). Copies may be obtained through The Executive Secretary, 
International Union of Crystallography, 5 Abbey Square, Chester 
CHI 2HU, England. 
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The less rigid ring B, consisting of N(4), C(8), C(7), Table 2. Final atomic coordinates and Lle, values (A 2) 
C(6) and C(5), is coplanar within 0.241 (I), 0.252 (II) 	 for f3-epoxyheliotridine (I) 
and 0.235 A (III). Its conformation depends mainly on 
the configuration of the oxirane ring and of the C(7) 
hydroxyl. Thus, in (I), N(4), C(8), C(7) and C(6) form 
a plane which is coplanar within 0.073 A. For (II), 
similarly, the most coplanar atoms are C(8), N(4), C(5) 
and C(6) with a greatest deviation from the plane of 
0.004 A. In (III) the plane of C(8), N(4), C(5) and C(6) 
is coplanar within 0.027 A. 
l'?• 	 1'D 
oill .. 




Fig. 1. fi-Epoxyheliotridine (the bond-length errors are within 
0-003 A). 
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Fig. 2. a-Epoxyheliotridine (the bond-length errors are within 0.004 
A). 
Fig. 3. a-Epoxyretronecine (the bond-length errors are within 0.004 
A). 
Here and in Tables 3 and 4 (I 
x 3' z U,,, 
-2037 (3) 0-0558 (3) -0.03448 (1) 0.032 CO 
C(2) - 02375 (3) 0.2205 (3) -0.3831 (I) 0.041 
C(3) -046118 (4) 0.2345 (3) -0.4047 (I) 0.044 
N(4) -0.5596 (3) 00603 (2) -0.3919 (I) 0.034 
C(5)  -0-6008 (4) -0.0427 (3) -0.4608 (I) 0-043 
C(6)  -0-5950(4) -0.2282 (3) -0.4318 (I) 0.043 
C(7)  --0-4077 (3) -0.2279 (3) -0.3768 (I) 0.033 
C(8) 0-4105 (3) -0.0426 (3) -0.3436 (I) 0-029 
C(9)  -0.0362 (3) 0-0212 (3) -0.2860 (I) 0-040 
0(I) -0-4365 (3) -0-3599(2) -0.3224 (I) 0.051 
0(2) 0.1350 (2) 01373 (2) -0.29050 (9) 0.043 
0(3) -0-1285 (2) 0-0801 (2) -0.42154 (9) 0•044 
Table 3. Final atomic coordinates and 
for a-epoxyheliotridine (II) 
x 	 1' 	 z 
C(I) 	0-7680 (4) 	1-08176 -0-6899 (3) 
C(2) 0.5617 (4) 1.0671 (4) 	-0-6433 (4) 
C(3) 0-5116 (4) 	0-8985 (4) -0.6305 (4) 
C(5) 0-6854 (5) 0-6625 (4) 	0.7172 (4) 
C(6) 0-7885 (5) 	0-6807 (4) 0.8622 (4) 
C(7) 0-7879 (4) 0-8561 (4) 	-0.8931(3) 
C(81 	0-8505 (4) 	0-9186 (4) -0-7047 (3) 
C(91 0-8175 (4) 1-2170 (4) 	-0.7877 (3) 
N(4) 	0-7254 (3) 	0-8 I f. I (4) -0.6200 (3) 
0(I) 09463 (4) 09101 (4) 	-0-9687 (3) 
0(2) 	1.0551 (3) 	1-2515(4) -0.7311 (2) 
0(3) 0-7754 (3) 1-1164 (3) 	-0-5110 (2) 














Table 4. Final atomic coordinates and U0, values (A 2 ) 
for a-epoxyretronecine (III) 
X ) Z 14,, 
C(I) 0.1926 (2) 0.56820 -0-3065 (2) 0028 
C(2)  0.4067 (3) 0-5618 (3) -0.3327 (2) 0.040 
C(3)  0.4716 (3) 0-3900 (3) -0.3384 (3) 0.044 
N(4) 0.2738 (2) 0.2968 (3) - 0.3655 (2) 0.032 
C(5)  0.2980(4) 0.1435 (3) -0.2623(3) 0.051 
C(6)  0-1385 (3) 0.1494 (3) -0.1530 (2) 0043 
C(7) 0-1074 (3) 03283 (3) -0.1256 (2) 0.032 
C(8)  0-1155 (2) 03968 (2) -03048 (2) 0.026 
C(9)  0-1095 (3) 0-7013 (3) -0.2167(2) 0.035 
0(1) 0.2782 (2) 0.3921 (2) 0.0125 (2) 0.041 
0(2) --0-1144(2) 0-7212 (2) -0.2769 (2) 0.039 
0(3) 0-2271 (2) 0.6059 (2) -0.4797 (2) 0.040 
Table 5. Angles (°) with e.s.d.'s in parentheses for (I), 
(II) and (III) 
(I) (H) (III) 
C(8)-C(11- C(2) 108.6 (2) 107-2 (2) 107-3 (I) 
C(9)-C(1)- C(8) 120.5 (2) 122.5 (2) 122.3 (I) 
0(3)-CI I)--C(8) 111.0(21 112.0(2) 110.2(1) 
C(3)--C(2)- C(I) 108.8(2) 109.0(2) 109.0(1) 
0(3)-02)-C(3) 113-0 (2) 1132 (2) 113.2 (2) 
C(5)- N(4)-C(3) 115.4 (2) 1139 (2) 114.5 (1) 
C(81-N(4)-C(5) 107.3 (2) 107• I (2) 106.6 (I) 
C(7)-C(6)-C(5) 103.5 (2) 104.4 (2) 104.3 (I) 
0( I)-C(7)-C(6) 109-6 (2) 115-6(2) 111.4(1) 
N(4)-C(8)--C(1) 105.5 (2) 105.1 (2) 105.3 (I) 
C(7)-C(8)-N(4) 106.2(1) 104.9(2) 106.3(1) 
C(2)-0(3)--C(1) 60.1 	(I) 60.8 (I) 60.5 (I) 
C(9)-C(1)-- C(2) 125.4 (2) 124.4 (2) 125.0 (1) 
0(3)-C(1)--C(2) 59.9 (1) 59.2 (2) 59.2 (I) 
0(3)-C(I)--C(9) 116.2(2) 115-1 	(2) 116-1 (I) 
0(3)-C(2)--C(1) 60.0 (1) 60.0(2) 60.4 (I) 
N(4)-C(3)-C(2) 105.6 (2) 105.0 (2) 105.5 (1) 
C)8)-N(4)-C(3) 109.0 (2) 107.4 (2) 108.1 (1) 
061-C(5)--N(4) 102.8 (2) 105.7 (2) 106.7 (1) 
C)8)-C(7)--C(6) 103-6 (2) 101.5 (2) 101.4 (1) 
0( 1 )-C(7)--C(8) 113.9 (2) 110.1 	(2) 109.8 (1) 
C(7)-C(8)-C(1) 116.8 (2) 115.4 (2) 117.1 	(I) 
0(2)-C(9)-C(I) 112.7 (2) 112.3 (2) 113.9 (I) 
,.. 
C(7) 	 .- 
, 	(7) 
ca l 	C( 11 
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Table 6. Selected torsional angles (°)for (I), (II) and (III) 
E.s.d.'s are -0-3°. 
(I) (II) (III) (1) (II) (III) 
N(4) 	C(8)-C(1)-C(9) 1625 1684 1658 C(2)-0(3)-C(1)-C(2) 99.9 975 98.6 
C(8)-C(1)-C(9)-0(2) 1733 115.2 122.6 N(4)-C(8)- CM-C(2) 7.5 145 10.6 
C( I)-C(2)-C(3)-N(4) 1 	I-1 15.5 154 N(4)-C(8)-C(7)-C(6) 2 2 390 34-9 
C(8)-C(1)-C(2)-C(3) 2.2 0 6 2.8 N(4)-C(8)-C(7)-0(1) 1616 5-8 83-0 
N(4)-C(8)- C(1) 	0(3) 56-6 8-6 52.2 C(8)-C(7)-C(6)-C(5) 32-7 38-2 374 
N(4)- C(3)-C(2)-0(3) 53.5 49.1 49.7 C(7)-C(6)-C(5)-N(4) 41.2 23-7 26.7 
C(1)-0(3)-C(2)-C(3) 99.1 99.3 99.5 C(7)-C(8)-N(4)-C(5) 13.5 25-0 192 
Table 7. Intermolecular distances (A) 
E.s.d.'s for N-0 distances are -0.004 A. 
(III) 	van der Waals distance 
N(4) 	-0(2) 2.70 2-73 2.77 2.90 
N(4)...0(02) 1.76 1.84 186 270 
All three structures show intermolecular contacts 
between N(4) and 0(2) (Table 7) which are somewhat 
shorter than the combined van der Waals radii. The 
N(4). • • H(02) distances confirm hydrogen bonding 
(Hamilton & Ibers, 1968). The orientation of the C(9) 
hydroxyl [0(2)] seems to be influenced by the position 
of the epoxide oxygen 10(3)1, although the real distance 
0(2)•0(3) 2.887 (I), 2.802 (II) and 3.699 A (III) is 
greater than the 0-0 van der Waals distance. Finally, 
the ORTEP views of (I), (II) and (III) (Figs. 1, 2 and 3) 
indicate that the C(9)-OH and C(7)-OH bonds are 
anti to each other in each case. 
We gratefully acknowledge financial support of this 
work by the National Cancer Institute of NIH 
(CA31490) and we thank Professor J. Aaron Bertrand 
for his assistance in various calculations. 
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Abstract. Mr = 
30.849 (1), b 
1623.4 A 3 , Z = 
0.71073 A, ,u 
272.5, orthorhombic, Pna21 , a = 
=8.248 (2), c = 6.381 (2) A, V = 
4, Dx = 1.332 g cm-3, /1.(Mo Ka) = 
= 2.689 cm- ', F(000) = 592, T = 
0108-2701/85/091348-03$01.50 
183 (1) K, R = 0.0499 for 810 observed reflections. 
Exhibiting non-crystallographic twofold rotation sym-
metry, the molecular structure displays effects of 
intramolecular strain associated with bulky substituent 
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Synthesis of Pyrrolizidine Alkaloids Indicine, Intermedine, Lycopsamine, and 
Analogues and Their N-Oxides. Potential Antitumor Agents 
Leon H Zalkow,* Jan A. Glinski,/ Leslie T. Gelbaum, Thomas J. Fleischmann, Laureen S. McGowan, 
and Maureen M. Gordon 
School of Chemistry, Georgia Institute of Technology, Atlanta, Georgia 30332. Received June 29, 1984 
(-)- and (+)-trachelanthic and (-)- and (+)-viridifloric acids were synthesized and their isopropylidene derivatives 
were regiospecifically coupled, at C-9, with (-)-retronecine (2) obtained by hydrolysis of monocrotaline (1), isolated 
from Crotalaria spectabilis. Hydrolysis, followed by oxidation, led to the N-oxides of indicine (7), intermedine (13), 
lycopsamine (15), and the new nonnatural product 16, respectively. Each of these analogues was screened in the 
P388 lymphocytic leukemia system at the same time as indicine N-oxide, and the results were compared. Other 
related analogues were prepared and similarly screened and the results compared with those from indicine N-oxide. 
The antitumor activity of the pyrrolizidine alkaloids has 
been recognized for about 20 years. 1,2 Culvenor3 first 
observed that the active compounds were not significantly 
cytotoxic in cell culture and the in vivo activity was par-
ticularly noteworthy in the Walker 256 system, which is 
known to be sensitive to alkylating agents. These workers 
concluded that the same functionalities, in particular, an 
allylic oxygen function, were responsible for both hepa-
totoxicity and antitumor activity. Schoental 4 first reported 
that hepatotoxicity was related to unsaturation (see 1, 
monocrotaline) and soon thereafter, Culvenor et al. 6 pro- 
Cr3 ?H 
H3C-CH-C- C -CH3 
I 	I 
OC OH co 
2 C - 7 13 - 0H 3, C - 7 • - OH 
4, C-7 a -OH 9, C -7 P -OH 
posed that alkylation of biological nucleophiles in the liver 
was responsible for the toxicity, after showing that C-1 
allylic esters could be displaced by nucleophiles. In 1968, 
Mattocks 6 demonstrated that "metabolic pyrroles" pro-
duced in the liver were more reactive than the parent 
alkaloids to alkylation and there was a good correlation 
between hepatotoxicity and the amount of "metabolic 
pyrrole" produced.? Dehydroretronecine (9) has been 
shown to produce the same pattern of lesions in vivo as 
its macrocyclic diester parent, monocrotaline (1), 8 and 
esters of heliotridine (4) are metabolically converted into 
dehydroheliotridine (3) in vivo.' The "metabolic pyrroles" 
have been postulated as arising by C-hydroxylation at the 
C-3 allylic position in the pyrrolizidine nucleus, followed 
by elimination of water to give! the dehydroalkaloid. 7 This 
metabolic system, however, is known not to be the same 
as the one that oxidizes the free bases to N-oxides.'° 
Dehydroretronecine (9) has been shown to produce cova-
lent adducts at C-7 with the thiol groups of cysteine and 
t On leave from the University of Warsaw, Warsaw, Poland. 
0022-2623/85/1828-0687$01.50/0 
glutathione.n [ 3H]Dehydroretronecine shows significant 
binding to bovine serum albumin and to calf thymus DNA 
in vitro with greatly increased binding at lower pH.' In 
vivo experiments have shown that binding to protein is 
much greater than to nucleic acids. 12,13 
It has been suggested that pyrrolizidine N-oxides per 
se are not hepatotoxicm and their toxicity might arise only 
to the extent that they are converted to their corresponding 
bases. The route of drug administration would then be 
crucial, since reduction of N-oxides to free bases takes 
place in the gastrointestinal tract after oral administra-
tion.'6 A comparison of the toxicity of heliotrine (5), with 
its N-oxide (6), by intraperitoneal (ip) administration to 
the rat, showed acute LD 50 of 300 mg/kg for the former 
and 5000 mg/kg for the latter, indicating that this N-oxide 
was only minimally converted to its free base.' 6  
Indicine (7) and its N-oxide (8) were first isolated from 
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1962, 195, 570. 
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(15) We thank Dr. Matthew Suffness, Head, Plant and Animal 
Products Section, Natural Products Branch, Developmental 
Therapeutics Program, National Cancer Institute, for making 
available to use his review on the biological activity of pyr-
rolizidine alkaloids to appear as part of a section on pyrroliz-
idine alkaloids in a forthcoming volume in "The Alkaloids". 
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Heliotropium indicum in 1961 as part of an investigation 
of potentially hepatotoxic planth. 17 In 1976, the antitumor 
activity of indicine N-oxide (8) was discovered by a 
bioassay-directed fractionation of H. indicum. 18 Indicine 
N-oxide (8), given ip is a more active antitumor agent than 
indicine (7) or heliotrine N-oxide (6) and indicine N-oxide 
administered orally is inactive. 19 Thus, indicine is not 
responsible for the antitumor activity of indicine N-oxide. 
A comparison of the extent of metabolism and urinary 
excretion of indicine N-oxide (8) and heliotrine N-oxide 
(6) reveals the importance of subtle structural changes. 
Thus, 24 h after ip administration of indicine N-oxide, 
100% could be accounted for in the urine as unchanged 
N-oxide (97%), indicine (2%), and indicine conjugates 
(1%). Under identical conditions, only 45% of heliotrine 
N-oxide could be accounted for, with 9.7% of this as he-
liotrine N-oxide conjugates. After oral administration, 
recovery of indicine N-oxide and metabolites was only 
77.1% of which 26.9% was unchanged N-oxide, 0.6% was 
N-oxide conjugates, 37.4% was free indicine, and 12.2% 
was conjugated indicine. 19 
Indicine N-oxide has progressed to clinical studies at the 
National Cancer Institute, and these studies are continu-
ing. The activity of indicine N-oxide in leukemia is sig-
nificant, and the responses seen have been in patients who 
have failed induction of remission with the best standard 
agents, generally in combination. The two major toxicities 
seen to date were severe unpredictable myelosuppression 
and hepatotoxicity. Indicine N-oxide is a drug with good 
patient acceptance, since it does not cause nausea, vom-
iting, fever, rashes, or other discomforts seen with many 
anticancer agents. 15 The mechanism of the antitumor 
activity of indicine N-oxide is unclear at this time. It has 
been suggested that while the reduction of indicine N-oxide 
occurs only to a small extent after ip administration to 
mice 19 or rabbits2° or intravenous (iv) administration in 
monkeys21 or the human,2° there could be increased re-
duction of indicine N-oxide in hypoxic tumor cells which 
would also be more acidic, leading to site specificity of 
production of metabolic pyrroles and selectivity to tumor 
cells over normal cells. 15 
In view of the antitumor activity of indicine N-oxide, 
its toxicities as observed in the clinic, and the differences 
in the metabolism and urinary excretion between the re-
lated N-oxides of indicine and heliotrine, we undertook 
this investigation to prepare all of the necic acid isomers 
of indicine N-oxide and some related analogues in suffi-
cient quantities for in vivo screening in the P388 lym-
phocytic leukemia system in direct side by side comparison 
with indicine N-oxide. 
(17) Mattocks, A. R.; Schoental, R.; Crowley, H. C.; Culvenor, C. C. 
J. J. Chem. Soc. 1961, 5400. 
(18) Kugelman, M.; Liu, W.-C.; Axelrod, M.; McBride, T. J.; Rao, 
K. V. Lloydia 1976, 39, 125. 
(19) Powis, G.; Ames, M. M.; Kovach, J. S. Res. Commun. Chem. 
Path. Pharmacol. 1979, 24, 559. 
(20) Powis, G.; Ames, M. M.; Kovach, J. S. Cancer Res. 1979, 39, 
3564. 
(21) El Dureer, S. M.; Tilley, K. F.; Lloyd, H. H.; Hitt, D. L. Cancer 
Tret. Rep. 1982, 66, 183. 
Chemistry. Our synthetic procedure evolved around 
the coupling of optically pure synthetic necic acids with 
the optically pure necine retronecine (2). Because of the 
quantity needed, we felt that none of the elegant total 
syntheses of retronecine in the literature were suitable for 
our needs. 22-27 With some modification of the procedure 
previously described, 28 we are now able to obtain relatively 
large amounts of retronecine (2) from readily available 
natural monocrotaline (1) very quickly. Next, we turned 
our attention to the preparation of the optically pure necic 
acids. (±)-Trachelanthic acid was prepared by hydroxy-
lation of trans-a-isopropylcrotonic acid 29,3° with osmium 
tetraoxide in the presence of chloric acid according to the 
procedure of Kochetkov et a1. 31 (±) -Viridifloric acid was 
prepared as previously described31,32 by the hydroxylation 
of trans-a-isopropylcrotonic acid with tungsten trioxide 
and 30% hydrogen peroxide. Previous workers have re-
ported the resolution of (±)-trachelanthic and (f)-viridi-
floric acid with use of brucine 3°,32 and a-phenylethyl-
amine. 31 In our hands the use of (+)-a-phenylethylamine 
and (-)-a-phenylethylamine gave better results. Thus, the 
recrystallized salt from (+)-a-phenylethylamine and 
(f)-viridifloric acid gave, on acid hydrolysis, (+)- 
(2R,3R)-viridifloric acid (10), while the salt from (-) -a-
phenylethylamine gave (-)-(2S,3S)-viridifloric acid (11). 
Kochetkov et al. 31 mistakenly report the reverse of these 
results in their paper. In a similar manner, (+)-a-
phenylethylamine with (±)-trachelanthic acid deposited 
a salt which, after recrystallization and hydrolysis, yielded 
(-)-(2R,3S)-trachelanthic acid (12), while the use of (-)- 
a-phenylethylamine provided (+)-(2S,3R)-trachelanthic 
acid (13). After completion of this phase of our work, new 
stereoselective syntheses of viridifloric and trachelanthic 
acids were reported, 38 '34 but these do not appear to offer 
any immediate practical advantages over the procedures 
utilized. 
Having in hand the requisite necine, retronecine (2), and 
necic acids 10-13, our next goal was the regiospecific 
coupling of the two components at C-9 of retronecine. In 
addition to indicine (7), two of the three remaining isomers 
are known natural products. Intermedine (14) is the C-9 
0 0 0 0 
HO—C' HO 
HO OH OH < > HO . 	
OH H OH HO H HO 	H H 
CH3 	 CH3 
12 	 13 
14, C-9 ester of 13 with 2 
15, C-9 ester of 11 with 2 
16, C-9 ester of 10 with 2 
ester of retronecine and (+)-trachelanthic acid (13), while 
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(23) Ohsawa, T.; Ihara, M.; Fukumato, K. J. Org. Chem. 1983, 48, 
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(25) Tufariello, J. J.; Lee, G. E. J. Am. Chem. Soc. 1980, 102, 373. 
(26) Vedejs, E.; Martinez, G. R. J. Am. Chem. Soc. 1980, 102, 7993. 
(27) Geissman, T. A.; Waiss, A. J., Jr. J. Org. Chem. 1961, 27, 139. 
(28) Gelbaum, L. T.; Gordon, M. M.; Miles, M.; Zalkow, L. H. J. 
Org. Chem. 1982, 47, 2501. 
(29) Adams, R.; Herz, W. J. Am. Chem. Soc. 1950, 72, 155. 
(30) Dry, L. J.; Warren, R. L. J. Chem. Soc. 1952, 3445. 
(31) Kochetkov, N. K.; Likhosherstov, A. M., Kulakov, V. N. Tet-
rahedron 1969, 25, 2313. 
(32) Adams, R.; Van Duuren, B. L. J. Am. Chem. Soc. 1952, 74, 
5349. 
(33) Ladner, W. Chem. Ber. 1983, 116, 3413. 
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lycopsamine (15) is the C-9 ester of retronecine and (-)-
viridifloric acid (11). The C-9 ester of retronecine and 
(+)-viridifloric acid (16) has never been reported either as 
a natural product or synthetically. Culvenor and Smith 
reconstituted intermedine (14) and lycopsamine (15) by 
treating 1-(chloromethyl)-1,2-dehydro-7/3-hydroxy-8a-
pyrrolizidine, prepared by treating retronecine (2) with 
thionyl chloride,36 with the :sodium salts of trachelanthic 
and viridifloric acids recovered from hydrolysis of the 
alkaloids intermedine and lycopsamine, respectively. This 
work is of historical significance since it was the first re-
ported synthesis of hepatmocic pyrrolizidine alkaloids. 
However, no yields were given and a recent attempt to 
utilize this procedure gave unsatisfactory results. 37 Re-
cently, Piper et a1. 37 reported the synthesis of 3H-labeled 
indicine N-oxide by the coupling of the isopropylidene 
derivative of (-)-trachelanthic acid, obtained by hydrolysis 
of indicine, with retronecine, labeled in the hydroxymethyl 
group, and also derived from indicine, using N,N'-di-
cyclohexylcarbodiimide (DCC) in the presence of 4-(di-
methylamino)pyridine (DMAP) in toluene, followed by 
hydrolysis of the acetonide. A 50% yield of indicine, as 
a viscous colorless oil, was reported after TLC purification. 
Indicine, intermediate, and lycopsamine, as true for many 
pyrrolizidine alkaloids, are notorious for their propensity 
not to crystallize. Thus, intermedine was first reported 
almost 20 years ago and has been isolated from a number 
of sources but only recently was it reported crystalline.' 
In 1983, X-ray crystal structure determinations were finally 
reported for intermedine and lycopsamine. 4' 
Recently, there has been intensified interest in inter-
medine and lycopsamine as human health hazards in 
herbal teas 42 and in honey." Since intermedine and ly-
copsamine commonly cooccur in plants, interest in their 
separations has recently taken advantage of high-per-
formance liquid chromatography,"" ion-pair absorption 
chromatography," and chromatography of their borate 
complexes." Recent advances in mass spectrometry" and 
13C NMR46," have been used in their analyses, and as 
discussed below, the use of 300-MHz 1H NMR spectros-
copy permits one to distinguish between indicine (7) and 
all of its isomers (14-16). 
(35) Culvenor, C. C. J.; Smith, L. W. Aust. J. Chem. 1966, 19, 1955. 
(36) Culvenor, C. C. J.; Dann, A. T.; Smith, L. W. Chem. Ind. 1959, 
20. 
(37) Piper, J. R.; Kari, P.; Shealy, Y. F. J. Labeled Compd. Ra-
diopharm. 1981, 18, 1579. 
(38) Warren, F. L. Alkaloids (N Y.) 1970, 12, 245 and references 
therein. 
(39) Zalkow, L. H.; Bonetti, S.; Gelbaum, L.; Gordon, M. M.; Patil, 
B. B.; Shani, A.; VanDerveer, D. J. Nat. Prod. 1979, 42, 603. 
(40) Herz, W.; Kulanthaivel, P.; Subramanian, P. S.; Culvenor, C. 
C. J.; Edgar, J. A. Experientia 1981, 37, 683. 
(41) Mackay, M. F.; Sadek, M.; Culvenor, C. C. J. Acta Crystallogr. 
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(43) Culvenor, C. C. J.; Edgar, J. A.; Smith, L. W. J. Agric. Food 
Chem. 1981, 29, 958. 
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192, 474. 
(46) Huizing, H. J.; Malingre, T. M. J. Chromatogr. 1981, 205, 218. 
(47) Frahn, J. L.; Culvenor, C. C. J.; Mills, J. A. J. Chromatogr. 
1980, 195, 379. 
(48) Dreifuss, P. A.; Brumley, W. C.; Siphon, J. A.; Caress, E. A. 
Anal. Chem. 1983, 55, 1036. 
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1982, 35, 1173. 
(50) Roedes, E.; Wiedenfeld, H.; Stenyl, P. Arch. Pharm. (Wein-
heirn, Ger.) 1982, 315, 87. 
Attempts to couple the isopropylidene derivatives of the 
necic acids 10-13 with retronecine according to the pro-
cedure of Piper et a1., 37 as previously mentioned, failed, 
in our hands, to give decent yields with use of toluene, 
chloroform, or ether as solvent integration in the absence 
or presence of DMAP. In the absence of DMAP, no cou-
pling at all was observed. Better results were obtained with 
N,N'-carbonyldiimidazole (CDI) as the coupling agent 
according to the procedure of Hoskins and Croutm but 
substituting DMF for THF as the solvent. We recently 
reported the use of CDI in the synthesis of the semisyn-
thetic analogues 9-0-[(S)-(+)-2-hydroxy-2-phenyl-
butyryfliretronecine (17) and 9-0- [ (R)-(-)-2-hydroxy-2- 
phenylbutyryl] retronecine (18).28  Thus, the iso- 
HO H CH2OR 
- 
17, R. HO -C --(0) 
El 	 
-c am  
18,R-(0)- -08 
El 
propylidene derivatives of (+)-(2S,3R)-viridifloric acid,63 
 (-)-(2S,3S)-viridifloric acid,62 (-)-(2R,3S)-trachelanthic 
acid, and (+)-(2S,3R)-trachelanthic acid, 66,66 respectively, 
were prepared as previously described by Piper et al. 37 for 
(-)-trachelanthic acid, and then they were coupled with 
retronecine with use of CDI and imidazoylsodium in a 
small volume of DMF. Interestingly, no coupling was 
observed in chloroform, THF, or ether and only a few 
percent reaction was observed in DMF, Me 2SO, or HMPA 
in the absence of imidazoylsodium. In the presence of the 
latter in DMF, yields of 50-70% were obtained, and the 
reaction was regiospecific, giving no detectable amounts 
of the C-7 esters or diesters. 
As might be expected, when the coupling reaction was 
carried out with retronecine (2) in the presence of 3 equiv 
of the isopropylidene derivative of racemic trachelanthic 
acid, unequal amounts of the two diastereomeric coupled 
products were obtained as determined by integration of 
the C-9 proton signals of the deprotected esters in the 
NMR (see below for discussion of NMR data). 
The unprotected esters indicine (7), intermedine (14), 
lycopsamine (15), and 16 were obtained by hydrolysis of 
the protected esters with 0.6 N HC1 followed by basifica-
tion and extraction with chloroform. A short chromatog-
raphy gave analytically pure material. The present 
syntheses of the four isomers indicine (7), intermedine (14), 
lycopsamine (15), and the new isomer 16 and their corre-
sponding isopropylidene derivatives by the procedure 
outlined permitted us to investigate the use of 300-MHz 
high-resolution 1 H NMR spectroscopy in CDC1 2 as a sol-
vent, as a tool to distinguish between these diastereomers. 
(51) Hoskins, W. M.; Crout, D. H. G. J. Chem. Soc., Perkin Trans 
1, 1977, 538. 
(52) Crowley, H. C.; Culvenor, C. C. Aust. J. Chem. 1959, 12, 694. 
(53) Mohanraj, S.; Subramanian, P. S. J. Chem. Soc., Chem. Com-
mun. 1978, 423. 
(54) Mohanraj, S.; Herz, W. J. Nat. Prod. 1982, 45, 328. 
(55) Locock, R. A.; Beal, J. L.; Doskotch, R. W. Lloydia 1966, 29, 
201. 
(56) Culvenor, C. C. J. Aust. J. Chem. 1954, 7, 287. 
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Culvenor and Smith35 first showed that lycopsamine and 
intermedine could be distinguished by their C-methyl 
signals in the 60-MHz NMR spectra of mixtures, and re-
cently Mohanraj and Herz54 showed that viridiflorates and 
trachelanthates of saturated necines could be differentiated 
by means of the magnetically nonequivalent isopropyl 
methyl groups in C6D6 and by chemical shifts and patterns 
of the H-4' and H-9 signals at 270 MHz. The iso-
propylidene derivatives, in fact, turn out to be very useful 
in distinguishing between these diastereomers when their 
NMR spectra are examined together with the parent 
compounds. Thus, the chemical shift position of the 
terminal methyl group of the acid side chain (C-4') allows 
one to determine which family, the trachelanthic acid 
family (indicine 7 or intermedine 14) or the viridifloric acid 
family (lycopsamine 15 5' or unknown 16), the alkaloid 
belongs to as follows: indicine (7), 1.15 d; intermedine (14), 
1.19 d; lycopsamine (15), 1.25 d; and 16, 1.25 d. For the 
corresponding isopropylidene derivatives the values are as 
follows: 1.43 d, 1.44 d, 1.29 d, and 1.25 d, respectively. 
Likewise, the chemical shift position of the C-3' proton of 
the acid side chain in the isopropylidene derivatives can 
be used to distinguish the trachelanthates (4.29 and 4.32) 
from the viridiflorates (4.22 and 4.22). Whereas the 
chemical shift positions of the C-3' protons in the parent 
alkaloids are similar for lycopsamine (15) (3.96 q), 16 (3.96 
q), and indicine (7) (4.00 q), that for intermedine (14) (4.09 
q) is clearly distinguishable. The same can be said for the 
isopropyl methine proton (C-5') of intermedine (14) (2.03 
hept), indicine (7) (2.13 hept), lycopsamine (15) (2.16 hept), 
and 16 (2.14 hept). Having decided which family the un-
known alkaloid belongs to, an examination of the C-9 
chemical shifts in the parent alkaloids and their iso-
propylidene derivatives permits an unequivocal structure 
assignment. Thus, for the parent alkaloids indicine (7) and 
intermedine (14) the C-9 shifts are very different: 7 (5.07 
d, 4.57 d) and 14 (4.84 d, 4.75 d), whereas those of ly-
copsamine (15) (4.84 d, 4.73 d) and 16 (4.86 d, 4.71 d) are 
not very useful. Even in this case, an examination of the 
3$ and 5a chemical shifts in 15 (3$, 3.38 dd; 5a, 3.24 dd) 
and 16 (3$, 3.50 dd; 5a, 3.42 dd) allows a distinction. 
However, of greater utility was an examination of the C-9 
chemical shifts in the protected esters of lycopsamine (4.74 
d, 4.67 d), 16 (4.91 d, 4.57 d), indicine (4.80 d, 4.61 d), and 
intermedine (4.77 d, 4.63 d) in which case lycopsamine and 
16 are readily distinguished. Thus, high-resolution NMR 
spectroscopy was used in this work to determine the optical 
purity of the coupled products. 
For comparison purposes, the related nonnatural prod-
ucts 19 and 20 were prepared by coupling the racemic 
threo-2,3-dihydroxy-2-methylbutyric acids, 55 as their iso-
propylidene derivatives, to give the protected mixture of 
esters. The free mixture of diasteriomeric esters 19 and 
20 were obtained, as previously described, by hydrolysis. 
In this case, the coupling of the racemic protected acid gave 
approximately a 1:1 mixture of diastereomeric protected 
esters. No attempt was made to resolve the acids prior to 
coupling, and the diastereomeric mixtures (esters and 
protected esters) were screened as their N-oxides, with 
interesting results, as described below. Finally the simple 
esters 21-23 were prepared for screening. While 21 has 
not previously been reported in the literature, the di-
benzoate 24 was first reported as a synthetic product 6°'61 
(57) Broch-Due, A. E.; Aasen, A. J. Acta Chem. Scand., Ser. B 1980, 
B34, 75. 
(58) Myers, G. S.; et al. J. Am. Chem. Soc. 1955, 77, 3348. 
(59) Siddiqi, M. A.; Suri, K. A.; Suri, 0. P.; Atal, C. K. Phyto-
chemistry 1978, 17, 2049. 
and more recently as a natural product isolated from 
Caccinia glauca.59 We observed the dibenzoate as a minor 
product in the preparation of 21 and converted 21 into the 
dibenzoate 24 for the purpose of identifying the minor 
product. In the preparation of the C-9 mono(phenyl-
acetate) 22, the C-7 mono(phenylacetate) 25 was isolated 
after chromatography, as a minor product, and its spectral 
properties are also included in the Experimental Section. 
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Biology. All of the compounds submitted for screening, 
except for 22 and 23, were transformed into their water-
soluble N-oxides by treatment of their chloroform solutions 
with m-chloroperbenzoic acid, followed by passage of 
gaseous ammonia through the solution to precipitate the 
acids. A short chromatography gave the N-oxides, which 
were characterized by 1H NMR and TLC and quickly 
sealed under vacuum for submission for screening. The 
screening results are outlined in Table I. Our primary goal 
was to compare the compounds in question with indicine 
N-oxide and, in particular, to determine if any of the di-
astereomers (14, 15, 16 N-oxides) or closely related isomers 
(19, 20 N-oxides) were more potent than indicine N-oxide. 
Also, included in Table I are some totally synthetic com-
pounds (21-23, 17, and 18). Since all of the compounds 
were compared, side by side, with indicine N-oxide, the 
latter appears in Table I each time a group of compounds 
was screened. Indicine N-oxide, in every case, was screened 
at dose levels of 1600, 800, 400, and 200 mg/kg since it is 
not a particularly potent drug, whereas our initial synthesis 
(60) Constantine, M. F.; Mehta, M. D.; Ward, R. J. Chem. Soc. C 
1967, 397. 
(61) Mattocks, A. R. J. Chem. Soc. C 1969, 2698. 
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(T - C) 
% 
T/C 
group I' indicine 1600 06/06 -2.2 142 
N-oxide 800 06/06 -3.2 160 
(7 N-oxide) 400 06/06 -1.6 151 
200 06/06 -1.6 133 
21 N-oxide 70 06/06 -1.0 118 
35 06/06 -0.1 109 
17.5 06/06 -0.7 110 
8.75 06/06 -0.4 107 
intermedine 192 06/06 -1.1 109 
N-oxide 96 06/06 -0.1 107 
(14 N-oxide) 48 06/06 -0.4 105 
24 06/06 -0.1 100 
lycopsamine 192 06/06 -1.1 123 
N-oxide 96 06/06 -0.3 114 
(15 N-oxide) 48 06/06 -0.6 114 
24 06/06 -0.0 107 
16 N-oxide 192 06/06 -4.8 118 
96 05/06 0.1 116 
48 06/06 1.3 100 
24 06/06 -0.4 100 
group II indicine 160) 06/06 -3.7 117 
N-oxide 800 06/06 -3.3 200 
(7 N-oxide) 400 06/06 -1.9 145 
200 06/06 -0.5 120 
21 + 22 84 06/06 0.1 114 
N-oxide 42 06/06 0.3 117 
21 06/06 -0.1 108 
10.5 06/06 0.0 104 
19 + 20 68 06/06 -0.4 131 
N-oxide 34 06/06 -0.4 127 
17 06/06 0.0 117 
8.5 06/06 -0.3 115 
group III indicine 1601) 05/06 -5.8 
N-oxide 800 06/06 -4.7 200 
(7 N-oxide) 400 06/06 -4.3 191 
200 06/06 -2.9 170 
22 480 06/06 -2.1 116 
240 05/06 -0.1 105 
120 06/06 -0.6 109 
60 06/06 -0.3 97 
30 06/06 -0.5 99 
15 06/06 -0.8 97 
23 480 06/06 -2.7 114 
240 06/06 -0.8 108 
120 06/06 -0.1 108 
60 06/06 -0.4 105 
30 06/06 -0.3 109 
15 06/06 -0.6 105 
group IV indicine 160() 05/06 -2.9 
N-oxide 800 06/06 -2.6 112 
(7 N-oxide) 400 06/06 -1.7 146 
200 06/06 -0.7 140 
17 + 18 300 06/06 -2.2 166 
N-oxides 150 06/06 -2.1 157 
75 06/06 -1.7 149 
37.5 06/06 -1.1 146 
° Screening was carried out under the auspices of the National 
Cancer Institute. For detailed explanations of procedures and 
data, see Instruction 14, Screening Data Summary Interpretation 
and Outline of Current Screen Drug Evaluation Branch, Develop-
mental Therapeutics Program, Division of Cancer Treatment, Na-
tional Cancer Institute, Bethesda, MD 20205. b Q01D X 9. Single 
dose for 9 days. 'Within each group, the indicine N-oxide, indi-
cated as the first entry, serves as the internal control. 
of the diastereomers provided only sufficient material to 
screen at a maximum dose of -200 mg/kg. Our intent 
was to resynthesize any of these diastereomers which ap-
peared more potent than indicine N-oxide. As can be seen, 
none of the diastereomers (group I) appear to be more 
potent than indicine N-oxide and, indeed, do not appear 
to be more potent than the simple N-oxide C-9 mono- 
benzoate of retronecine (21). Group II of Table I is of 
interest. Thus, the diastereomeric mixture of N-oxides of 
19 and 20 appears to show promise with T/C = 131 at 68 
mg/kg and T/C = 127 at 34 mg/kg. It may very well be 
that the potency of one of these isomers is even much 
greater. The screening results for the diastereomeric 
mixture of 19 and 20 were of sufficient interest that we 
were requested by NCI to supply an additional 500 mg to 
continue testing. It is also interesting to note that the 
corresponding isopropylidene derivatives appear to be in-
active in terms of the assay. Group III is not particularly 
interesting since the free synthetic amines 22 and 23 do 
not show very good potency even at concentrations of 480 
mg/kg. Finally, we have included in Table I, the screening 
data, presented here for the first time, for the mixture of 
synthetic N-oxides of 17 and 18 (group IV) whose synthesis 
has been previously reported. 28 These are clearly more 
potent than anything else in Table I. 
Experimental Section 
General Methods. Proton nuclear magnetic resonance ('H 
NMR) spectra were obtained by using either a Varian T-60 
spectrometer or a Bruker WM-300 spectrometer equipped with 
an Aspect 2000 data system. Chemical shifts are reported relative 
to internal Me4Si (5 0) or CHC13 (6 7.24). IR spectra were recorded 
on a Perkin-Elmer 299 or a Beckman fR 4240 spectrophotometer. 
Optical rotations were taken with a Perkin-Elmer 141 polarimeter 
or on a Bendex ETL-NPL automatic polarimeter type 143A. Mass 
spectra were obtained by using a Varian MAT 112S spectrometer 
interfaced with an SS200 data system. Melting points were taken 
on a Kofler hot stage and are uncorrected. Column chromatog-
raphy was carried out with EM aluminum oxide 90 active, activity 
III, eluting with Baker HPLC toluene and methanol mixtures. 
TLC was performed on EM precoated aluminum oxide 150 F-254 
plates or aluminum oxide 60 PF254 plates. 
(±)-Viridifloric Acid. (±)-Viridifloric acid was synthesized 
by the hydroxylation of trans-a-isopropylcrotonic acid with 
tungsten trioxide and 30% hydrogen peroxide as previously de-
scribed by Adams and Van Duuren." Yields of 35-46% of re-
crystallized (ether-hexane) material of mp 149-151 °C were ob-
tained: lit. 32 mp 150 °C; 1 H NMR (CDC13, CD3OD) 5 0.92 (d, 6 
H), 1.27 (d, 3 H), 2.12 (hept, 1 H), 4.02 (q, 1 H); EIMS, (m/e) 
(relative intensity) 41 (43), 43 (67), 45 (39), 56 (34), 85 (42), 103 
(100), 118 (53); CIMS, m/e (relative intensity) 163 (M + 1, 18), 
117 (100). 
(±)-Trachelanthic Acid. (±)-Trachelanthic acid was prepared 
by the hydroxylation of trans-a-isopropylcrotonic acid with os-
mium tetraoxide in the presence of chloric acid according to the 
procedure of Kochetkov et al.' Yields of 85% of recrystallized 
(ether-hexane) material of mp 117-119 °C were obtained: lit.' 
mp 116-118 °C; 1H NMR (CDC13, CD3OD) 5 0.98 (d, 6 H), 1.24 
(d, 3 H), 2.10 (hept, 1 H), 4.14 (q, 1 H); EIMS, m/e  (relative 
intensity) 43 (59), 45 (34), 57 (35), 85 (42), 103 (100), 118 (73); 
CIMS, m/e (relative intensity) 163 (M + 1, 67), 117 (100). 
(+)-Viridifloric Acid and (-)-Viridifloric Acid. An ethereal 
solution of 5.3 g of (±)-viridifloric acid was treated with 1.05 equiv 
of (+)-a-phenylethylamine. After 6 h, 3.8 g of crystalline salt was 
collected. The mother liquor was evaporated to dryness, acidified 
with 30% sulfuric acid, and extracted five times with ether. 
Evaporation of the ether gave 3.2 g of acid, which was dissolved 
in ether and treated with (-)-a-phenylethylamine, similarly, to 
give 3.2 g of salt. The mother liquor was again, as above, converted 
into free acid, which, as before, was treated with (+)-a-phenyl-
ethylamine, affording an additional 0.9 g of salt. An attempt to 
obtain a second crop of the salt with (-)-a-phenylethylamine did 
not yield any crystals. 
The combined crop of salt from (+)-phenylethylamine was 
crystallized three times from ethanol to give 2.3 g of salt: mp 
167-169 °C; [a] 26D -12.2° (c 1, EtOH). This salt was dissolved 
in a small volume of 30% sulfuric acid, extracted five times with 
ether, and dried over sodium sulfate, and the ether was removed 
by evaporation to give 1.21 g of (+)-viridifloric acid: mp 119 °C; 
[a] 23D +2.8° (c 1, H2O) [lit. 31 mp 126-127 °C; lit.31 [a]210  +1.97  
(c 1, H2O)]. The first report of natural (+)-viridifloric acid was 
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recorded recently" from the hydrolysis of coromandaline: mp 
122-124 °C; [a]26D  +3.1° (c 0.5, EtOH); 1H NMR and mass spectra 
reported53,54 similar to that recorded here for (f)-viridifloric acid. 
The salt of (-)-a-phenylethylamine gave, after two recrystal-
lizations, 1.8 g of crystals: mp 168-169 °C; [a]250 +10.0° (c 1, 
EtOH) [lit. 31 mp 158-159 °C, [a] 21D +8.5° (c 1, EtOH)]. From 
this, as above, was obtained 0.90 g of (-)-viridifloric acid: mp 
126-127 °C (lit." mp 126-126.5 °C); [a] 25D -2.7° (cl,H20) [lit.31 
 [a]21D -2.0° (c 1, H 2O)]. (-)-Viridifloric acid obtained from hy-
drolysis of lycopsamine35 was reported to show mp 121.5-124 °C, 
undepressed on admixture with (-)-viridifloric acid. 52 Further 
recrystallization of this sample from ether/light petroleum fol-
lowed by prolonged drying at 70 °C under vacuum gave a product 
of mp 137-138 °C with softening at 124 °C." Crowley and 
Culvenor52 state that the melting point of (-)-viridifloric acid is 
markedly influenced by minute amounts of tenacious impurities. 
(-)-Viridifloric acid from lycopsamine was reported" to show 1a1 20D 
- 0.8° (c 1.52, H2O), while that from hydrolysis of echinatine was 
reported52 to show [a] 20D -1.3° (water). 
(+)-Trachelanthic Acid and (-)-Trachelanthic Acid. The 
resolution of (f)-trachelanthic acid (8.6 g) was performed similarly 
to that described above to yield 4.5 g of salt from (-)-a-
phenylethylamine: mp 168-170 °C (lit. 31 mp 156-158 °C); [a] 25D 
- 9.0° (c 1, EtOH) [lit.31 [a]220 -9.4° (c 1, EtOH). Hydrolysis gave 
2.13 g of (+)-trachelanthic acid: mp 89-90 °C (lit. 31 mp 89-90 
°C); [a] 23D +2.15° (c 1.7, H2O) [lit." [a] 240 3.8° (c 1, H2O)]. 
Hydrolysis of natural intermedine was reported" to yield (+)- 
trachelanthic acid with mp 92-93 °C, while hydrolysis of rinde-
rine" was reported to yield (+)-trachelanthic acid with mp 91-93 
°C. In neither of the latter two cases were optical rotations 
reported directly for the isolated trachelanthic acid. Culvenor 56 
 reported the isolation of (+)-trachelanthic acid from the hydrolysis 
of supinine with [a]118D +2.3° (c 1.7, EtOH) and mp 93-94 °C and 
showed that the specific rotation of (+)-trachelanthic acid in water 
decreased at increasing concentration! 
The salt (3.8 g) from (+)-a-phenylethylamine showed mp 
168-170 °C and [a] 25D -11.6° (c 1, EtOH). From this was obtained 
1.86 g of (-)-trachelanthic acid: mp 89-90 °C; [a]26D  -2.15° (c 
1.8, H2O) [lit." mp 90-91 °C; lit31 [a]22D -2.4° (c 1, H2O)]. A recent 
report" of the isolation of (-)-trachelanthic acid from the hy-
drolysis of heliovincine gives mp 91-92 °C, [a] 20D -1.9° (c 0.53, 
EtOH), and IR, 1H NMR, and MS spectra similar to those ob-
tained in the study. (-)-Trachelanthic acid isolated by hydrolysis 
of the first isolated indicine 17 was reported to show mp 94 °C and 
[a]E, -3.4° (no solvent or concentration indicated). 
4-(1-Methylethyl)-2,2,5-trimethy1-1,3-dioxolane-4- 
carboxylic Acids. Isopropylidene Derivatives of (-)- and 
(+)-Viridifloric Acid and (-)- and (+)-Trachelanthic Acid. 
The isopropylidene derivatives of the necic acids were prepared 
by a procedure analogous to that described by Piperr for the 
preparation of the isopropylidene derivative of (-)-trachelanthic 
acid. Thus, 160 mg of the acid, dissolved in 1.6 mL of 2,2-di-
methoxypropane, was treated with 25 AL of concentrated HC1. 
The reaction mixture was kept at 25 °C for 90 min. The brown 
solid resulting from removal of the solvent was recrystallized from 
ethyl ether to give yields in the range of 60-90%. The following 
properties were obtained for the isopropylidene derivatives. 
4(R )- (1-Methylethyl)-2,2,5 (S )-trimethy1-1,3-dioxolane-4- 
carboxylic acid ((-)-trachelanthic acid isopropylidene): mp 
53-54 °C (lit. 37 mp 51-53 °C); [a] 25D +34.8° (c 1, EtOH) 
[a]25D +35.9 ± 0.5° (c 1, EtOH)]. 
4(S )-(1-Methylethyl)-2,2,5 (R )-trimethy1-1,3-dioxolane-4- 
carboxylic acid ((+)-trachelanthic acid isopropylidene): mp 
52-53 °C; [a] 25D -27.3° (c 1, EtOH); 1H NMR for both trache-
lanthic acid isopropylidenes (CDC1 3), 5 0.89 (d, 3 H), 1.00 (d, 3 
H), 1.44 (s, 3 H), 1.52 (s, 3 H), 1.47 (d, 3 H), 2.18 (hept, 1 H), 4.33 
(q, 1 H); MS for both trachelanthic acid isopropylidenes, EIMS, 
m I e (relative intensity) 59 (100), 71 (17), 83 (16), 99 (25), 101 (23), 
127 (18), 157 (58), 187 (41); CIMS, 203 (M + 1, 100). Anal. 
(C161-6304) C, H. 
4(R )-(1-Methylethyl)-2,2,5 (R )-trimethy1-1,3-dioxolane-4- 
carboxylic acid ((+)-viridifloric acid isopropylidene): mp 
63-65 °C; [450 -0.61° (c 1, EtOH). 
4 (S )-(1-Methylethyl)-2,2,5 (S )-trimethy1-1,3-dioxolane-4- 
carboxylic acid ((-)-viridifloric acid isopropylidene): mp 
63-64 °C; [a] 25D 0.81° (c 1, EtOH); 1H NMR for both viridifloric  
acid isopropylidenes (CDC1 3), 5 1.05 (d, 6 H), 1.40 (d, 3 H), 1.45 
(s, 3 H), 1.60 (s, 3 H), 2.13 (hept, 1 H), 4.32 (q, 1 H); MS for both 
viridifloric acid isopropylidenes, EIMS, m/e  (relative intensity) 
59 (100), 71 (17), 83 (18), 99 (31), 104 (27), 127 (16), 157 (64), 158 
(15), 187 (32), CIMS m/e  (relative intensity) 203 (M + 1, 100). 
Anal. (C 101-1 1804) C, H. 
Coupling of the Isopropylidene Derivatives of (-)- and 
(+)-Viridifloric Acid and (-)- and (+)-Trachelanthic Acid 
with Retronecine. The following general procedure was used. 
One equivalent of the isopropylidene derivative of the necic acid-
and 1.1 equiv of CDI were dissolved in DMF (-50 mL/g of necic 
acid derivative), and the solution was allowed to stand 10-15 min. 
Then 1 equiv of imidazoylsodium and 1 equiv of retronecine were 
added, and the solution was kept at 25 °C for 24 h. Evaporation 
of the solvent in vacuo left an oily residue which was distributed 
between water and chloroform. Several chloroform extracts were 
combined and back-extracted with water until all traces (as de-
tected by TLC) of retronecine and imidazole were removed. If 
necessary, the products were sometimes further purified by column 
chromatography on activity III alumina, eluting with toluene 
containing up to 1.5% methanol. Yields of 50-70% were re-
peatedly obtained. The following spectral data were obtained 
for the intermediate isopropylidene derivatives of 7, 14, 15, and 
16 respectively. 
Isopropylidene derivative of indicine (7 isopropylidene): 
noncrystallizing gum; EIMS, m/e (relative intensity) 93 (46), 94 
(32), 99 (16), 136 (32), 138 (100), 157 (31), 187 (5), 222 (2), 254 
(3), 324 (3), 339 (1); 1 H NMR (CDC13) 5 0.81 (d, 3 H), 0.97 (d, 3 
H), 1.37 (s, 3 H), 1.47 (s, 3 H), 1.43 (d, 3 H, C-4'), 1.97 (br, 2 H), 
2.10 (hept, 1 H), 2.7 (br, 1 H), 3.22 (dd, 1 H), 3.38 (dd, 1 H), 3.88 
(d, 1 H), 4.12 (1 H), 4.23 (1 H), 4.29 (q, 1 H, C-3'), 4.61 (d, 1 H, 
C-9), 4.80 (d, 1 H, C-9), 5.83 (s, 1 H, C-2). 
Isopropylidene derivative of intermedine (14 iso-
propylidene): noncrystallizing gum; EIMS, ml e (relative in-
tensity) 93 (68), 94 (44), 99 (15), 136 (29), 138 (100), 157 (24), 187 
(1), 222 (1), 254 (1), 324 (1); 1H NMR (CDC13) 5 0.85 (d, 3 H), 
1.00 (d, 3 H), 1.33 (s, 3 H), 1.47 (s, 3 H), 1.44 (d, 3 H, C-4'), 2.00 
(br, 2 H), 2.13 (hept, 1 H), 2.70 (br, 1 H), 3.25 (dd, 1 H), 3.40 (dd, 
1 H), 3.91 (d, 1 H), 4.14 (1 H), 4.26 (1 H), 4.32 (q, 1 H, C-3'), 4.63 
(d, 1 H, 9), 4.77 (d, 1 H, 9), 5.86 (br s, 1 H, 2). 
Isopropylidene derivative of lycopsamine (15 
isopropylidene): noncrystallizing gum; EIMS, m/e 93 (63), 94 
(35), 99 (16), 136 (20), 137 (19), 138 (100), 157 (31), 187 (3), 254 
(2), 295 (3), 324 (5), 339 (1); 41 NMR 5 0.98 (d, 3 H), 1.01 (d, 3 
H), 136 (s, 3 H), 1.50 (s, 3 H), 1.29 (d, 3 H, 4'), 1.95 (br, 2 H), 2.07 
(hept, 1 H), 2.73 (br, 1 H), 3.25 (dd, 1 H), 3.39 (dd, 1 H), 3.92 (d, 
1 H), 4.12 (1 H), 4.21 (1 H), 4.22 (q, 1 H, 3'), 4.67 (d, 1 H, 9), 4.74 
(d, 1 H, 9), 5.90 (br s, 1 H, 2). 
Isopropylidene derivative of 16: noncrystallizing gum; EIMS, 
m/e  93 (58), 94 (32), 99 (13), 136 (24), 137 (14), 138 (100), 157 
(25), 187 (3), 254 (1), 295 (2), 324 (4); 1H NMR 5 0.96 (d, 3 H), 
0.98 (d, 3 H), 1.37 (s, 3 H), 1.57 (s, 3 H), 1.25 (d, 3 H, 4'), 2.00 
(br, 2 H), 2.07 (hept, 1 H), 2.70 (br, 1 H), 3.24 (dd, 1 H), 3.37 (dd, 
1 H), 3.91 (d, 1 H), 4.15 (1 H), 4.29 (1 H), 4.22 (q, 1 H, 3'), 4.57 
(d, 1 H, 9), 4.91 (d, 1 H, 9), 5.87 (br s, 1 H, 2). Anal. 
(C 18H29N05• 1 / 2H20) C, H, N. 
Indicine (7), Intermedine (14), Lycopsamine (15), and 
Isomer 16. A typical procedure for the conversion of the iso-
propylidene intermediates, mentioned above, to the parent al-
kaloids was as follows. The isopropylidene intermediates were 
taken up in an excess of 0.6 N HC1 (5x) solution and this solution 
was allowed to stand at 25 °C for 24 h. The solution was then 
made alkaline by the addition of K2CO3 and finally extracted with 
chloroform. The chloroform solution, after drying over sodium 
sulfate, was passed through a short column of activity III Merck 
alumina. Evaporation of the chloroform eluent gave the desired 
alkaloid with the properties shown below. 
Indicine (7). Isolated as a viscous gum shown to be homo-
geneous by TLC on aluminum oxide, eluting with toluene-
methanol (9:1) and detection by iodine. Piper et al.' also reported 
isolation of synthetic labeled indicine as a gum, whereas a melting 
point of 97-98 °C has been reportedr for indicine isolated from 
natural sources. For 7: [a]200 +11.2° (c 1, EtOH) [lit." [a] 20D 
 +22.3° (c 1.65, EtOH)] from Heliotropium indicum; no [a] re-
ported by Piper,' 1 11 NMR (CDC13) 5 0.90 (d, 3 H, 6'), 0.93 (d, 
3 H, 6'), 1.15 (d, 3 H, 4'), 1.97 (m, 2 H, 6« and 60), 2.13 (hept, 
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1 H, 5'), 2.7 (m, 1 H, 50), 3.23 (dcl, 1 H, 5a), 3.40 (dd, 1 H, 30), 
3.90 (d, 1 H, 3a), 4.00 (q, 1 H, 3'), 4.13 (br s, 1 H, 8a), 4.26 (br 
s, 1 H, 7a), 4.57 (d, 1 H, 9), 5.07 (d, 1 H, 9), 5.89 (s, 1 H, 2). This 
spectrum is consistent with that of Piper" run in Me 2S0-d6. The 
13C NMR in CDC13 was identical with that reported recently by 
Jones et a1. 49 Piper" reports the 13C NMR in Me2S0-d6. EIMS, 
m/e (relative intensity) 43 (100), 45 (36), 57 (41), 67 (21), 80 (35), 
85 (30), 93 (93), 94 (73), 103 (54), 118 (47), 120 (56), 136 (43), 138 
(89), 139 (28), 156 (7), 254 (4), 299 (1). 
Intermedine (14): mp 137-138 °C 	mp 140-142 °C), 
isolated from Conoclinium coelestinum (Eupatorium coelesti-
num); [a]25D +5.0° (c 0.5, EtOH) [lit " [a] 20D +4.8° (c 2.39, EtOH), 
isolated from Amsinckia intermedia;lit. 49 [a]p +7.8° (no tem-
perature of concentration reported), isolated from C. coelestinum; 
lit.47 mp 141-142 °C, [a] 20D +9.8° (c 1.49, EtOH), crystallized from 
acetone after purification as borate complex]; 1H  NMR (CDC13) 
(5 0.91 (d, 3 H, 6'), 0.92 (d, 3 H, 6'), 1.19 (d, 3 H, 4'), 1.95 and 2.01 
(m, 2 H, 6a and 6$), 2.03 (hept, 1 H, 5'), 2.70 (m, 1 H, 5$), 3.28 
(dd, 1 H, 5a), 3.42 (dd, 1 H, 3$), 3.90 (d, 1 H, 3a), 4.09 (q, 1 H, 
3'), 4.13 (br a, 1 H, 8a), 4.24 (br s, H, 7a), 4.75 (d, 1 H, 9), 4.84 
(d, 1 H, 9), 5.94 (s, 1 H, 2). This spectrum is consistent with the 
recently reported spectrum of Herz at al. 4° The 73C NMR in CDC13 
 was identical with that reported by Jones et al.49 EIMS, m/e 
(relative intensity) 53 (16), 67 (20), 80 (28), 93 (100), 94 (82), 120 
(8), 138 (87), 139 (29), 156 (5), 255 (2), 299 (2). 
Lycopsamine (15): isolated as a viscous gum homogeneous 
by TLC; [a] 25E, +1.2° (c 1.2, EtOH) [lit.' [a] 20D +3.1° (c 5.98, 
EtOH), isolated as a pure gum by countercurrent extraction from 
Amsinckia intermedia; lit.47 mp 132-134 °C; [a] 2°D +5.7° (c 0.89, 
EtOH) by crystallization from acetone after purification as borate 
complex]; 1H  NMR (CDC13) S 0.86 (d, 3 H, 6'), 0.91 (d, 3 H, 
1.25 (d, 3 H, 4'), 1.95 (m, 2 H, 6a and 0), 2.16 (hept, 1 H, 5'), 2.70 
(m, 1 H, 55), 3.25 (dd, 1 H, 5a), 3.88 (dd, 1 H, 35), 3.90 (d, 1 H, 
3a), 3.96 (q, 1 H, 3'), 4.15 (br s,1 H, 8a), 4.26 (br s, 1 H, 7a), 4.73 
(d, 1 H, 9), 4.84 (d, 1 H, 9), 5.89 (a, 1 H, 2). This spectrum is 
consistent with but of higher resolution than those previously 
reported for lycopsamine. 36,4747 The 13C NMR spectrum in CDC13 
 was identical with that reported by Jones et al.49 EIMS, m/e 
(relative intensity) 67 (17), 80 (22), 93 (80), 94 (71), 120 (12), 138 
(100), 139 (35), 156 (9), 255 (2), 299 (3). 
C-9 ester of retronecine with (+)-viridifloric acid (16): 
isolated as a noncrystallizing gum homogeneous by TLC; [a] 26D 
+1.6° (c 1, EtOH); NMR (CDC1 3) 5 0.85 (d, 3 H, 6'), 0.91 (d, 
3 H, 6'), 1.25 (d, 3 H, 4'), 1.95 (m, 2 H, 6a and 6$), 2.14 (hept, 
1 H, 5'), 2.70 (m, 1 H, 50), 3.42 (dd, 1 H, 5a), 3.50 (dd, 1 H, 3$), 
3.90 (d, 1 H, 3a), 3.96 (q, 1 H, 3'), 4.15 (br s, 1 H, 8a), 4.26 (br 
s, 1 H, 7a), 4.71 (d, 1 H, 9), 4.86 (d, 1 H, 9), 5.90 (s, 1 H, 2); EIMS, 
m/e (relative intensity) 43 (100), 67 (31), 80 (36), 93 (82), 94 (71), 
138 (52), 156(3), 170 (1), 212 (2), 256 (1), 290 (0.1); exact calcd 
for C 16H26N06 299.1734, found 299.1786. Anal. (C 16H26N06. 1 / 
4H20) C, H, N. 
N-Oxides of Indicine (7), Intermedine (14), Lycopsamine 
(15), and 16. The N-oxides were prepared by the following 
modified procedure. One equivalent of the alkaloid in chloroform 
was treated with 1.5 equiv of m-chloroperbenzoic acid and the 
solution was allowed to stand at room temperature for 20 min. 
Then, excess gaseous ammonia was passed through the solution, 
and the resulting precipitated ammonium salts were removed by 
filtration. After concentration, the filtrate was passed through 
a short column of activity III alumina, eluting with 0-4% methanol 
in chloroform. In each case, isolated' N-oxides were shown to be 
homogeneous and different from their parent alkaloids by TLC 
and by their III NMR spectra. The N-oxides in chloroform 
solution were placed in vials and the solvent was removed under 
vacuum, leaving a glass in each case, and the vials were sealed 
and sent for screening. 
Retronecine 9-(2',3'-Dihydroxy-2°-methylbutyrate) (19, 20). 
Racemic threo-2,3-dihydroxy-2-methylbutyric acid was prepared 
by the hydroxylation of tiglic acid with tungsten trioxide and 30% 
hydrogen peroxide according to the procedure of Adams and Van 
Duuren' in 86% yield: mp 106-108 °C mp 110-111 °C); 
'H NMR (CDC13, CD30D) 51.23 (d, 3 H), 1.55 (s, 3 H), 3.97 (q, 
1 H); EIMS, m/e 43 (93), 45 (65), 72 (38), 89 (17), 90 (100), 119 
(2); CIMS, 135 (M + 1, 100%). 
Racemic threo-2,3-dihydroxy-2-in ethylbutyric acid was con-
verted into its isopropylidene derivative as previously described  
in 85% yield: mp 65.5-67 °C; 71-1 NMR (CDC13, CD30D) b 1.35 
(d, 3 H), 1.54 (s, 3 H), 1.44 (s, 3 H), 1.61 (s, 3 H), 4.14 (q, 1 H); 
EIMS, m/e (relative intensity) 59 (59), 71 (32), 99 (12), 129 (23), 
159 (16); CIMS, m/e  175 (M + 1, 100). Anal. (C8H 1404) C, H. 
One equivalent of the above isopropylidene derivative and 1.1 
equiv of CDI were dissolved in ethanol-free, dry chloroform. When 
CO2 evolution ceased, 0.9 equiv of retronecine was added and the 
reaction mixture was allowed to stand at 45 °C for 20 h. The usual 
workup gave an 82% yield of a pure mixture of C-9 diastereomeric 
diastereomer), derivatives of 19 and 20: mp 111-117 °C (from 
acetone); 711 NMR (CDC13) S 1.22 and 1.23 (d, 3 H, two diaste-
reomers, 4'), 1.37 (s, 3 H, 7'), 1.47 (s, 3 H, 7'), 1.52 and 1.56 (s, 
3 H, two diastereomers, 5'), 1.95 (br m, 2 H, 6), 2.70 (m, 1 H, 50), 
3.21 (t, 1 H, 5a), 3.38 (m, 1 H, 3/3), 3.89 (d, 1 H, 3a), 4.04 (q, 1 
H, 3'), 4.11 (br s, 1 H, 8a), 4.18 and 4.25 (br, 1 H, two diaste-
reomers, 7), 4.62 and 4.82 (d, 2 H, C-9 protons of one diastereo-
mer), 4.71 and 4.78 (d, 2 H, C-9 protons of one diastereomer), 5.86 
(s, 1 H, 2); EIMS, Rile (relative intensity) 43 (17), 71 (12), 93 (58), 
94 (38), 129 (24), 136 (24), 138 (100), 159 (4), 226 (1), 267 (3), 296 
(7), 311 (0.5); CIMS, m/e  (relative intensity) 312 (M + 1, 100). 
Anal. (C I6H2oN06• 1 / 4H20) C, H, N. 
The N-oxides of the above protected esters of 19 and 20 were 
prepared as previously described and the N-oxides were obtained 
as a noncrystalline glass, showing a single spot by TLC, with the 
following 11-1 NMR (CDC13 + 5% CH3OH): S 1.15 (d, 3 H, 4'), 
1.32 (s, 3 H, 7'), 1.40 (s, 3 H, 7'), 1.47 and 1.48 (s, 3 H, two 
diastereomers, 5'),1.93 (br d, 1 H, 60), 2.51 (m, 1 H, 6a), 3.61 (m, 
2 H, 5), 3.98 (q, 1 H, 3'), 4.33 and 4.36 (AB q, 2 H, 3a and 30), 
4.50 (br s, 1 H, 8), 4.54 (br s, 1 H, 7), 4.74 (s, 2 H, 9), 5.66 (s, 1 
H, 2). 
The mixture of deprotected esters 19 and 20 was prepared from 
the protected esters as previously described to give the mixture 
of esters 19 and 20 as a noncrystalline glass which showed a single 
spot by TLC: 41 NMR (CDC1 3) b L13 (d, 3 H, 4'), 1.36 (s, 3 H, 
5'), 1.90 (br m, 2 H, 6), 2.65 (m, 1 H, 50), 3.18 (t, 1 H, 5a), 3.36 
(dd, 1 H, 3$), 3.74 (q, 1 H, 3'), 3.87 (d, 1 H, 3a), 4.08 (m, 1 H, 8), 
4.23 (m, 1 H, 7), 4.82 and 4.65 (d, C-9 of one diastereomer), 4.77 
and 4.68 (d, C-9 of other diastereomer), 5.80 (s, 1 H, 2); EIMS, 
m/e (relative intensity) 43 (32), 80 (31), 93 (72), 120 (20), 138 (100), 
156 (4), 227 (3), 254 (4), 271 (5); exact mass calcd for C 13H2INO6 
 271.1420, found 271.1439. Anal. (C13H21 N05.1 /2H20) C, H, N. 
The N-oxide of the above mixture of 19 and 20 was prepared 
as previously described to give a glassy substance, homogeneous 
by TLC with the following 711 NMR (CDC13, CH3OH): (5 1.15 and 
1.13 (d, 3 H, C-4 diastereomers), 1.29 (s, 3 H, 5), 1.95 (m, 1 H, 
60), 2.54 (m, 1 H, 6a), 3.65 (q, 1 H, 3'), 4.33 (d, 1 H, 3$), 4.40 (d, 
1 H, 3a), 4.61 (m, 1 H, 7), 4.84 and 4.76 (d, C-9 one diastereomer), 
4.78 and 4.71 (d, C-9, the other diastereomer), 5.90 (s, 1 H, 2). 
C-9 Monobenzoate of Retronecine (21). 1,1'-Cabonyldi-
imidazole (376 mg, 2.32 mmol) and benzoic acid (236 mg, 1.94 
mmol) were dissolved in 25 mL of dry THF under a nitrogen 
atmosphere. After the mixture was stirred at room temperature 
for 1 h, 300 mg (1.94 mmol) of retronecine was added. After the 
mixture stood at room temperature for 16 h, the THF was re-
moved and the residue was taken up in 25 mL of chloroform. The 
latter solution was washed three times with 20 mL of water and 
then dried over MgSO 4 and the solvent removed in vacuo to give 
474 mg (94%) of a colorless oil shown to be homogeneous by TLC 
on alumina using benzene-methanol (9:1) and shown by NMR 
to be 23: 111 NMR (CDC13) 5 1.95 (m, 2 H, 6a and 60), 2.66 (m, 
1 H, 50), 3.23 (m, 1 H, 5a), 3.41 (dd, 1 H, 30), 3.91 (d, 1 H, 3a), 
4.19 (br s, 1 H, 8), 4.29 (br s, 1 H, 7), 4.93 (br s, 2 H, 9), 5.88 (br 
s, 1 H, 2), 7.48 (m, 2 H), 8.01 (m, 2 H); EIMS, m/e  (relative 
intensity) 83 (55), 85 (38), 93 (100), 94 (23), 105 (20), 126 (11), 
136 (12), 137 (29), 138 (16), 154 (12); exact mass calcd for C15" 
1-1 17NO3 259.1208, found 259.1188. Anal. (C151117NO3. 7/6CHC13) 
C, H, Cl. 
The N-oxide of 21 was prepared as previously described for 
the other N-oxides. The dibenzoate was present in the original 
reaction mixture as a minor impurity and was identified by 
converting the monobenzoate to the dibenzoate with benzoyl 
chloride and pyridine. The dibenzoate is known both as a natural 
product, isolated from Caccinia glauca,59 and as a synthetic 
material prepared by diesterification from retronecine 8Q 81 We 
present here, for the first time, useful high-resolution 1H  NMR 
(CDC13) data for the dibenzoate: 5 2.17 (m, 2 H, 6a and 6$), 2.73 
694 
(m, 1 H, 50), 3.35 (m, 1 H, 5a), 3.52 (dd, 1 H, 3$), 4.02 (d, 1 H, 
3a), 4.47 (br s, 1 H, 8), 5.51 (br s, 1 H, 7), 4.91 and 4.87 (AB q, 
2 H, 9), 5.94 (br s, 1 H, 2), 7.36, 7.46, 7.89 (aromatic). 
C-9 Mono(phenylacetate) of Retronecine (22). Compound 
22 was prepared as described above for 23 and the crude reaction 
mixture was chromatographed on activity III alumina. The major 
product, C-9 monoester 22, was eluted in CHC1 3-CH 3OH (97:3). 
For 22: 11-1 NMR (CDC13) S 1.85 (m, 2 H, 6a and 6$), 2.66 (m, 
1 H, 5$), 3.16 (dd, 1 H, 3$), 3.32 (m, 1 H, 5a), 3.83 (d, 1 H, 3a), 
4.06 (br s, 2 H, 7 and 8), 4.69 (br s, 2 H, 9), 5.68 (br s, 1 H, 2), 
7.26 (m, aromatic), 3.62 (s, 2 H, 2'); EIMS, m/e  (relative intensity) 
53 (13), 55 (20), 57 (12), 60 (14), 66 (16), 67 (12), 68 (21), 69 (11), 
70 (17), 80 (17), 81 (27), 82 (11), 92 (16), 94 (100), 95 (48), 96 (12), 
136 (10), 137 (13), 138 (23), 139 (22); CIMS, m/e (relative intensity) 
274 (M + 1, 33), 69 (100); exact mass calcd for C16HisNO3 273.1366, 
found 273.1379. Anal. (C i6H0NO3. 1 / 4H20) C-7 H. For C-7 
monoester 25: mp 83-85 °C; 1H NMR (CDC13) S 2.05 (m, 2 H, 
6a and 6$), 2.55 (q, 1 H, 5$), 3.14 (dm, 1 H, 50), 3.28 (m, 1 H, 
3$), 3.83 (d, 1 H, 3$), 3.93 (s, 2 H, 9), 4.23 (br s, 1 H, 8), 5.27 (q, 
1 H, 7), 5.38 (d, 1 H, 2), 3.54 (s, 2 H, CH 2Ph), 7.2-7.3 (aromatic); 
EIMS, m/e  (relative intensity) 68 (12), 80 (95), 81 (14), 91 (42), 
93 (12), 94 (34), 106 (61), 111 (100), 120 (10), 123 (34), 124 (26), 
136 (25), 137 (47), 255 (23), 273 (7); exact mass calcd for C 16.1-119NO3 
 273.1366, found 273.1326. 
C-9 Ester of Retronecine and Isovaleric Acid (23). Com-
pound 23 was prepared as described above and the crude product 
was chromatographed on activity III alumina, and 25 , the major 
product, was eluted in chloroform: 1H NMR (CDC13), run at 60 
MHz, consistent with that of other C-9 monoesters run at 300 
MHz mentioned above; EIMS, m/e  (relative intensity) 41 (16), 
80 (18), 93 (100), 94 (35), 135 (15), 137 (35), 138 (37), 155 (21), 
239 (1); exact mass calcd for C I3H2iNO3 239.1522, found 239.1508. 
Anal. (C 33H21NO3. 1 / 2H20) C, H. 
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